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Abstract 
Human glyoxylate reductase/hydroxypyruvate reductase (GRHPR) is a D-2- 
hydroxyacid dehydrogenase found predominantly within the liver, and is essential for 
the removal of the reactive metabolic product glyoxylate. Primary hyperoxaluria type 2 
(PH2) disease, which is characterised by increased urinary oxalate and L-glycerate 
levels leading to calcium oxalate deposition and decreased renal function, is caused by 
mutations in the gene for GRHPR. 
In this study the first crystal structures of the human GRHPR enzyme are reported. 
Structures of apo, binary and ternary forms of GRHPR are reported, the latter being the 
first structure of a true ternary complex of an enzyme from the D-2-hydroxyacid 
dehydrogenase family. These confirm one of two previously proposed models for 
substrate binding. The crystal structures have also been used to explain the unusual 
substrate specificity of the GRHPR family of enzymes and the reduction in GRHPR 
activity associated with missense mutations that lead to PH2. 
Additionally, an enzymatic investigation is also reported and shows that within the cell 
there is likely to be a fine balance between GRHPR and L-lactate dehydrogenase in 
their turnover of glyoxylate and hydroxypyruvate substrates. The data suggest that 
turnover by GRHPR is favoured due to cellular conditions rather then a kinetic 
preference. 
Separately, human sorting nexin 1 (SNX1) - an important component of the endosomal 
sorting pathway - has also been recombinantly expressed and purified. This includes 
truncated forms comprising its component phox-homology (PX) and 
Bin/Amphiphysis/Rvs (BAR) domains. Attempts to produce crystals of these proteins 
have so far been unsuccessful. 
Finally, studies regarding the interaction of plant RKIP/PEBP proteins with their 
potential binding partners were also initiated. While unsuccessful, this work was useful 
as the starting point for future studies of these proteins in higher order complexes. 
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Chapter 1 Introduction 
1.1 Overview 
The human metabolic enzyme glyoxylate reductase /l ydroxypyruvate reductase 
(GRHPR) is predominantly found in the liver and plays an important role in the 
metabolism of glyoxylate. Mutations within the gene coding for this enzyme have been 
found to be the cause of the rare, recessive disorder Primary Hyperoxaluria type 2 
(PH2) which is typified by the overproduction of oxalate and L-glycerate (reviewed in 
Danpure and Purdue, 1995; Danpure and Rumsby, 2004). However, despite its 
importance in the pathology of PH2, little detailed structural or enzymatic information 
has been available for GRHPR including the mechanism by which its substrate 
specificity is achieved. Consequently, studies to investigate the structure and kinetics 
of this important enzyme have been undertaken and are described in this thesis. Some 
of these are also presented in the publications arising from this work which are listed in 
Appendix 1. 
Two additional exploratory structural projects have also been undertaken, one 
involving the human sorting nexin 1 protein involved in endosomal sorting and the 
other, plant members of the RKIP/PEBP family of proteins. These proteins interact 
with diverse ligands and the structural determinants of their ligand specificities are 
unclear. All aspects of these projects, including a background introduction and relevant 
methodology are included in the appropriate chapters. 
1.2 Glyoxylate metabolism 
Glyoxylate is a reactive metabolite whose abnormal metabolism results in the over 
production of oxalate and consequently leads to the pathology of the primary 
hyperoxalurias (Figure 1.1, Frederick et al., 1963). The source of glyoxylate in human 
liver has long been unclear, but recent work suggests the majority is derived from the 
metabolism of hydroxyproline (a component amino acid of collagen) in hepatocyte 
mitochondria (Knight et al., 2006b). 
i 
The key enzymes involved in the further metabolism glyoxylate have been identified as 
glyoxylate reductase/hydroxypyruvate reductase (GRHPR, Cramer et al., 1999), 
glycolate oxidase (GO, Richardson and Tolbert, 1961) and alanine: glyoxylate 
aminotransferase (AGT, Danpure and Jennings, 1986), largely in view of the 
importance of this pathway in the primary hyperoxalurias. 
GRHPR activity is found predominantly within the cytosol of liver cells where it 
catalyses the reduction of both glyoxylate and hydroxypyruvate using NADPH as a 
coenzyme. A small component is also found in the mitochondria (Mistry, Danpure and 
Chalmers, 1988; Cramer et al., 1999). Both AGT (Danpure and Jennings, 1986) and 
GO (Jones, Morrell and Gould, 2000) are liver specific, peroxisomal enzymes (Figure 
1.1). Like GRHPR, a small amount of AGT activity is present in liver mitochondria, 
but this enzyme (AGT2) has no homology with the peroxisomal form (Baker et al., 
2004). The importance of GRHPR and AGT2 activity in the mitochondria is unknown. 
Consequently, within a healthy individual glyoxylate is reduced in the cytosol (or 
mitochondria) to glycolate by GRHPR (Figure 1.1). The glycolate then moves into the 
peroxisome where it is oxidised back to glyoxylate by GO and a transamination 
reaction takes place to produce pyruvate and glycine (Figure 1.1). The resulting 
pyruvate can be recycled back to alanine via a transamination reaction with serine, also 
catalysed by AGT (Xue et al., 1999). This reaction produces hydroxypyruvate which is 
in turn reduced to D-glycerate by GRHPR, which subsequently enters the 
gluconeogenesis pathway. The activity of AGT in the production of hydroxypyruvate 
has been shown to play a significant role in gluconeogenesis from serine in human liver 
(Xue et al., 1999). 
Why the conversion of glyoxylate to glycolate prior to its entry to the peroxisome is 
required is unclear, but is likely due to the permeability of this organelle. The 
permeability of the peroxisomal membrane to glycolate is poorly understood. While rat 
hepatocyte peroxisomes appear freely permeable to glycolate (Verleur and Wanders, 
1993) human hepatocyte peroxisomes are seen to show a small increase in glycolate 
metabolism when the membrane is disrupted, indicating some transport restriction 
(Baker et al., 2004). The permeability of the organelle to glyoxylate has not been 
determined. 
2 
The cytoplasmic enzyme L-Lactate Dehydrogenase (L-LDH) can catalyse the reduction 
of hydroxypyruvate to L-glycerate (Meister, 1952) and the oxidation of glyoxylate to 
oxalate (Sawaki, Hattori and Yamada, 1967, Figure 1.1). However the role of L-LDH 
in normal glyoxylate metabolism, when both L-LDH and GRHPR are present, is not 
clear. This question is partially addressed within this thesis. Although a small amount 
of oxalate is normally produced in a healthy individual it is unclear if this results either 
from the activity of L-LDH or GO (Danpure and Purdue, 1995). The ability of L-LDH 
to catalyse the oxidation of glyoxylate has led to it being proposed as the source of the 
excess oxalate that results in the pathology associated with a small number of inherited 
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1.3 The primary hyperoxalurias 
Primary hyperoxalurias are a group of inherited metabolic defects where the 
predominant feature is the overproduction of oxalic acid (oxalate) which cannot be 
metabolised. Under normal conditions endogenously produced oxalate (and the small 
amount absorbed from the diet) is removed by glomerular filtration in the kidney and 
excreted in the urine (Williams, Johnson and Smith, 1971). An increase in oxalate 
production, or intake, is usually accompanied by an increase in the level excreted in the 
urine (hyperoxaluria). Excessive production of oxalate is potentially life-threatening 
due to the poor solubility of its calcium salt at physiological pH (reviewed in Danpure 
and Purdue, 1995). The deposition of calcium oxalate can block tubular structures, 
disrupt cellular interactions and kill the cells in which it is deposited. Because of the 
role of the kidney in the excretion of oxalate, this is the key site where deposition 
occurs (nephrocalcinosis) and thus calcium oxalate constitutes the major component of 
many renal stones. Deposition is not limited to the kidney, however, and can occur at 
various sites within the body with the most detrimental being bone, the myocardium of 
the heart and vessels of the extremities (Danpure and Purdue, 1995). Additionally, 
nephrocalcinosis decreases the ability of the kidney to clear oxalate from the body 
leading to further deposition which can eventually lead to renal failure and reduced life 
expectancy. 
Hyperoxaluria can have both environmental and genetic causes. A small number of 
genetic (primary) hyperoxalurias have currently been identified. The best studied of 
these are primary hyperoxaluria type 1 (PHI) and primary hyperoxaluria type 2 (PH2) 
(reviewed in Danpure and Purdue, 1995; Danpure and Rumsby, 2004; Danpure, 2005). 
A third hyperoxaluria, classified as "atypical" has been identified but its underlying 
cause is not understood (Monico et al., 2002). While the enzyme and metabolism 
specifically involved in PH2 is the basis of this thesis, PHI will briefly be introduced 
due to its causative defect being in the same metabolic pathway as PH2 and the clinical 
similarities of the two disorders. 
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1.3.1 Primary hyperoxaluria type 1 
Primary hyperoxaluria type 1 is a rare, recessive disordered that is caused by mutations 
within the liver specific peroxisomal enzyme alanine: glyoxylate aminotransferase 
(AGT, Kamoda et al., 1980; Danpure and Jennings, 1986). AGT catalyses a 
transamination reaction between the reactive metabolite glyoxylate and alanine, 
producing pyruvate and glycine (Figure 1.1). When AGT is dysfunctional the build up 
of glyoxylate is instead removed via its oxidation to oxalate or reduction to glycolate, 
both reactions being catalysed by glyoxylate oxidase (GO) (Richardson and Tolbert, 
1961). Consequently both hyperoxaluria (always) and hyperglycolic aciduria (usually) 
are signatures of PHI, with the insolubility of calcium oxalate leading to the pathology 
associated with this disorder. 
Over 50 mutations of the AGT gene have been identified with approximately half of 
these being missense mutations and result in the change of one amino acid for another 
(Danpure, 2005). The determination of a crystal structure of the AGT enzyme (Zhang 
et al., 2003) has greatly assisted understanding of these mutations and initiated drug 
design strategies. 
1.3.2 Primary hyperoxaluria type 2 
Primary hyperoxaluria type 2 has long been identified as the result of a deficiency in 
hydroxypyruvate reductase activity, due to its characteristic of both hyperoxaluria and 
L-glyceric aciduria (Williams and Smith, 1968b). Subsequent identification of a dual 
lack of both hydroxypyruvate and glyoxylate reductase activity in the liver of PH2 
patients (Mistry, Danpure and Chalmers, 1988) has facilitated the identification of the 
underlying genetic defect; mutations of the glyoxylate reductase/hydroxypyruvate 
reductase (GRHPR) gene (Cramer et al., 1999; Rumsby and Cregeen, 1999). The 
resulting metabolic blockage of both glyoxylate and hydroxypyruvate reduction can, as 
previously mentioned (section 1.2), be overcome by the catalytic ability of the 
cytoplasmic enzyme L-LDH (Figure 1.1). However, with the majority of glyoxylate 
now being metabolised by this enzyme, excessive oxalate is produced and results in the 
pathology seen with PH2. Additionally, the alternative reduction of hydroxypyruvate 
produces L-glycerate which is not normally seen in urine (Williams and Smith, 1968a), 
resulting in the defining feature of PH2, L-glyceric aciduria. 
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PH2 is both less common and less severe then PHI, although there is evidence for its 
misdiagnosis (Leumann and Hoppe, 1999; Rumsby et al., 2001). The fact that PH2 is 
less severe then PHI may arise from glyoxylate itself crossing the peroxisomal 
membrane and hence being available to AGT without the need for the glycolate 
intermediate, although the permeability of the peroxisome to glyoxylate has not been 
determined. Additionally the presence of AGT2 within the mitochondria (Baker et al., 
2004) may help to reduce the effect of PH2. 
Unlike PHI, only a small number of mutations have been identified within the human 
GRHPR gene of PH2 patients and have been shown, through expression and activity 
trials, to be the genetic cause of the disorder (Cramer et al., 1999; Webster et al., 2000; 
Cregeen et al., 2003; Takayama et al., 2007 and reviewed in Danpure and Rumsby, 
2004). The majority of these mutations are small deletions or single base substitutions 
that result in a truncated peptide due to the creation of termination codons. The most 
common PH2 mutation is the deletion of guanosine at base 103 (103de1G) which is 
responsible for 39% of known mutated alleles and results in termination of translation 
after only 44 amino acids (Webster et al., 2000; Cregeen et al., 2003). Further 
mutations that cause premature termination are scattered throughout the gene sequence, 
generating another approximately 43% of the identified mutant alleles (Webster et al., 
2000; Cregeen et al., 2003). Further identified mutations include missplicing events 
and 7 missense mutations: Gly165Asp and Met322Arg (Webster et al., 2000), 
Asn312Asp (personal communication Dr D. Dinour, Israel), Glu113Lys (Takayama et 
al., 2007), Glyl60Arg and Arg302His (personal communication Dr G. Rumsby, UCL 
Hospitals, London) and Arg302Cys (Cregeen et al., 2003). The majority of these 
mutations occur in residues conserved within the D-2-hydroxyacid dehydrogenase 
family or with the GRHPR sub-family (Figure 1.2). As has been demonstrated for the 
AGT enzyme, the elucidation of the human GRHPR crystal structure will enable the 
mechanism by which these substitution mutations affect the catalytic ability to be 
interpreted and should facilitate future drug discovery work. Accordingly, these 




While the detection of excessive oxalate in the urine is used as an initial diagnosis tool 
for suspected primary hyperoxaluria, it does not distinguish between PHI and PH2 
which is important for the determination of the correct treatment course. Additionally, 
both secondary features, hyperglycolic aciduria (PHI) and L-glyceric aciduria (PH2) 
are not always present, leading to a suspicion PH2 may be under diagnosed (Danpure 
and Purdue, 1995; Rumsby et al., 2001). 
The identification of the exact enzymatic cause of these two disorders has allowed the 
introduction of enzymatic testing via liver biopsies, although this is rapidly being 
superceded by other methods. The identification of the genetic origin and of the most 
prevalent mutations has allowed the development of a genetic screening approach, 
although in many cases confirmation by liver analysis is still required (Rumsby, 
Williams and Coulter-Mackie, 2004). In the case of PH2, as GRHPR is expressed 
throughout the body (although predominantly in the liver, Cramer et al., 1999) 
enzymology tests are being extended to blood mononuclear cells (Knight et al., 2006a) 
although questions have been raised regarding the appropriateness of this method 
(Ghat, Williams and Rumsby, 2005; Rumsby, 2006). 
1.3.4 Treatment options 
The treatment options can be divided into those that treat the symptoms of calcium 
oxalate deposition and those that treat the enzymatic cause (reviewed in Danpure and 
Purdue, 1995; Danpure and Rumsby, 2004; Danpure, 2005). While the symptoms of 
PHI and PH2 are similar, with varying degrees of severity, effective treatment of the 
underlying cause is dependent on the primary hyperoxaluria type present, making 
correct diagnosis essential. 
Standard treatment of the symptoms during the early stages include: a high fluid intake 
to increase the excretion of oxalate, restricting the dietary intake of oxalate, and dialysis 
in later stages. Renal transplantation is also used in late stage cases, but is only a 
temporary solution as oxalate deposition continues (Danpure and Purdue, 1995). 
Optimally, treatment should `fix' the underlying defect. This is achieved in PHI via 
liver transplantation as this is the sole location of this enzyme, but has not been used in 
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PH2 as it is spread more widely throughout the body. In some cases PHI can be partly 
regulated by increasing the intake of Pyridoxine (vitamin B6), the precursor to the AGT 
cofactor (Watts et al., 1979). Gene therapy and the use of chemical chaperones to 
stabilise certain AGT mutations have been proposed as future treatments (Danpure, 
2005). Again, the more disseminated location of GRHPR makes current gene therapy 
less suitable for treatment of PH2, and the lack of a structure of the human GRHPR 
enzyme has precluded substantial drug discovery work. This is further discussed in 
relation to the GRHPR structure in Chapter 3. 
With the establishment of hydroxyproline as the likely precursor of glyoxylate (and 
therefore oxalate in the primary hyperoxalurias, Knight et al., 2006b) the inhibition of 
its transport into the mitochondria (or cell) or its metabolism to glyoxylate has been 
suggested (Coulter-Mackie, 2006). This would have the advantage of being useful for 
the treatment of both PHI and PH2. Additionally, the partial inhibition of human L- 
LDH may be an option in the treatment of PH2, by allowing the glyoxylate blockage to 
be overcome by other means, such as increased excretion or AGT(2) function. 
Although complete inhibition of L-LDH is unlikely to be desirable due to its other 
cellular functions, it is currently being targeted for other diseases (personal 
communication Prof. L. Brady), although not specifically for PH2. 
1.4 D-2-hydroxyacid dehydrogenases 
Recognition of sequence homology between a number of plant and bacterial enzymes 
lead to the establishment of the D-specific 2-hydroxyacid dehydrogenase family 
distinct from, and unrelated to, the L-specific family (Grant, 1989; Kochhar et al., 
1992b). Both types of enzyme catalyse identical chemical reactions, but produce 
opposite stereo isomer products. Subsequent sequence comparisons have placed the 
human GRHPR enzyme within the D-specific 2-hydroxyacid dehydrogenase family. 
While formate dehydrogenase (FDH) is an atypical member of the family as its is 
neither stereo specific nor a hydroxyl acid dehydrogenase, its strong sequence 
homology with D-2-hydroxyacid dehydrogenases (Vinals, Depiereux and Feytmans, 
1993) and its early crystallographic structure determination resulted in it being the first 
enzyme to give structural insight into this family (Lamzin et al., 1994). Other, D-2- 
9 
hydroxyacid dehydrogenases followed including a bacterial (Hyphomicrobium 
methylovorum) GRHPR (Goldberg, Yoshida and Brick, 1994), D-2 hydroxyisocaproate 
dehydrogenase from Lactobacillus casei (D-HicDH, Dengler et al., 1997) and a D- 
lactate dehydrogenase (D-LDH) from L. bulgaricus (Razeto et al., 2002). A structure 
based sequence alignment of these proteins is shown in Figure 1.3. 
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Each monomer of these dimeric enzymes consists of two distinct a/p/a globular 
domains: the coenzyme binding domain and the substrate binding domain (Figure 1.3). 
Both domains have similarity to the Rossmann fold and share a core structure (Figure 
1.3 insert). Between these domains is the active site cleft in which the binding sites for 
coenzyme and substrate are located. A comparison of apo and holo structures has 
shown that during catalysis the substrate binding domain moves as a rigid body towards 
the coenzyme binding domain, leading to shielding of the active site from solvent 











Figure 1.3 Overlay of monomers from characteristic D-2-hydroxyacid dehydrogenases. 
A) Overlay of monomers superimposed via their coenzyme binding domain. FDH: holo (yellow, 
Lamzin et a!., 1994), D-LDH: holo (green, Razeto et al., 2002) D-LDH: binary (blue, Razeto et al., 
2002), D-GDH: apo (red, Goldbery, Yoshida and Brick, 1994), D-HicDH: ternary (magenta, Dengler et 
a!., 1997). Boxed insert is a schematic of the core domain structure conserved between domains. 
Cylinders represent a-helices, triangles ß-sheets and dashed lines non-direct links (adapted from 
Kutzenko, Lamzin and Popov, 1998). 
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1.4.1 Binding of substrate 
While a growing number of D-2-hydroxyacid dehydrogenase protein structures have 
been solved, uncertainty had remained regarding the exact orientation of substrate 
within the active site. The identities of the residues involved in the catalytic activity of 
the D-2-hydroxyacid dehydrogenase family have long been established by mutational 
and chemical modification studies (Kochhar, Chuard and Hottinger, 1992; Kochhar et 
al., 1992a; Taguchi and Ohta, 1993,1994). These residues have subsequently been 
confirmed in corresponding structural work (Goldberg, Yoshida and Brick, 1994; 
Lamzin et al., 1994; Dengler et al., 1997; Razeto et al., 2002) and are indicated in 
Figure 1.2. 
However, as none of these previous structures is a true ternary complex, combining 
coenzyme and substrate (-analogue) with a closed domain conformation, the precise 
mode of substrate binding has been unclear. Two models have been proposed based on 
holo (ternary-like) structures, which contain coenzyme and an anion at the active site; 
such as FDH + azide (Lamzin et al., 1994) and D-LDH + sulphate (Razeto et al., 
2002). These two models differ predominantly in their prescribed role for the single 
active site arginine (Figure 1.4). Both models explain the stereochemistry of this 
family by positioning the substrate in a manner that presents its si face to the 
nicotinamide NC4 hydrogen, resulting in the formation of the D-isomer product. 
The first model was proposed based on comparisons with L-LDH structures, the holo 
structure (NADH + azide) of FDH (Lamzin et al., 1994) and the apo structure of H. 
methylovorum glyoxylate reductase (Goldberg, Yoshida and Brick, 1994). In this 
model the substrate carboxylate group interacts with the active site arginine via 
bifurcated hydrogen bonds (Figure 1.4), similar to the interaction seen in L-LDH 
(Wigley et al., 1992). 
A second binding mode was later proposed, initially based on a structural model of L. 
bulgaricus D-LDH (Vinals et al., 1995) and again when the crystal structure of D-LDH 
from L. pentosus was found to closely match this (Stoll, Kimber and Pai, 1996). In this 
model the active site arginine forms bifurcated charged hydrogen bonds to a single 
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carboxylate oxygen of the substrate and also its keto oxygen (Figure 1.4). In this model 
the arginine both acts in substrate binding and catalysis via the polarisation of the 
substrate carbonyl bond, which is supported by kinetic studies (Taguchi and Ohta, 
1994). While partial structural support for this second model is available, it is based on 
structures with inappropriate domain conformations (Dengler et al., 1997) or unusual 
active site features (Kumar et al., 2002). Consequently, despite this second model of 
substrate binding being generally accepted (Figure 1.4b), no structural confirmation has 



















Figure 1.4 The two models for substrate binding in the D-2-hydroxyacid dehydrogenase family. 
A) The active site arginine forms bifurcated bonds to the carboxylate group of the substrate ('R' 
represents any attached group). B) The arginine binds the carboxylate group and polarises the carbonyl 
bond, assisting catalysis. In model (b) additional residues are involved in binding the carboxylate group 
but are not included for clarity. Adapted from Razeto et al., (2002). 
1.4.1.1 Substrate specificity 
Substrate specificity varies widely across the D-2-hydroxyacid dehydrogenase family. 
D-HicDH has low specificity and will act on a large range of 2-oxocarboxylic acids 
with various side groups (represented by `R' in Figure 1.4, Dengler et al., 1997). In 
contrast, the GRHPR members are highly specific and will only catalyse the substrates 
glyoxylate and hydroxypyruvate (Figure 1.5), which have very specific groups. While 
these same substrates are present in plants (Givan and Kleczkowski, 1992), bacteria 
(Chistoserdova and Lidstrom, 1991) and humans (Rumsby and Cregeen, 1999) the 
structural determinants of this substrate specificity are unknown. While one of the 
earliest D-2-hydroxyacid dehydrogenase structures solved was that of a bacterial 
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GRHPR (Goldberg, Yoshida and Brick, 1994) this provided minimal information on 
the mechanism of substrate specificity in this family as it was in the apo form with 
nothing bound in the active site. Since the solution of the human ternary GRHPR 
structure presented in this thesis, the structure of two further bacterial GRHPR enzymes 
have been produced from Thermus thermophilus (PDB code 2CUK) and Pyrococcus 
horikoshii (Yoshikawa et al., 2007). Both of these enzymes show a high level of 
sequence identity to the human form, 42% and 39% respectively. However, as these 
enzymes have only been solved either in the apo state (T. thermophilus) or with 
sulphate in the active site (P. horikoshii) they do not assit in the understanding of 
substrate specificity of the group. The determinants of this specificity can only be 
reliably understood with the structure of one of these GRHPR enzymes with a substrate 
analog bound in the active site. 
H0 HOCH2 0 
OO0O 
glyoxylate hydroxypyruvate 
Figure 1.5 Schematic of the two physiological substrates of human GRHPR. 
1.5 Thesis aims 
To further understanding of the GRHPR family of enzymes and their role in PH2 
disease, studies described in this thesis aimed to address two main goals: 
1) To produce crystallographic structures of the three states of human GRHPR 
(apo, binary and ternary) and use these to understand its substrate and coenzyme 
specificity and the pathology of PH2 mutations. Additionally, structural 
confirmation of the mode of substrate binding within the D-2-hydroxyacid 
dehydrogenase family was to be clarified (Chapter 3). 
2) To characterise the kinetics of human GRHPR under `near-physiological' 
conditions in order to allow their direct comparison to similarly produced 
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ý, 
results from L-LDH. It was intended that this information could be used to help 
understand the flux of these metabolites through the glyoxylate metabolic 
pathway (Chapter 4). 
Additionally, a number of other projects involving unrelated components were also 
initiated. These will be introduced later in the thesis, and aimed to: 
3) Establish soluble expression and purification procedures for human Sorting 
Nexin 1 (SNX1), or parts thereof, to initiate structural studies of its ligand 
specificity (Chapter 5); and 
4) Using crystallography, to investigate the interaction of two plant RKIP/PEBP 
proteins, TFL 1 and FT, with their potential phosphorylated ligands (Chapter 6). 
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Chapter 2 Methods 
2.1 Methods overview 
This chapter consists of all the methods specific to the work undertaken during this 
thesis on human GRHPR. In addition, a number of the methods described herein were 
used in relation to the two additional projects described in Chapter 5 and Chapter 6 and 
will be referred back to during those chapters where appropriate. 
2.2 General materials 
All buffers were made from high grade products and using Milli Q water (Millipore). 
Large volumes (>50m1) were vacuum filtered through 0.2µm cellulose nitrate filters 
(Sartorius), while smaller volumes were filtered using 0.2µm cellulose acetate syringe 
filters (Sartorius). Size exclusion chromatography (gel filtration) buffers were 
degassed before use and unless indicated, all columns were run using an AKTA purifier 
controlled by the Unicorn software (GE Healthcare). To prevent cross-contamination 
all Histidine (poly-His) tagged proteins were purified on individual HiTrap Ni2+ affinity 
columns (Amersham Biosciences). 
2.3 GRHPR 
2.3.1 Supplied GRHPR 
Human GRHPR cDNA was supplied by Dr G. Rumsby (University College London 
Hospitals, London) pre-cloned into the expression vector pTrcHisB. This construct 
consists of the 987 base pair (bp) open reading frame coding for the 328 amino acid 
native protein plus a small length of 5' and 3' untranslated sequence. This had been 
inserted in-frame and downstream from a6 histidine (hexa-His) tag via KpnI and 
HindIII restriction sites (5' and 3' respectively). Expression from this results in a 40 
kDa N-terminally His-tagged protein, comprising a 48 amino acid tag and 328 amino 
acids of native GRHPR. Full cloning and initial expression/activity tests can be found 
in Rumsby and Cregeen (1999). The vector also contains the ampicillin resistance gene 
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and for selection purposes 50pg. m1"' of ampicillin was always present. This construct 
is referred to as pTrcHisB-HPR from here on. 
2.3.2 PCR modification of GRHPR 
The pTrcHisB-HPR vector was modified by the polymerase chain reaction (PCR) to 
include an N-terminal fused thrombin cleavage sequence (LVPRAS) directly before the 
start of the native enzyme. This would allow for the removal of all but two of the tag 
amino acids (AS). A forward primer was designed containing a KpnI restriction site, 
the thrombin recognition sequence and 25bp complementary to the start of the open 
reading frame, while the reverse primer was from Rumsby and Cregeen (1999) and 
contains a Hind1II restriction site (Figure 2.1). All primers used in this thesis were 
produced by Invitrogen and supplied as lyophilised powder. The primers were 





5'-G CAAG CTTCCCTTGGCTCTGCCTGTGGATCC-3' 
Figure 2.1 Primers for thrombin site insertion into GRHPR. 
Restriction enzymes sites are underlined, with a Kpnl site in the forward primer and a HindIII site in the 
reverse. The DNA sequence coding for the thrombin recognition sequence (LVPRAS) is in bold. 
The PCR reaction mix consisted of 1.75 enzyme units (U) Expand High Fidelity 
Polymerase (Roche), Ix Expand Buffer + MgC12 (Roche), both primers at 2µM, dNTPs 
(50pmol) and 1µl of pTrcHisB-HPR as the template. This was made up to a final 
volume of 50µ1 with Elgastat water. A PCR machine (Progene) was used to create the 
thermal cycling program required for amplification. Initial DNA denaturation was 
undertaken at 94°C for 4 minutes followed by 25 cycles of 94°C for 1 minute, 48°C for 
45 seconds, 72°C for 1 minute for denaturation, annealing and amplification 
respectively. PCR reactions were then held at 4°C until required. 
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2.3.3 PCR product verification and purification 
To ascertain the success of the PCR, Tris-HCI-acetate-EDTA (TAE) buffer was used to 
prepare a 1% agarose gel. Both the gel and running buffer (TAE) contained a small 
amount of ethidium bromide (EtBr), which upon intercalation with double stranded 
DNA and exposure to UV light fluoresces, provided a means of visualising the DNA. 
The PCR reactions were electrophoresed through this gel for 45min at 110 volts. 
Correctly sized DNA products were identified by comparison to concurrently run 
molecular weight markers (Hyperladder, Bioline) under UV light. Care was taken to 
minimise sample exposure to UV light as this can cause mutations within the PCR 
product and inhibit later ligations. PCR products of the correct size were sliced from 
the gel using a sterile scalpel and subsequently extracted from the agarose using the 
Quick Gel Extraction Kit (Qiagen), following manufacturers' instructions. Purified 
PCR product could be stored at -20°C indefinitely. 
2.3.4 pGEM-Teasy ligation 
Many restriction enzymes are known to cleave inefficiently when their recognition 
sequence is near the end of a linear DNA fragment, making it difficult to clone PCR 
products directly into expression vectors (Marchuk et al., 1991). This problem was 
avoided by using an intermediate cloning step into the pGEM-Teasy vector system 
(Promega). This linearised, high-copy number vector contains single 3' terminal 
thymidines at both ends. These thymidines prevent empty vector recircularisation and 
provide overhangs directly compatible with the extra deoxyadenosine added to the 3'- 
ends of PCR products by the Expand High Fidelity Polymerase. Additionally, PCR 
insertion takes place within the coding region of the a-peptide of ß-galactosidase, 
allowing the identification of successful recombinants via blue/white screening. This 
vector contains the ampicillin resistance gene and unless stated 50gg. ml-1 of ampicillin 
was present in all cultures. 
Ligations into pGEM-Teasy were performed in accordance with the manufacturers 
protocol. Briefly, 5µl of 2x Rapid Ligation Buffer, 1 µl of linear pGEM-Teasy (50ng) 
and lµl T4 DNA Ligase (3U) were mixed with 3µl of purified PCR product. A 
negative control ligation was also run, where the PCR product was replaced with 
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Elgastat water. Ligation reactions occurred at 4°C overnight and were then frozen at - 
20°C until transformed. 
2.3.5 Bacterial transformation 
To ensure efficient transformation and allow for blue/white selection, Escherichia coli 
NovaBlue SinglesTM super calcium competent cells (Novagen) were used. For each 
transformation, a 25µl aliquot of cells was allowed to thaw on ice and a 1.5µl sample of 
the ligation mix added. A5 minute incubation on ice was followed by a 40 second, 
42°C heat shock in a thermostated water bath. This induces plasmid uptake by the 
bacteria, which are then placed back on ice for 2 minutes. Room temperature SOC 
media was added to give a final volume of 100µl. An aliquot of the transformed 
bacteria (30µl) were spread onto pre-treated Luria Bertani (LB) agar plates containing 
ampicillin. Pre-treatment of the LB agar plates consisted of them being spread with 
20gl of O. 1M Isopropyl-ß-D-thiogalactopyranoside (IPTG) and 6Oµ1 of 20mg. m1'' 5- 
bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-Gal), then left at 37°C to fully 
dry. This provides the induction and substrate required for blue/white selection. Plates 
were incubated at 37°C overnight. 
2.3.6 Blue/white selection 
Blue/white colony screening allows for the easy choice of likely successfully ligated 
plasmids. It relies on the fact that the E. coil ß-galactosidase enzyme (LacZ) will turn 
the normally colourless X-gal into an insoluble blue product. The addition of the IPTG 
induces the NovaBlue strain to express the LacZS1 peptide, while only recircularised 
but empty pGEM-Teasy will express active LacZa peptide. Both active peptides are 
required for full LacZ activity and result in blue colonies. The presence of a ligated 
insert in pGEM-Teasy inactivates the LacZa peptide, rendering these colonies white. 
After overnight growth at 37°C, transformation plates were examined for white 
colonies. Six white colonies were picked with sterile toothpicks, re-streaked onto 
ampicillin/LB agar plates and re-grown overnight at 37°C. 
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2.3.7 Verification of inserted DNA and sequencing 
A small number of cells from each of the 6 selected colonies were transferred to 
individual universals containing 10ml LB broth and ampicillin. These were grown with 
shaking (300 rpm) overnight at 37°C. Plasmid DNA was extracted from 5m1 of these 
cultures using the QlAprep Spin Miniprep kit (Qiagen), following manufacturers 
instructions. Plasmid DNA was eluted from the spin columns in 50µ1 of storage buffer 
(10mM Tris-HCI, pH 8.5). To verify the presence of insert DNA (blue/white selection 
is not 100% accurate) double restriction digests of the purified plasmid were 
performed. In brief, a 5µl aliquot of purified plasmid was digested with 1µl each of 
KpnI and HindIII (all restriction enzyme used in this thesis were supplied by Roche) in 
total volume of 25µl. Digestion reactions were incubated at 37°C for a minimum of an 
hour and analysed by 1% agarose gel electrophoresis. Correctly sized inserts were 
identified by comparison with known molecular weight markers under UV light. 
Two plasmids containing correctly sized inserts were sent for gene sequencing 
(Cogenics Inc. ) using the pGEM primers M13 forward and M13 reverse, which flank 
the insert. Only plasmids of confirmed, correct sequence were then used for further 
sub-cloning. 
2.3.8 Expression vector preparation 
The pTrcHisB-HPR construct was digested to remove the original GRHPR coding 
region and prepare it for the insertion of the modified version. This was done by 
KpnIlHindlII double digestion on a 15µ1 aliquot of pTrcHisB-HPR in a total volume of 
20µl. Digestion occurred over an hour at 37°C, after which calf alkaline phosphatase 
(CAP) was added to catalyse the removal of 5' phosphate groups further preventing 
recircularisation. Digested and phosphatased vector was electrophoresed through a 1% 
agarose gel and a linear, vector sized band was identified, excised from the gel and 
purified away for the gel by the Quick Gel Extraction Kit. To provide insert, pGEM- 
Teasy containing the PCR product was treated in the same fashion, leaving out the 
phosphatase step and gel purifying the insert sized band. Care was taken to avoid 
excessive UV exposure and excise only the required DNA band. 
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Ligation and transformation was implemented as described for pGEM-Teasy (sections 
2.3.4 and 2.3.5). Briefly, linearised pTrcHisB vector was mixed with digested insert in 
a 1: 6 ratio (0.5µ1: 3µ1) and T4 ligase (lµl). After overnight incubation at 4°C, 2µl of 
ligation mix was transformed into the E. cola expression strain Rosetta (Novagen). Due 
to resistance of this strain to chloramphenicol these transformants were given 30 
minutes at 37°C to recover in the absence of antibiotics. The entire transformed cell 
mix (100µl) was then spread on LB agar plates containing ampicillin and 
chloramphenicol (34gg. ml"'). Large colonies present after overnight growth at 37°C 
were selected and the presence of the insert confirmed by double digestion as described 
in section 2.3.7. The thrombin cleavable construct will be referred to as pTrcHisB-T- 
GRHPR from here on and its expression product as T-GRHPR. 
2.3.9 Cell line storage 
For short term storage and direct use, transformed bacterial cell lines were streaked 
onto LB/agar plates containing appropriate antibiotics. These plates provided a source 
of individual colonies and were stored at 4°C for a maximum of one week, before being 
re-streaked onto fresh plates. Cells for long term storage were first grown as 10ml LB 
broth cultures at 37°C overnight. A 0.7ml aliquot of these cells was mixed with 0.3ml 
of 50% sterile glycerol and stored at -80°C. 
2.3.10 Expression tests and scaleup 
A single colony was picked using a sterile toothpick and used to inoculate a 10ml LB 
broth culture containing appropriate antibiotics. After overnight grown at 37°C with 
shaking (300rmp), lml of this was used to inoculate a 100ml LB culture. Growth of 
this culture at 37°C was monitored by optical density (OD) measured at 600nm 
(Lambda 25 spectrophotometer, Perkin Elmer). Upon reaching an OD of 
approximately 0.6, a 5ml sample was taken (uninduced) and recombinant protein 
expression induced in the remainder by the addition of IPTG to a final concentration of 
1mM. Induced 5ml samples were taken at 1 hour time points for the following 5 hours 
and again after overnight expression. All samples were centrifuged (5,000g, 10 
minutes), the supernatant discarded and the pellet frozen at -20°C. 
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Each cell pellet was resuspended in 500µl phosphate buffered saline (PBS) and 
sonicated (VibraCell sonicator, Sonics) using a micro tip. Sonication was performed at 
an amplitude (Ampl) of 35% for 3x 15 second bursts with samples kept on ice 
throughout. A lOµ1 sample of total protein was taken prior to the remainder being 
centrifuged (18,000g, 10 minutes) to separate soluble from insoluble, with a subsequent 
20µl sample of the soluble supernatant being taken. Recombinant protein expression 
was analysed on 12% Sodium dodecyl sulphate Polyacryliamide Gels (SDS-PAGE). 
Both samples had SDS sample loading buffer (30% glycerol, 5% SDS, 50mM EDTA, 
50mM Tris-HCI pH 7.0,5% ß-mercaptoethanol) added (3: 1 ratio) and were heated to 
100°C for 5 minutes before SDS gel loading. Electrophoresis was run at 180V for 60 
minutes, after which gels were coomassie stained (25% ethanol, 10% acetic acid, 
0.25% w/v Coomassie Blue) and destained (20% ethanol, 5% acetic acid) to allow 
visualisation of protein bands. Recombinant protein was identified by comparison to a 
simultaneously run molecular weight marker (Sigma). All protein gels were 
undertaken in an identical manner. 
Large scale expression proceeded in 1L LB media and was largely the same as for trial 
expressions, except the entire 10ml overnight culture was used to inoculate the litre. 
After protein expression had been induced for the appropriate length of time, bacterial 
cells were pelleted by centrifugation (5,000g, 5 min, Sorvall RC6), resuspended in 
40m1 PBS and re-centrifuged (5,000g, 10 min, Sorvall Legend RT). These cell pellets 
could be stored at -20°C until required. 
2.3.11 Nickel affinity purification 
The expression of recombinant protein with a hexa-His tag allows for a quick and easy 
first purification step due to the tight, reversible affinity of the tag for nickel (Ni2) 
(Schmitt, Hess and Stunnenberg, 1993). To purify recombinant T-GRHPR, a large 
scale expression cell pellet was resuspended in 30m1 GR Nickel Loading Buffer 
(20mM Tris-HC1 pH 8.5,500mM NaCl, 20mM imidazole, 10% glycerol, 1mM ß- 
mercaptoethanol) with an EDTA-free protease inhibitor (Roche). Cell disruption was 
accomplished by sonicating the resuspension on ice at 60% Ampl, for 5x 20 second 
bursts using the standard probe (VibraCell, Sonics). A 20 second pause between each 
burst was used to prevent sample overheating and potential protein denaturation. Cell 
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debris and insoluble proteins were pelleted by centrifugation at 15,000g for 25 minutes 
(Sorvall RC6). A 5m1 HiTrap Ni2+ affinity column (Amersham Biosciences) was 
freshly charged with Ni2+ and equilibrated in buffer, according to manufacturers 
instructions. The clarified supernatant was loaded onto this column manually at 
approximately 2ml. min I using a 20ml syringe. The flow through was retained and the 
column attached to an AKTA purifier. At a flow rate of lml. min 1,5 - 10 column 
volumes (CV) of Loading Buffer (or until a flat A28Q, m reading was achieved) was used 
to wash non-specifically bound protein from the column. Bound protein was then 
eluted over a 0.02M - 1M gradient of imidazole at a flow rate of lml. min' and lml 
fractions collected. Fractions corresponding to A280m peaks were kept, analysed by 
SDS-PAGE and those containing recombinant protein pooled. 
2.3.12 Measuring protein concentration 
The amount of protein present in the pooled sample was measured by absorbance at a 
wavelength of 280nm (Lambda 25 spectrophotometer, Perkin Elmer). Because the low 
grade imidazole used in the purification contains contaminants that also absorb at this 
wavelength, an appropriate blank was always used. The predicted molecular weight of 
T-GRHPR (40,651 Da) and its theoretical extinction coefficient (29450 M"'cm) were 
both calculated with Protparam (Expasy; http: //ca. expasy. org) and used to estimate 
protein concentration using the Bear-Lambert equation (A = c. l. c). 
2.3.13 Removal of the poly-His tag 
To facilitate removal of the tag, lOU of thrombin (Amersham Biosciences) were added 
per mg of recombinant protein. The mixture was left for 16hrs at 18°C to ensure 
complete cleavage. The digested protein was then buffer exchanged into GR Nickel 
Loading Buffer by rounds of dilution and subsequent concentration using a lOkDa cut- 
off Vivaspin concentrator (Vivascience). This was passed through a HiTrap Ni2+ 
affinity column connected directly to a lml Benzamidine column (Amersham 
Biosciences). The Ni2+ column bound any uncleaved protein (T-GRHPR) and free tag, 
while the Benzamidine column removed the thrombin. The flow through contained 
cleaved GRHPR and was retained for further purification. 
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2.3.14 Gel filtration 
The resulting GRHPR was buffer exchanged into GR Gel Fil. Buffer (20mM Tris-HC1 
pH 8.5,100mM NaCl, 1mM ß-mercaptoethanol) and concentrated (Vivaspin 10 kDa 
MWCO, Vivascience) to approximately 0.5m1. Gel filtration was run on a pre- 
equilibrated HiLoad 16/60, Superdex 75 prep grade column (Amersham Biosciences) 
run at 0.3ml. min' and 2m1 fractions were collected. Those corresponding to A28 0,, m 
peaks were kept and analysed by SDS-PAGE, with those containing pure recombinant 
protein pooled and used in all further studies. The predicted molecular weight of 
GRHPR (35,826 Da) and its theoretical extinction coefficient (27960 M-'cm) were 
used for protein concentration calculations. 
2.3.15 GRHPR crystallisation 
Purified GRHPR was buffer exchanged into 20mM Tris-HC1 pH 8.5 with 1mM ß- 
mercaptoethanol by 3 rounds of 20-fold dilution and concentration (Vivaspin 10 kDa 
MWCO, Vivascience). A final protein concentration of 5.5 mg. ml'', as calculated by 
A280 readings was achieved and used in crystallisation trials. All crystallisations were 
performed by the vapour-diffusion method. 
2.3.15.1 Initial crystallisation screens 
GRHPR, like other D-2-hydroxyacid dehydrogenases was expected to be able to form 3 
different enzyme: ligand states; apo - no ligands, binary - just co-enzyme bound and 
ternary - co-enzyme and "substrate-like" molecule. Crystallisation trials were 
implemented in attempts to crystallise all 3 states. Concentrated protein was incubated 
on ice for 30 min with either just nicotinamide adenine dinucleotide phosphate 
(NADPH, Sigma) or NADPH and di-sodium oxalate (Sigma). Additionally, two 
different concentrations of these were tried. Table 2.1a lists the different protein: ligand 
combinations set up in attempts to produce the 3 different states. These incubations 
were then centrifuged (18,000g, 5min) prior to the crystal tray set up. Initial crystal 
screens were established as sitting drop vapour-diffusions in 96-well plate format 
(Intelli Plate, Hampton Research) using a number of commercially available crystal 
screens (Table 2.1b). 
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a) 
Crystal State Co-enzyme "Substrate-like" 
Apo - - 
Binary 2mM NADPH - 
Binary 0.2mM NADPH - 
Ternary 2mM NADPH 5mM di-sodium oxalate 
Ternary 0.2mM NADPH 0.5mM di-sodium oxalate 
b) 
Crystal Screen Manufacturer No. of conditions 
Crystal Screen (CS) I and II Hampton Research 96 
PEG/Ion Screen Hampton Research 48 
CS Lite Hampton Research 48 
JBScreen 1- 4 Jena Bioscience 96 
JBScreen 5-8 Jena Bioscience 96 
JBScreen 9 and 10 Jena Bioscience 48 
Table 2.1 Crystallisation screening for three GRHPR states. 
a) protein: ligand combinations set up during the screening process, b) commercial screens used for initial 
condition screening. 
To set up the screens, 8-channel pipettes were used to allow entire columns to be done 
simultaneously. This minimised the length of time each drop was exposed to the air 
and therefore decreased evaporation. Firstly, 50µl of screen solution mother liquor was 
transferred to the reservoirs. Then using an electronic 8-channel pipette, a1 t1 air gap 
was aspirated, followed by 2µl of protein `complex' and finally 2µl of reservoir 
solution. This was then dispensed in to the upper sample well of the crystallisation 
plate, with the air gap ensuring all liquid was expelled. No manual mixing of the drops 
was performed. The plates were sealed (ClearSeal Film, Hampton Research) and left to 
equilibrate at 18°C for at least 48hrs before being inspected for crystal growth with a 
light microscope (Wild MZ8, Leica). The plates were subsequently re-checked 
regularly. 
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2.3.15.2 Crystal optimisation 
Screen conditions containing successful `hits' - defined as the presence of birefringent 
`crystals' or phase separation - were selected for further screening in an attempt to 
produce improved crystals. Screen conditions were used as a starting point around 
which the precipitant concentration and buffer pH was varied. During optimisation, the 
buffer pH was altered by 0.5 (initial) and 0.25 (fine screening) pH units, salts were 
varied in 0.05M steps and polyethylenglycols (PEGs) in 2% w/v alterations. 
Optimisation was attempted in VDXTM pre-greased 24-well plates (Hampton 
Research), using the hanging drop vapour diffusion method. To begin with, 700µl of 
optimisation mother liquor was transferred to the reservoir, with 2µl pipetted onto the 
centre of an OptiClear PlasticTM cover slip (Hampton Research). Next, 2µl of the 
protein `complex' was pipetted directly onto the mother liquor drop, the cover slip 
carefully inverted and sealed over its corresponding reservoir. As with the screens, 
these plates were left to equilibrate at 18°C for at least 48hrs before being inspected for 
crystal growth. 
Further improvement of selected conditions was attempted using the Additive Screen 
(Hampton Research). Here, a 24-well plate is used to screen a single mother liquor 
condition using the addition of a small amount of various ions, salts, organics and 
chaotropes. This was set up following manufactures' instructions, with identical 
reservoir solutions and 2µl protein/2 tl reservoir/0.2µl additive drops. Volatile 
additives were added in a 1: 10 ratio to the reservoir solution and drops set up directly 
from this. 
2.3.15.3 Seeding 
Both seeding and streaking (below) are a method of introducing nucleation points into a 
crystallisation condition that may not produce them on it own. It provides a mechanism 
to separate favourable crystal growth conditions from favourable crystal nucleation 
conditions, and can dramatically improve crystals. These techniques were only applied 
during apo protein crystallisation. 
Crystal seeds were created using the Seed Bead Kit (Hampton Research) following the 
manufacturers' instructions. Briefly, the Seed Bead Kit consists of a microcentrifuge 
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tube containing a small ball, the seed bead. As the apo crystals were quite small, a 
number of them were selected and transferred to a large drop (5µl) of their mother 
liquor. This was pipetted into the seed bead tube with another 40µ1 of their mother 
liquor. Where the drop had been was rinsed with a further 5µl to make sure all crystals 
had been transferred, giving a total final volume of 50µl. The tube was then vortexed 
for 90 seconds, allowing the seed bead to crush the crystals. This provided the "seed 
stock" and was further diluted with mother liquor from the original condition as 
needed. Seeding was initially undertaken using the Phoenix nanolitre robot (Art 
Robbins Instruments) into Structure Screen I and II HT-96 and PACT premierTM HT- 
96 screens (Molecular Dimensions Limited, MDL). This was based on the robotic 
seeding method of D'Arcy, Villard and Marsh, (2007). Seed stock dilutions of 10- and 
200-fold were used. The screen was set up at with 3.5mg. ml' of GRHPR, using a 
1: 2: 3 ratio of seed solution, reservoir and protein (0.1µ1: 0.2µ1: 0.3µ1). The 96-head first 
deposits 50µ1 reservoir solution then the 0.2µl sitting drop. This is followed by the 
nano-head adding the protein (0.31il) then the seed solution (O. 1µ1), with extensive 
washing between. Promising hits were then further screened by manually setting up 
hanging drops with the same 1: 2: 3 ratio (0.6µ1: 1.2µ1: 1.8µ1) and seed dilutions of 10- 
and 50-fold. 
2.3.15.4 Streaking 
Streaking is attempted where supersaturation of the drop has occurred but spontaneous 
nucleation cannot. This is known as the metastable zone. To find this zone, the 
condition that produced the best apo crystal was selected and re-screened over a 
stepwise reduction in protein or precipitant concentration. Each new condition was 
prepared as triplicate hanging drops to allow for seed dilution by sequential streaking. 
These drops were allowed to equilibrate for 24hrs and only those conditions that 
produced predominantly clear drops were then streaked. Streaking was done using a 
cats whisker. This was first touched to a "best of the bad" apo crystal where it picked 
up minuscule fragments (nucleation seeds) and then successively pulled through the 3 
`dilution' drops. The streaked drops were re-sealed over their reservoirs and the 
whisker rinsed in MilliQ water to remove mother liquor and excess seeds. The process 
was then repeated for the next condition. 
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2.3.16 Diffraction data collection 
All diffraction testing and data collection were undertaken at 100 Kelvin (K) using a 
synchrotron source of X-rays, either at the UK Daresbury SRS, Warrington or 
Diamond Light Source, Didcot. Cryosolutions for crystal freezing were made using the 
same reservoir conditions that the crystal came from including, where appropriate, 
additives, co-enzyme and inhibitor. A range of glycerol concentrations within the 
cryosolution were tested to find the lowest concentration which produced a clear, 
glassy drop upon freezing. Using a crystal pin (Hampton Research or Spine) with a 
nylon loop of similar size to the crystal, a visually good crystal was selected and 
transferred from its drop into a drop of cryosolution. The crystal was then instantly re- 
looped and placed on the goniometer head in the path of a 100 K cryostream, ready for 
X-rays. Cryocooling crystals prior to data collection is known to reduce the problem of 
radiation damage and is of particular importance at a synchrotron source (reviewed in 
Garman and Owen, 2006). Test diffraction images were taken at various angles, 
exposure time and detector distance to determine; a) if data from the crystal was worth 
collecting, b) what combination of time and distance produced the `best' resolution and 
c) was data at certain angles worse then others. Alternatively, the crystal was frozen on 
its pin by fast immersion in liquid nitrogen and transferred to a cold Dewar for storage 
or transport. 
2.3.17 Data processing 
The programs used for data processing in this thesis are incorporated into the HKL2000 




2.3.17.1 Data indexing and integration LIBRARY 
The position of diffraction peaks are dictated by the unit cell and Bravais Lattice of the 
crystal and therefore their accurate identification is required for the determination of 
correct cell parameters. The program Denzo was used to automatically pick a small 
number (70 - 100) of spot positions. The accuracy of these picks was inspected by eye 
in the XDisplayF program, with some manual intervention for spot removal or addition 
where deemed necessary. Where multiple lattices were present efforts were made to 
only select stronger peaks, being from the major lattice. Rounds of refinement in 
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Denzo, initially in the primitive triclinic (P1) lattice, improves spot position leading to 
an improvement in cell parameters. This was done across a 3D window of 5 frames 
which was found to help with selection of the predominate lattice. Additionally, the 
areas designated to define the spot and the local background were visually inspected. 
Where necessary the size of these areas were altered to avoid including excess 
background in the spot region (spot size) and avoid nearby spots being included in the 
background definition (box size), maximising the signal to noise ratio. After 
refinement statistics stabilised, the Bravais Lattice table was inspected. Here, the spot 
positions are distorted to fit the parameters for each lattice type. The Bravais Lattice 
with the highest symmetry and requiring only minimal distortion was selected. Further 
rounds of refinement apply this lattice to the data and visual inspection is used to 
confirm spots are still being correctly picked. 
A profile fitting radius was defined to include approximately 50 reflections across the 
3D window. As the data is integrated the radius helps determine accurate diffraction 
intensities for each spot, as the profiles of each reflection are compared to other nearby 
spots. 
2.3.17.2 Scaling 
Integration of each reflection is done on an arbitrary scale, therefore scaling is 
performed to put the intensities of reflections with the same index on the same scale. 
This is important as effects such as the variable diffracting ability of the crystal in 
different orientations can alter the intensity of reflections across frames. Multiple 
rounds of scaling are implemented to refine the intensities (ScalePack). An error model 
is used to estimate the systematic errors in each resolution shell. This is adjusted using 
improved estimates, outputted as the linear R-factor in the ScalePack log file. The 
scale factor error value is also altered to produce an overall Chi2 value near 1.0. 
Additionally, the data was defined to extend to the lowest resolution shell where the I/a 
(intensity/error) is approximately 2. Data beyond this point was not used. Scaling 
results in a list of the positions (hk1 indices) and intensities of reflections, giving a 
complete description of the diffraction data. 
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2.3.18 Molecular Replacement 
Molecular replacement was accomplished using programs from the Collaborative 
Computational Project 4 suite (1994, CCP4). Data from ScalePack was first converted 
in CCP4 mtz format, using ScalePack2mtz. An mtz file contains hkl indices, intensity 
information, observed structure amplitudes (Fobs), a list of reflections and FreeR flags 
(for refinement analysis). To determine the number of protein monomers in the 
asymmetric unit (AU), the Matthews Cell Content Analysis program was used. This 
produces a Matthews coefficient and calculates the percentage solvent content of the 
asymmetric unit based on the monomeric molecular weight of the protein. The most 
likely number of monomers present can then be determined. Phaser version 1.3 
(Storoni, McCoy and Read, 2004) was used to carry out the molecular replacement. 
Phaser works by taking a model of reasonable sequence homology (greater then 25%) 
and using maximum likelihood to determine its rotation and translation function. 
Probability statistics are used to select the most likely solution, where a "Z-score" 
(number of standard deviations above the mean value) of greater then 6 indicates a 
`possible' solution. The solution is also refined by calculating and improving the Log 
Likelihood Gain (LLG), which measures how much better the data is predicted by the 
model as opposed to a random collection of the same atoms. This should increase as 
the model is improved and explains more of the data. Potential atom clashes within the 
solution can also be allowed for. 
2.3.18.1 Molecular replacement of the ternary data 
Only one protein structure was available with high enough sequence identity to be used 
in molecular replacement for the human GRHPR, the H. methylovorum D-glycerate 
dehydrogenase (Goldberg, Yoshida and Brick, 1994). This has a sequence identity of 
34% and was available in the Protein Data Bank (PDB; http: //www. rcsb. org) under the 
code 1 GDH. This crystal structure had been solved in the apo form and contained a 
dimer in the asymmetric unit. Non-protein atoms (water and sulphate ions) were 
deleted from this file and searches were executed using either the dimer or one 
monomer chain as the search model. Further searches treated the two distinct domains 
known to be present in this family of enzymes - the substrate-binding domain, residues 
1 to 99 and 291 to 321, and the coenzyme binding domain, residues 100 to 290 
(numbering as in 1GDH) - as separate search models. 
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2.3.18.2 Molecular replacement of the apo data 
The successful solution of the human GRHPR structure allowed this to be used as the 
molecular replacement model for the apo data. To minimise bias in the domain 
positions in the model, the substrate-binding domain (5 - 105,300 - 328, numbering as 
in the human sequence) and the coenzyme binding domain (108 - 297) were used in 
separate sequential searches. Again, all non-protein atoms (water, sulphate ions and 
ligand atoms) were deleted from the ternary file prior to its use in molecular 
replacement. 
2.3.19 Model building and refinement 
Once a molecular replacement solution is found, theoretical structure factors can be 
calculated based on this model (Fcaic). Electron density maps are calculated by Phaser 
(and later by Refmac5) based on the differences between the Fobs (Fo) and Fcaic (Fc) and 
include phase information estimated from the model. Two maps are produced to assist 
in improving the model so that it explains the data better. The difference map (Fo-Fc) 
shows areas where atoms need to be added (positive density) and areas were model 
atoms need to be removed (negative density). As phase information is calculated from 
the model, density tends to be biased towards reproducing the model. A 2Fo-Fc map 
reduces this bias by strengthening the importance of the observed amplitudes and was 
used during model building. In these studies, visualisation of the maps and manual 
model alterations were performed in Coot (Emsley and Cowtan, 2004). Here the model 
was altered by the realignment of backbone atoms and the mutation and reorientation of 
side chains to better fit the density maps. During final stages of model building, ligand 
atoms, waters and other ions were also added where appropriate. 
Interspaced with model building were rounds of refinement. This refines the model 
coordinate positions in an attempt to reduce the difference between the Fobs and Fcaic. 
As the model now matches the data closer, improved density maps can be generated. 
These were fed back into model building for further improvements. The program 
Refmac5 (Murshudov, Vagin and Dodson, 1997) from the CCP4 suite was used for 10 
cycles of restrained refinement after each stage of model building, outputting the 
refined model and both density maps. Where required, restraints were added to the 
32 
refinement process to ensure the root mean square (RMS) deviation of bond angles and 
lengths were retained at reasonable values. Furthermore, non-crystallographic 
restraints were used during early refinement to ensure that initially identical protein 
chains did not vary. Restraints were gradually loosened as the maps improved when 
the loosening had a positive effect on the R values. For a final round of refinement, the 
Translation/Libration/Screw (TLS) Motion Determination server 
(http: //skuld. bmse. washington. edu/-tlsmd; Painter and Merritt, 2006) was used to 
create a number of TLS groups for each monomer. This divides the protein chain into 
multiple fragments (groups) and models each as a rigid body undergoing vibrational 
motion. This produces a modified structure model file containing the TLS group 
definitions and a TLS tensor file. This is then refined in Refmac5. In addition, 
simulated annealing was attempted using the Crystallography and NMR System (CNS) 
software. However this proved ineffective in reducing the R values. 
The success of refinement is shown by the convergence between the Fobs and FCaic, 
measured by the RAS,. Additionally, an Rfr,, is calculated from a subset (5%) of 
reflections not used during the refinement, providing an unbiased measure of model 
improvement. Once the R values, particularly the RfrC,, stopped decreasing the model 
was considered fully refined. 
Unless otherwise stated all protein superpositions were undertaken using the function 
implemented in CCP4mg (Potterton et al., 2002) and figures were made in PyMOL 
(DeLano, 2002). 
2.3.20 Validation 
During refinement the model was analysed by the inbuilt validation tools in Coot and 
later by SFCHECK (Vaguine, Richelle and Wodak, 1999) or MolProbity (using the all- 
hydrogen option, Davis et al., 2007). Ramachandran outliners and bad rotamers were 
identified and improved. Any changes were followed by refinement of the new model. 
2.3.21 Mutagenesis 
Specific mutants were made in an effort to test the effect, via kinetic studies, of single 
amino acid changes on the substrate specificity of GRHPR. Mutations were created 
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using the QuickChange® Site-Directed Mutagenesis Kit (Stratagene). Primers were 
designed for each mutation; 29bp in length, starting and ending in a cytosine (C) or 
guanosine (G) and with the codon to be altered in the middle (Table 2.2). The mutant 
codon was selected so as to require the minimal change from the original. 
Site Primer Sequence 










Table 2.2 Primers used in mutagenesis of GRHPR. 
In all cases reverse primers are the complement of the forward. 
The PCR reactions for each mutant were undertaken separately and consisted of 2.5U 
PfuTurbö DNA Polymerase, Ix Reaction Buffer, lµl dNTP mix (all supplied in the 
kit) and the forward and reverse primers (125ng of each). The pTrcHisB-T-GRHPR 
(50ng) was used as the template and the final reaction volume of 50µ1 was made up 
with Elgastat water. The PCR cycling protocol was implemented as in Table 2.3. 
Temperature Time No. of rounds 
Initial DNA denaturation 95°C 30 seconds 1 
Denaturation 95°C 30 seconds 
Annealing 55°C 1 minute 16 
Amplification 68°C 5 minutes 
Hold 4°C Indefinite 
Table 2.3 PCR protocol used during site directed mutagenesis of GRHPR. 
Following PCR, IOU of the methylation specific restriction enzyme DpnI was added to 
the reaction. This was incubated at 37°C for an hour, during which time the original 
template DNA is digested leaving only the mutated strands for transformation. A 10 
aliquot of the DpnI digested mix was transformed into 50gl of XL1-Blue 
Supercompetent Cells (Stratagene) as described in section 2.3.5. Transformed cells 
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grew overnight at 37°C on tetracycline (IOµg. m1-')/ampicillin LB agar plates. A 
number of resulting colonies were selected, grown as 10ml liquid cultures and the 
plasmid purified. The successful incorporation of the mutations was confirmed by 
sequencing using the pTrcHis sequencing primers, pTrcHisF(orward) and R(everse) 
(Cogenics Inc). Additionally, the double mutant L59V/S296A was made by 
performing the same procedure using the S296A primers and an already confirmed 
L59V mutated plasmid as the template. Plasmids containing the correct mutation were 
then transformed into E. coli Rosetta, with expression and purification performed as for 
the native protein. 
2.3.22 Kinetics 
2.3.22.1 Native GRHPR 
The enzyme activity was calculated by observing the change in absorbance at 340nm 
(Perkin Elmer spectrophotometer) due to the breakdown of the cofactor NADPH (or 
NADH) (c = 6220M-l. cm 1). All assays (triplicates) were run in 100mM potassium 
phosphate buffer pH 7.5,37°C, with a final volume of 1mL. Substrates and cofactors 
were made up as required in the same buffer. The concentration of the cofactor 
(NADPH or NADH) was kept at 0.3mM in all assays and the substrate concentration 
was varied. Glyoxylate was varied from 0.02mM - 1mM, and hydroxypyruvate from 
0.02mM - 0.5mM. Lineweaver-Burk plots (1Napp VS. 1/[substrate] as described by the 
equation below (Mathews, van Holde and Ahern, 2000), were used to determine the KM 
and Vm. of the reaction, where VaP' is µmoles of NADH or NADPH consumed per 
minute. 
1 1KM 11 
`Tapp LVmajLSJ 3 Vmax 
2.3.22.2 GRHPR Mutants 
The kinetic studies of the mutant proteins were performed largely as for the native 
protein, except a 96-well UV spectrophotometer (Versamax, Molecular Devices) was 
used controlled by the SOFTmaxPro software. All assays were attempted with 
NADPH at 0.3mM in a final volume of l00µ1. All potential substrates (glyoxylate, 
hydroxypyruvate and pyruvate) were varied from 100mM - 0.02mM. 
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Chapter 3 The structure of human GRHPR in 3 states 
3.1 Chapter overview 
This chapter describes the modification of the GRHPR expression vector, protein 
purification and subsequent crystallisation of the ternary, binary and apo states of this 
enzyme. Structure solution and refinement are described, followed by a discussion of 
the overall protein structure. Differences between the ternary and apo structures are 
discussed and comparisons made with the structures of related proteins. As the ternary 
structure of GRHPR represents the first structure of a D-2-hydroxyacid dehydrogenase 
family member to be solved as a true ternary complex, the model of substrate binding 
and stereospecificity for this family can be confirmed and is discussed. This chapter 
will include the proposition of a structure based model explaining the known substrate 
specificity of this enzyme, which is further discussed in Chapter 4. Finally, the chapter 
will conclude with an explanation of the potential effects of known PHII mutations. 
The structures of the human GRHPR ternary and binary states produced during this 
thesis have been published (Booth et al., 2006) and is listed in Appendix 1. 
3.2 Results 
3.2.1 Molecular biology 
3.2.1.1 T-GRHPR vector construction 
The originally supplied GRHPR expression vector (pTrcHisB-HPR) resulted in the 
production of protein with a large N-terminal tag. This was likely to be detrimental for 
crystallisation, so PCR was used to insert the nucleotide sequence of the thrombin 
recognition site directly prior to the initial methionine of the GRHPR enzyme. The 
PCR product was electrophoresed through 1% agarose gels to separate the product 
from free dNTPs, primers and template. Figure 3.1a shows the result of the PCR, 
visualised due to the intercalation of the EtBr with the DNA producing UV 
fluorescence. After gel extraction and ligation into pGEM-Teasy, transformation into 
E. coli Nova Blue was carried out and the subsequent agar plates checked for white 
colonies. As expected, only 2 or 3 colonies were present on the negative control plate 
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and all were blue. This both indicates the absolute requirement of NovaBlueTM cells 
for ampicillin resistance provided by the vector and suggests that some pGEM-Teasy 
may be able to re-circularise, or is present in circular form in the commercial product. 
The agar plates from the PCR ligation showed approximately 50 colonies, of which less 
than 10 appeared blue. A number of white colonies were selected, recombinant 
plasmid DNA purified and digested to confirm the presence of the insert (Figure 3.1b). 
Vectors containing insert of the correct size were sequenced to establish that no 
mutations had been created during PCR. A sequenced insert was subsequently ligated 
into linearised pTrcHisB. The transformation of this into E. coli Rosetta produced a 
single colony. Again, recombinant plasmid DNA was prepared and digested 
confirming the creation of the pTrcHisB-T-GRHPR expression vector (Figure 3.1 c). 
3.2.2 Purification 
The E. cola Rosetta strain contains the pRARE plasmid which provides the strain with 
extra tRNAs for codons rarely used in E. coil genes but more common in human genes. 
This makes it an excellent bacterial expression host for many human proteins. Small 
scale expression trials showed that the minor change to the vector and the change in 
host, compared to that already published (Rumsby and Cregeen, 1999), had had no 
detrimental effect and soluble protein was being produced (results not shown). 
Initial purification of soluble T-GRHPR was carried out using standard Ni2+ affinity 
chromatography. Once bound to the affinity column and non-bound protein had been 
washed off, a shallow gradient of imidazole (20mM - 200mM) was used to elute the 
recombinant protein and separate it from any non-specific/weakly bound proteins. The 
elution profile of the protein was tracked by A280 measurements. The principal peak 
elutes between imidazole concentrations of 150mM and 200mM and is preceded by a 
considerably smaller shoulder peak (Figure 3.2). Analysis by SDS-PAGE indicates 
that the major peak is comprised predominantly of recombinant GRHPR, which has a 
monomeric molecular weight of 40kDa (Figure 3.3). The shoulder peak contains 
proteins non-specifically bound to the affinity column but the GRHPR peak is largely 
pure with some contaminating proteins present at around 24kDa. Fractions containing 
this largely pure T-GRHPR were pooled and carried through to the next purification 
step. 
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Thrombin digestion was carried out overnight on those fractions deemed of acceptable 
purity. Scrutiny by SDS-PAGE of a cleaved aliquot showed no uncleaved recombinant 
protein (not shown). Purification proceeded via Ni2+ affinity and benzamidine 
columns, connected in series. The Ni2+ column further purified the sample by 
removing any remaining (if negligible) uncleaved T-GRHPR and some of the non- 
specific proteins while the benzamidine column removed the added thrombin (Figure 
3.4). 
Concentration of the resulting flow through and buffer exchanging prepared the now 
tag-less GRHPR for final purification by Superdex 75 gel filtration chromatography. 
By concentrating the sample to a small volume (0.5m1) and running the column slowly 
(0.3ml. min') a high degree of resolution could be achieved. The UV absorbance (A280) 
trace shows a large, symmetrical peak which corresponds to an elution volume of 
56.5m1 (Figure 3.5) and purified GRHPR (Figure 3.6). By previously running a 
number of know molecular weight standards down the column, an equation had been 
produced correlating the elution volume to the log of the molecular weight of the 
protein. This equation is given below and is used for all further volume to molecular 
weight conversions for the Superdex 75 gel filtration column: 
logMr = -1.4758(Velution/Vvio) + 6.8879, where Vviod= 41 
Consequently the elution volume corresponds to a molecular weight of approximately 
7lkDa and confirms the dimeric nature of GRHPR (predicted 72kDa) in solution. 
Inspection of the GRHPR on SDS-PAGE indicates a greater the 95% purity, making it 
suitable for crystallisation trials. Purified protein could be stored at -20°C for long 









Figure 3.1 Aga rose gels of T-GRHPR vector construction. 
1% agarose gels of, Lane I) DNA ladder with relevant sizes indicated, A) PCR product T-GRHPR (2), 
B) pGEM-Teasy digestions from selected white NovaBlueTM cells. The integrity of these inserts was 
confirmed by DNA sequencing, with one being selected to be cloned into pTrcHisB (4.4kbp), C) double 
digestion of final pTrcHisB-T-GRHPR vector showing presence of insert (2). All show the correct sized 


































Figure 3.2 Nickel affinity chromatography trace of heia-His tagged T-GRHPR. 
The elution of protein was detected by absorbance at 28Onm and the solid line corresponds to fractions 







Figure 3.3 SDS-PAGE of the nickel affinity purification of His-T-GRHPR. 
His-T-GRHPR 
First step purification of the thrombin cleavable, poly-His tagged GRHPR. Lane 1 contains molecular 




Figure 3.4 Thrombin cleavage of His-T-CRHPR. 
His-T-GRHPR 
GRHPR 
SDS-PAGE gel of the thrombin cleavage and subsequent purification to remove the poly-His tag from 
GRHPR. Lanes; 1) molecular weight markers, 2) His-T-GRHPR from Figure 3.3,3) GRHPR after His- 
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Figure 3.5 Size exclusion chromatography trace of human GRHPR. 
e 
120 140 
Cleaved protein from Figure 3.4 was concentrated and further purified via size exclusion 
chromatography. The elution of protein was detected by absorbance at 280nm and the solid line 
corresponds to fractions shown in Figure 3.6. The star indicates the peak point corresponding to a 
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Figure 3.6 SDS-PAGE of size exclusion chromatography of GRHPR. 
Final purification of human GRHPR; lane 1) molecular weight markers. Other lanes correspond to 
fractions marked with a solid line in Figure 3.5. 
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3.2.3 Crystallisation 
Extensive crystallisation screening was carried out in an attempt to find the best 
conditions for each of the 3 different enzyme states. Fresh protein was concentrated to 
5.5mg. m1"' and 96-well, sitting drop vapor diffusion plates set up. The appearance of 
crystals was noted after 1-2 weeks. Those conditions that produced the best 
appearing crystals for each enzyme state are listed in Table 3.1. Over all the hits, 
neutral pHs (6.5 - 7.5) dominated as did high molecular weight PEGs (8K and 20K). 
The crystals all had a similar, plate-like appearance and often occurred coincident with 
light to medium precipitant (Figure 3.7). Many hits were tested for their diffraction 
ability at the Daresbury synchrotron, and this was used as an important guide for 
choosing those conditions to further screen. In the case of the ternary state CS Lite hit, 
a data set of reasonable quality was collected from a thin crystal approximately 20011m 
by 500µm in size (Figure 3.7a). Further optimisation of these conditions was carried 
out as described in the methods but, for the ternary and binary forms, did not further 
improve crystal quality. Additionally, screens carried out with the higher 
concentrations of NADPH and oxalate (2mM and 5mM respectively) only produced 
very poor quality hits. As a comparison between the different states, it was noted that 
within the 96 conditions of Crystal Screen I and II (Hampton Research) the ternary 
complex produced crystallisation hits in 10.4% of conditions, the binary complex in 
8.3% and the apo form in 5.2%. 
Crystallisation of the apo state was also attempted using robot assisted seeding. Apo 
crystals produced from manual optimisation around the apo CS I hit (Table 3.1) were 
used to produce the seed stock. With seeding from the 10-fold seed dilution, a 9.4% hit 
rate was achieved across Structure Screen I and II HT-96 and 30% across PACT 
premier HT-96 (MDL). Hits occurred across a larger range of pHs (5 - 8) and in 
PEGs (1.5K and 6K) not seen without seeding. However, in no case had the overall 
crystal morphology changed from thin plates. Many of these hits were of sufficient 
size for diffraction testing, even though they came from small (0.6pl) drops. The 2 
conditions that produced the best crystals upon seeding are given in Table 3.2. Crystals 
from these conditions diffracted to a low resolution, however they could not be 
reproduced when manual optimisation was attempted. The best improvement of apo 
crystals came with lowering the protein concentration and streaking. This was largely 
concentrated around the CS I condition hit (Table 3.1). Initial fine pH, PEG and 
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magnesium screening resulted in reproducible crystals in 0.1M sodium cacodylate pH 
6.75,16% PEG 8K and 0.25M magnesium acetate tetrahyrate, which diffracted to 3.5A 
- 4A. Using this starting point and these crystals as the streak source, crystals were 
still produced even when the protein concentration had been lowered to lmg. m1''. 
Further improvements were made by lowering the PEG percentage in the streaked 
drops. In contrast, lowering the magnesium concentration resulted in heavy precipitant. 
The best crystal was eventually produced by streaking into drops setup with 3.5mg. ml' 
of GRHPR and 0.1M sodium cacodylate pH 6.75,10% PEG 8K and 0.25M magnesium 
acetate tetrahyrate as the mother liquor (Figure 3.7). 
Form Screen Buffer/pH Precipitant Salt/Additive 
Ternary CS Lite 0.1M sodium 15% PEG 8K 0.2M ammonium 
cacodylate H 6.5 sulphate 
JBS 1 0.1M HEPES pH 25% PEG 1K none 
7.5 
CS II 0.1M MES pH 12% PEG 20K none 
6.5 
Binary CS I 0.1M sodium 18% PEG 8K 0.2M calcium 
cacodylate H 6.5 acetate h drate 
CS II none 1.6M tri-sodium citrate none 
dehydrate H 6.5 
JBS 5 0.1M MES pH 10% PEG 20K none 
6.5 
Apo CS I 0.1M sodium 20% PEG 8K 0.2M 
cacodylate pH 6.5 magnesium 
acetate 
tetrahyrate 
JBS 1 0.1M MES pH 15% PEG 400 none 
6.5 
CS II 0.1M HEPES pH 1.6M ammonium 0.1M sodium 
7.5 sulphate chloride 
Table 3.1 Top 3 hits for each crystal form. 
The ternary and binary hits shown here are the result of crystal screens set up with the lower 




0.1M Bis-Tris-HC1 propane pH 6.5,0.2M sodium bromide, 20% 
w/v PEG 3350 
PACT premier" O. 1M Succinic acid, Phosphate, Glycine system pH 6.0,25% w/v 
PEG 1500 
Table 3.2 Top apo crystallisation conditions identified during seeding. 












Figure 3.7 Crystals of human GRHPR. 
Photographs of crystals relating to the top two conditions (left and right columns) given in Table 3.1; A) 
ternary, B) binary, C) apo. D) shows GRHPR apo crystals along the path of a streak. Final data came 
from the crystals indicated by arrows: A) Ternary; 5.5mg. m1-1,0.1 M sodium cacodylate pH 6.5,15% 
PEG 8K and 0.2M ammonium sulphate. D) Apo; streaking into 3.5mg. m1-', 0.1 M sodium cacodylate pH 
6.75,10% PEG 8K and 0.25M magnesium acetate tetrahyrate. The scale bar in the top left represents 
200µm and is applicable only to that crystal. The bar in the lower right represents 100µm and is 
applicable to the remaining photographs. 
44 
3.2.4 Data collection 
Many crystals were irradiated in order to find those with usable diffraction patterns. 
Due to the fragility of the crystals many cracked when looped from their drops and 
gave rise to smeared or multiple lattice diffraction patterns that could not be indexed. 
Others had an extremely long cell edge, resulting in poorly separated spots. 
Additionally, owing to the plate nature of the crystals, diffraction produced through the 
thin edge tended to be weaker and of lower quality. Test diffractions were used to 
determine the rotational position of this region so it was not included in early frames. 
Binary crystals never produced usable diffraction data. Below is given the collection 
strategies for those crystals that went on to produce the protein structures that will be 
discussed in this chapter. 
3.2.4.1 Ternary 
Despite extensive optimisation, the best data for the ternary crystal state came directly 
from the initial CS Lite condition (Table 3.1). Cryoprotectant for this crystal consisted 
of mother liquor (0.1M sodium cacodylate pH 6.5,15% PEG 8K and 0.2M ammonium 
sulphate), 0.2mM NADPH, 0.5mM oxalate and 30% w/v glycerol. X-ray diffraction 
data was collected at a wavelength (X) of 1.448A at the Daresbury SRS, Warrington, on 
PX beamline 14.1. Each diffraction image was the result of X-ray exposure for 20 
seconds through 0.5° oscillations. Image frames were collected with a Quantum 4 
charge-coupled device (CCD) detector (Area Detector Systems Corporation, ADSC) at 
a distance of 120mm from the crystal. A total of 319 images were collected, equating 
to 159.5°. Protein diffraction showed a marked decrease over the last 60 images. 
Example diffraction images are given in Figure 3.8. 
3.2.4.2 Apo 
The apo protein data was collected at the Diamond Light Source, Oxford, on beamline 
103, with %=0.95A. The crystal had been cryoprotected in mother liquor (0. l M 
sodium cacodylate pH 6.75,10% PEG 8K and 0.25M magnesium acetate tetrahyrate) 
with 30% w/v glycerol. Exposure to X-rays for 3 seconds through 1° oscillations 
produced usable data. A total of 360 diffraction images were collected with a Quantum 
315, a 3x3 CCD detector (ADSC) at a distance of 300mm. An example diffraction 
image is given in Figure 3.9. 
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Figure 3.8 Diffraction pattern from ternary CRHPR crystals. 
The upper image shows the data quality early in the collection, with the long cell edge evident by the 
closely spaced spots. The lower image shows the marked decrease in diffraction after 260 images 
(130°). 
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Figure 3.9 Diffraction pattern from the apo GRHPR crystal. 
The long cell edge is evident by the closely spaced spots. Unlike the ternary crystals, diffraction did not 
show a large decrease over the course of the collection. 
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3.2.5 Data processing 
3.2.5.1 Ternary data 
Despite the presence of what appeared to be a weakly diffracting secondary lattice, the 
automatic indexing procedure within Denzo (part of the HKL2000 suite, Otwinowski 
and Minor, 1997) easily picked the predominate lattice with minimal manual 
intervention. Unit cell parameters were initially refined in the PI space group with the 
expected long cell edge apparent. Visual scrutiny (in XDisplayF) indicated that the 
default "box size" used by Denzo was too large for the spot spacing, and was resulting 
in many spots being deemed `overlaps' and discounted. A significant reduction in box 
size and further refinement rounds lead to a large improvement in the refinement 
statistics, more accurate spot identification and a decrease in overlaps. Analysis of the 
Bravais Lattice table indicated a primitive monoclinic (P2) space group (Table 3.3). 
Subsequent rounds of refinement were carried out in the P2 lattice type to the edge of 
the detector. Predicted spot positions were seen to match the diffraction pattern 
closely. The data was then integrated in P2 and scaled using ScalePack. Systematic 
absences were noted on the k axis, indicating the presence of a screw axis (Figure 
3.10). This suggested the correct space group to be P21 and the data was reindexed as 
such. Due to later difficulties with molecular replacement, the data was reindexed and 
scaled using only the first 250 frames, removing those frames that showed a significant 
loss of diffraction. This resulted in improved scaling statistics and data that enabled the 
structure to be successfully solved. A final resolution of 2.2A was achieved, giving a 
completeness of 90.3% and an Rsym of 12.1%. All final scaling statistics are given in 
Table 3.5. 
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Lattice Metric tensor Best cell (symmeTris-HCled) 
distortion index Best cell (without symmetry restrains) 
primitive cubic 21.81% 66.72 77.90 151.26 79.97 91.45 91.12 
98.62 98.62 98.62 90.00 90.00 90.00 
Icentredcubic 31.34% 151.26 101.56 170.25 89.40 143.02 96.72 
141.03 141.03 141.03 90.00 90.00 90.00 
Fcentredcubic 31.87% 191.80 170.25 172.05 45.88 112.38 129.45 
178.03 178.03 178.03 90.00 90.00 90.00 
primitive rhombohedral 14.03% 151.26 157.62 163.76 36.78 24.03 29.12 
157.55 157.55 157.55 29.98 29.98 29.98 
72.31 72.31 450.32 90.00 90.00 120.00 
primitive hexagonal 14.31% 66.72 77.90 151.26 79.97 91.45 91.12 
72.31 72.31 151.26 90.00 90.00 120.00 
primitive tetragonal 5.48% 77.90 66.72 151.26 88.55 79.97 88.88 
72.31 72.31 151.26 90.00 90.00 90.00 
Icentredtetragonal 6.49% 77.90 66.72 304.97 101.46 94.99 88.88 
72.31 72.31 304.97 90.00 90.00 90.00 
primitiveorthorhombic 4.22% 66.72 77.90 151.26 79.97 91.45 91.12 
66.72 77.90 151.26 90.00 90.00 90.00 
C centred orthorhombic 2.12% 77.90 298.96 66.72 88.83 91.12 85.16 
77.90 298.96 66.72 90.00 90.00 90.00 
1 centred orthorhombic 5.20% 66.72 77.90 304.97 94.99 78.54 91.12 
66.72 77.90 304.97 90.00 90.00 90.00 
F centred orthorhombic 6.50% 101.56 103.55 304.97 101.15 86.34 81.16 
101.56 103.55 304.97 90.00 90.00 90.00 
primitive monoclinic 0.70% 77.90 66.72 151.26 91.45 100.03 88.88 
77.90 66.72 151.26 90.00 100.03 90.00 
C centred monoclinic 2.06% 298.96 77.90 66.72 91.12 91.17 94.84 
298.96 77.90 66.72 90.00 91.17 90.00 
primitive triclinic 0.00% 66.72 77.90 151.26 79.97 88.55 88.88 
Table 3.3 Bravais lattice table for the ternary GRHPR data. 
Output from DENZO (implemented within the HKL2000 data processing suite of programs) showing the 
most probable lattice type (bold), from the complete set of possible Bravais lattices. 
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Figure 3.10 Pseudo-precession image of the ternary data processed in space group P2. 
Image from the plane I=0. The vertical image (right hand side) shows a close-up view of the intensities 
present along the k-axis and corresponds to the smaller boxed region. Intensities are visible every second 
position only, indicating the presence of a screw-axis along k and thus diagnosing the space group to be 
P21. The image was produced using HKLVIEW (CCP4 suite; 1994, CCP4). 
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3.2.5.2 Apo data 
Unlike the ternary data, the automatic indexing procedure within Denzo failed to 
consistently pick a reasonable lattice and required some manual intervention. By 
manually removing a number of spot predictions clearly from a secondary lattice and 
the selection of clear lines of others, a reasonable lattice was produced. This went on to 
be successfully refined in P1, producing a unit cell clearly different to that of the 
ternary form. Again, due to the long cell edges the spots were very close together and 
the default box size required adjustment. Initial refinement and inspection of the 
Bravais Lattice table indicated P2 as the best lattice type. Further refinement, now in 
this lattice type, indicated the higher symmetry primitive orthorhombic (P222) lattice 
was appropriate (Table 3.4). Subsequent refinement in P222 produced well picked 
spots. The data was then integrated and scaled using ScalePack. The P222 lattice has a 
number of possible space groups (P222, P2221, P21212 and P212121) due to the 
possibility of various screw axes. Initial scaling was carried out in P222 and systematic 
absences investigated. Absences were clearly visible on the 1 and k axes and potentially 
the h making the likely space group was P212121. However, due to some violations of 
the expected absences P21212 could not be ruled out (Figure 3.11). Incorrect space 
group identification can have severe ramifications on the ability to find a molecular 
replacement solution. Therefore, the data was scaled as both P21212 and P212121 and 
molecular replacement undertaken. A solution was successfully found only in the 
P212121 space group, indicating this to be correct. A final resolution of 2.85Ä was 
used, giving data completeness of 91.0% and an R,. of 18.4%. All final scaling 
statistics are given in Table 3.5. 
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Lattice Metric tensor Best cell (symmeTris-HCled) 
distortion index Best cell (without symmetry restrains) 
primitive cubic 27.41% 195.41 66.59 114.46 90.00 90.43 90.00 
125.49 125.49 125.49 90.00 90.00 90.00 
I centred cubic 40.30% 206.45 225.73 132.42 115.64 98.98 35.33 
188.20 188.20 188.20 90.00 90.00 90.00 
Fcentredcubic 41.21% 235.35 236.76 235.35 58.01 147.13 111.75 
235.82 235.82 235.82 90.00 90.00 90.00 
primitive rhombohedral 20.96% 206.45 225.73 195.41 30.47 18.82 35.33 
209.20 209.20 209.20 28.20 28.20 28.20 
99.50 99.50 600.18 90.00 90.00 120.00 
primitive hexagonal 18.95% 195.41 114.46 66.59 90.00 90.00 90.43 
154.94 154.94 66.59 90.00 90.00 120.00 
primitive tetragonal. 12.88% 195.41 114.46 66.59 90.00 90.00 89.57 
154.94 154.94 66.59 90.00 90.00 90.00 
Icentredtetragonal 15.17% 114.46 66.59 411.84 99.30 105.71 90.00 
90.53 90.53 411.84 90.00 90.00 90.00 
primitive orthorhombic 0.18% 66.59 114.46 195.41 89.57 90.00 90.00 
66.59 114.46 195.41 90.00 90.00 90.00 
Ccentredorthorhombic 4.02% 66.59 396.46 114.46 89.58 90.00 99.67 
66.59 396.46 114.46 90.00 90.00 90.00 
Icentredorthorhombic 7.83% 66.59 114.46 411.84 105.71 80.70 90.00 
66.59 114.46 411.84 90.00 90.00 90.00 
Fcentredorthorhombic 7.93% 66.59 238.42 396.46 86.91 80.33 73.78 
66.59 238.42 396.46 90.00 90.00 90.00 
primitivemonoclinic 0.00% 114.46 66.59 195.41 90.00 90.43 90.00 
114.46 66.59 195.41 90.00 90.43 90.00 
Ccentredmonoclinic 4.02% 396.46 66.59 114.46 90.00 90.42 80.33 
396.46 66.59 114.46 90.00 90.42 90.00 
primitive triclinic 0.00% 66.59 114.46 195.41 89.57 90.00 90.00 
Table 3.4 Bravais lattice table for the apo GRHPR data. 
Output from DENZO (implemented within the HKL2000 data processing suite of programs) showing the 
most probable lattice type (bold), from the complete set of possible Bravais lattices. 
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Figure 3.11 Pseudo-precession image of the apo data processed in space group P222. 
(Legend on proceeding page) 
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Figure 3.8 Upper image (A) from the plane k=0. The vertical image (left hand side) shows a close-up 
view of the intensities present along the 1-axis while the horizontal image (middle) shows a close-up 
view of the intensities present along the h-axis. Both correspond to the smaller boxed regions in (A). 
Lower image (B) from the plane h=0. The horizontal image (bottom) shows a close-up view of the 
intensities present along the k-axis and corresponds to the smaller boxed region of (B). In all cases 
intensities are visible every second position only, indicating the likely presence of three screw-axes and 
the space group to be P212121. The image was produced using HKLVIEW (CCP4 suite; 1994, CCP4). 
Ternary Apo 
Space group P2, P212121 
_ Unit cell (A) a= 76.6, b= 66.9, c= 149.8 
= 98.22 
a= 67.36, b= 116.08, c= 198.23 
Resolution range 
(A) 
50 - 2.2 (2.28 - 2.2) 50 - 2.85 (2.95- 2.85) 
Number of unique 
reflections 
69056 (5483) 34609 (3272) 
U6 8.4 (2.1) 10.5 (2.0) 
R, % 12.1 27.5 18.4 79.1 
Completeness (%) 90.3 72.3 91.0 87.6 
_ Redundancy 2.6(2.2) 11.1 8.8 
_ Mosaici ° 0.586 1.11 
Table 3.5 Final scaling statistics for both the ternary and apo data sets. 
Values are for the complete dataset; bracketed values represent the highest resolution shell only. 
3.2.6 Molecular Replacement 
3.2.6.1 Ternary 
The ScalePack output file containing the hkl indices and intensities of reflections was 
converted into the CCP4 mtz format and the contents of the cell analysed, shown in 
Table 3.6. Considering the dimeric nature of GRHPR, a Matthews coefficient of 2.7 
and a solvent content of 53.6%, the asymmetric unit was predicted to contain 4 
monomers (2 dimers). 
Finding a molecular replacement solution for the ternary data proved difficult. Initial 
searches using either the H. methylovorum D-glycerate dehydrogenase (GRHPR) dimer 
to search for 2 copies or using the monomer searching for 4 copies failed. Large rigid 
domain movements are known to occur within this family of enzyme between the apo 
and ternary conformations. Therefore, despite the reasonable sequence identity, the 
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apo structure could not automatically be considered a good model for the ternary data. 
To compensate for these movements the model structure was split into its component 
domains and successive rounds of Phaser searches and refinement were used to find a 
solution (Figure 3.12). The two coenzyme binding domains (100 - 290) make up over 
60% of the dimer and were retained as a single search model. This domain shows 35% 
sequence identity with that of the human GRHPR and Phaser was used to search for 2 
copies of it within the asymmetric unit. This produced a weak solution for the first 
copy but improved upon addition of the second (Phaser round 1, Figure 3.12 and Table 
3.7a). Investigation of the resulting maps in Coot indicated reasonably continuous 
density for the backbone of the model. Some model building and refinement, including 
mutating the sequence to that of the human protein, was carried out and is described in 
detail in section 3.2.7.1. A subsequent Phaser search used a refined human coenzyme- 
binding domain dimer and a poly-alanine model of the bacterial substrate-binding 
domain (1 to 99,291 to 321). This successfully found good solutions for two of the 
expected four substrate-binding domains (Phaser round 2, Figure 3.12 and Table 3.7b). 
The Z-scores of 7.0 and over and the progressive increase in LLG indicate the success 
of this. Supporting this, Phaser had positioned the breaks of the domains near each 
other and they were linked by continuous Fo-Fc density. The missing amino acids 
were added and the domains joined. After mutation of these domains to the human 
sequence and partial refinement, this model was used in a final Phaser search which 
weakly found the remaining two substrate-binding domains (Phaser round 3, Figure 
3.12 and Table 3.7c). To find the final substrate-binding domain, clashes had to be 
allowed to produce a solution. While the Z-scores are low, the LLG does increase, 
indicating that the model is explaining the data better. The domain termini were again 
placed in proximity and could be joined through continuous Fo-Fc density and the 
clashes could be manually resolved. The Euler angles and fractional positions of the 
final solution are given in Table 3.7d. It should be noted that while both the T. 
thermophilus (PDB code 2CUK) and P. horikoshii (Yoshikawa et al., 2007) GRHPRs 
show higher sequence identity (42% and 39% respectively) then the H. methylovorum 
GRHPR and would have made more appropriate search models, they were not available 
at the time. 
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No. monomers/AU Matthews Coeff. %solvent 
2 5.3 76.8 
3 3.5 65.2 
4 2.7 53.6 
5 2.1 42.0 
6 1.8 30.4 
Table 3.6 Matthews analysis for the ternary GRHPR data. 
The star indicates the most likely description of the AU. 


















Figure 3.12 Schematic of how Phaser was used stepwise to find the full ternary GRHPR solution. 
The solution at the end of each round was used to create the search model for the subsequent round. The 
co-enzyme binding domains (squares) were retained as a dimer, while the substrate binding domain 
(circle) was used as a separate search model. Domains of the H. methvlovorum sequence are in green, 
those mutated to the human sequence are in blue, and the poly-alanine model is indicated in red. 
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a) 
Found Rot. Trans. LLG 
Z-score Z-score 
1st bacterial 6.8 5.8 64 
co domain dimer 
2nd bacterial 4.8 10.7 200 
co domain dimer 
b) 
Found Rot. Trans. LLG 
Z-score Z-score 
1st human co 11.9 9.5 221 
domain dimer 
2nd human co 10.8 30.3 765 
domain dimer 
1st polyA sub 3.5 7.0 829 
domain 
2nd polyA sub 3.8 8.3 895 
domain 
C) 
Found Rot. Trans. LLG Packing 
Z-score Z-score clashes 
1st human 17.2 10.3 351 0 
`trimer' 
2nd human 19.9 42.4 1308 0 
`trimer' 
1st human sub 4.4 5.2 1333 0 
domain 





1st 0.018 0.000 0.000 0.00001 -0.00087 0.00002 
trimer 
2nd 179.617 95.610 0.206 0.99793 -0.57638 0.50082 
trimer 
Ist sub 85.118 63.537 359.192 1.07518 -1.24749 0.16662 
domain 
2nd sub 94.127 116.435 177.630 0.90061 -0.74854 0.31953 
domain 
Table 3.7 Results of Phaser search rounds for ternary solution. 
Each table gives the Z-scores for the solution after each Phaser round as displayed in Figure 3.12. Table 




As for the ternary data, the ScalePack output file was first converted into CCP4 mtz 
format and Matthews analysis performed. Again the output (Table 3.8) suggests the 
unit cell contains 4 monomers (2 dimers), with a Matthews coefficient of 2.7 and a 
solvent content of 54.5%. 
The previously solved human ternary GRHPR structure was used as the molecular 
replacement model. Firstly, one of the dimers from the ternary asymmetric unit (chains 
A and B) was striped of its water, sulphate and ligand atoms. To reduce model bias in 
the potential domain movements, this search model was split into its separate domains. 
The coenzyme binding domains (108 - 297; numbering as from the human GRHPR) 
from both chains were retained in the dimeric form, and used as the first search 
ensemble. As this already consisted of the core of a dimer, 2 were expected to be found 
within the asymmetric unit. One substrate binding domain (from chain A, 5- 105 and 
300 - 328) was used as the second search ensemble, 4 of these were to be found within 
the asymmetric unit. Initial searchers in Phaser found one complete dimer and a partial 
dimer which was missing a single substrate binding domain (Table 3.9a). The two 
substrate binding domains identified with significant Z-scores (translational Z-scores of 
14.8 and 19.5) together with one of the coenzyme binding domain dimers formed a 
complete GRHPR dimer. This was extracted from the solution file and used to search 
for the other dimer. Both dimers were successfully found with no packing clashes, 
excellent Z-scores and a very high final LLG indicating the strength of this solution 
(Table 3.9b). The Euler angles and fractional positions of the final solution are given in 
Table 3.9c. 
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No. monomers/AU Matthews Coeff. %solvent 
2 5.4 77.3 
3 3.6 65.9 
4 2.7 54.5 
5 2.2 43.2 
6 1.8 31.8 
Table 3.8 Matthews analysis for the apo GRHPR data. 







ist co domain 
dimer 
15.9 28.5 382 
2nd co domain 
dimer 
13.1 52.1 1650 
1st sub domain 3.2 14.8 1763 
2nd sub domain 3.4 19.5 1884 








1st dimer 23.6 27.4 738 




1st 270.06 137.858 0.201 -0.31730 -0.00223 -0.12901 
dimer 
2nd 90.091 42.128 180.25 0.18248 0.00133 -0.12826 
dinier 
Table 3.9 Results of Phaser search rounds for apo solution. 
Each table gives the Z-scores for the solution after each Phaser round as described in section 3.2.6.2. 
Table a) round 1, b) round 2. Table (c) gives the Euler angles and fractional positions of the final 
solution. 
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3.2.7 Model building and refinement 
Model building was carried out using the graphics program Coot (Emsley and Cowtan, 
2004), while Refmac5 (Murshudov, Vagin and Dodson, 1997) was used for refinement. 
Programs from CNS were also used in an attempt to help refinement but found to offer 
little improvement. The success of refinement was monitored by a decline in both R 
values. Graphs representing the successive decline of the R values after specific major 
refinement steps are give in Figure 3.13, for the ternary data refinement and Figure 
3.14, for apo data refinement. The refinement steps are listed in Table 3.10 and Table 
3.12 respectively and will be described in more detail below. There are no initial R 
values (Refinement stage 0) as Phaser does not calculate them. The first R values are 
therefore the result of some alteration to the original Phaser solution. In between each 
major stage in refinement the resulting model and density maps were analysed and 
alterations to side-chain and mainchain positions were made where indicated by the Fo- 
Fc difference map. The successive rounds of Phaser searches and model building used 
it find the final ternary solution are represented schematically in Figure 3.12. 
3.2.7.1 Ternary 
Inspection of the maps produced from the initial Phaser solution of 4 bacterial 
coenzyme domains showed little identifiable side chain density, but a majority of 
continuous density for the mainchain. Some manual realignment of mainchain atoms 
and rounds of refinement in Refmac5 were carried out using tight non-crystallographic 
symmetry (NCS) restraints (stage 1). With NCS restraints it is possible to manually 
define regions of multiple protein chains that should remain the same and not be 
refined to a local minimum. This is important during early refinement where the model 
is of low quality and there is no data to suggest the chains are different. Additionally, a 
high weighting was placed on the geometric restraints to prevent refinement resulting 
in unreasonable geometry deviations. Subsequent examination of the density maps 
produced by Refmac5 showed a marked improvement in quality, with some side chain 
density visible. Based on the sequence alignment (Figure 1.2), the model was mutated 
to the human GRHPR sequence. This was assisted by the presence of a number of 
noteworthy areas of positive Fo - Fc density, which corresponded to large hydrophobic 
amino acids in the human sequence not present in the bacterial. These included Trp 
145, Tyr 149, Phe 230 and 240, and Tyr 255 (numbered as in human GRHPR). These 
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were used as set points around which the sequence could be mutated, ensuring the 
register was retained. Sections of one domain were mutated, the model run through 
Refmac5 and the resulting maps analysed for negative difference density over `new' 
sequence indicating a register mistake and the appearance of new positive density. As 
the domains became more human-like, the density maps overall improved and more 
side chains could be positively identified. Finally, all 4 coenzyme binding domain had 
been mutated to the human sequence and there could be reasonable confidence in the 
sequence register (stage 2). This produced a moderate decrease in both R values. 
While there was a small amount of unmodelled density visible in the region where the 
substrate binding domains were expected, this was not sufficient to proceed with 
manual building. Furthermore, automatic building with ARP/wARP (Perrakis, Morris 
and Lamzin, 1999) was not successful. One of the human sequence coenzyme domain 
dimers was used in the second Phaser search. 
A similar process was carried out on the two substrate binding domains found during 
the second Phaser search. Initial refinement of the main-chain positions (stage 3) was 
followed by mutation (stage 4). Here, positive density corresponding to Trp 9, Tyr 23, 
Phe 79 and Tyr 318 of the human sequence was used to confirm the register. The 
mutation of these domains resulted in a 5% decrease in both R values. Additionally, 
the 2 domains could be joined to their corresponding coenzyme domain. From these 
stages forward, NCS regions were defined separately for the different domains and 
restraints were applied. A `trimer' made up of a dimer of coenzyme domains and a 
single substrate binding domain was extracted from this model and used, along with a 
separate substrate binding domain in the final Phaser search. The addition of these 
final domains completed the protein content of the asymmetric unit, and their 
subsequent refinement resulted in further large R value decreases (stage 5). 
Over the next stages of refinement (6,7 and 8) the NCS restraints were gradually 
lowered. This was done slowly, first allowing the side-chains to refine independently 
and then loosening the restraint on the main-chain atoms. As the model improved the 
weighting towards geometric parameters over X-ray data was decreased without 
deterioration in geometry. Interspaced with these changes, the resulting maps were 
inspected and manual side chain adjustments made. These included fixing bad 















Figure 3.13 Graph of the decrease in R values over refinement of the ternary data. 
R, rys, and Rfrer values after the 
key refinement steps are included and correspond to the refinement steps 
described in Table 3.10. 
Stage Refinement Summary 
1 Tight NCS restraints and high weighting on geometric restraints 
2 Mutated coenzyme domain to human sequence 
3 Found 2 substrate binding domains - poly-Ala sequence 
4 Mutated both substrate binding domains to human sequence 
5 Found other 2 substrate binding domains - complete 2 human dimers 
6 Tight mainchain NCS restraints 
7 Loosening of NCS restraints 
8 Removal of NCS, lowering of weighting on geometric restraints 
9 Ligand addition (3 NADPH) and waters (away from binding groove; 50) 
10 Ligand addition and alteration (4 NADPH at '/2 occupancy, 2 oxalates at full 
occupancy), Coot automatic find waters (508), sulphate ions (7) 
I1 TLS refinement (10 TLS groups per monomer) 
12 Ligand occupancy alteration, oxalate was replaced by D-glycerate and final 
checks of waters and side chain occupancies (610 waters, 5 sulphate ions) 
Table 3.10 Major stages of refinement for the ternary data. 
Summarised notes describing the key stages involved in the refinement procedure employed for the 
ternary GRHPR structure. Each stage corresponds to a resulting Rr,,,, and Rfree value displayed in Figure 
3.13. 
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Additionally, a number of flexible (ie Arg and Lys), solvent exposed side chains 
showed no electron density. The occupancy of those atoms showing no density was set 
to zero to reflect their flexibility and subsequently rechecked after further refinement. 
During improvement and refinement of the protein model further positive density had 
progressively appeared in the surrounding solvent areas and in the groove between the 
coenzyme and substrate domains. At various positions, clear density for well 
coordinated waters was identified and these were manually added. Care was taken to 
initially only do this at regions away from the binding groove. Almost continuous 
density was clearly present in the binding groove of each GRHPR monomer in the 
position occupied by NADH in other complexed structures of this family. A NADPH 
monomer was imported into Coot and manually fitted to this density in 3 of the 4 
monomers. This resulted in a significant reduction of both R, ryst and Rfree (stage 9). A 
fourth NADPH molecule was fitted into the appropriate density of chain D and density 
in the substrate binding region was identified in chains A and C. This was originally 
modeled as oxalate as this is what was incubated with the protein prior to crystal 
growth. Gaps in the 2Fo - Fc map and negative density in the Fo - Fc map indicated 
that NADPH was not present at full occupancy and all were initially lowered to half 
occupancy. Further waters were identified with the Coot "find waters" option. This 
works by searching the asymmetric unit for unexplained density above a set sigma 
cutoff and automatically fitting water molecules to it. These locations were manually 
checked, and those waters in positions that lacked suitable coordination were deleted. 
Also, a number of larger positive density peaks were identified and modeled as 
sulphate ions from the crystallisation condition. The large decrease in R value seen at 
this stage (10) is likely due to the large increase in modeled waters. 
This model was fed into the TLSMD server (Painter and Merritt, 2006) where the 
protein chains were partitioned into multiple TLS groups. Each chain was divided into 
5,10 or 15 TLS groups and the resulting files inputted into Refmac5 to undergo TLS 
and restrained refinement. The use of 10 TLS groups provided the best reduction in R 
values (stage 11). In the final stages of refinement of the model, positive difference 
density was noted near the 01 position of the modeled oxalate. Modeling this density 
with a water molecule resulted in an insufficient hydrogen bonding distance. Analysis 
by electrospray ionization mass spectrometry (ESI-MS) was carried out on the di- 
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sodium oxalate (Sigma) used in the crystal tray set up. This showed a distinct peak at a 
mass corresponding to hydroxypyruvate (data not shown), one substrate for GRHPR. It 
was thought that during the incubation period prior to crystal tray set up, the GRHPR 
would convert this hydroxypyruvate into D-glycerate. Consequently, the substrate 
density was modeled and refined with D-glycerate rather then oxalate resulting in the 
density being well explained (Figure 3.22b). A final analysis of the density maps was 
carried out, checking water positions, side chain and ligand occupancies (stage 12). 
The N-terminal 6 residues, 4 from GRHPR and the 2 remaining tag amino acids, were 
disordered and no density was seen. These have been left out of the final model which 
contains two GRHPR dimers from residue 5 (chains A and C) or 6 (chains B and D) to 
the C-terminus at residue 328,610 waters and 5 sulphate ions. The presence of 
different ligands and their occupancy depended on which protein chain they were 
associated with and are described in Table 3.11. In summary, the final model contained 
two GRHPR dimers related to each other by an approximately 90° rotation along their 
short axis. Interdimeric contacts occur via ordered water molecules between coenzyme 
binding domains. Each dimer consists of a ternary (NADPH and D-glycerate bound) 
monomer and a binary (NADPH bound) monomer (Figure 3.17) and resulted in a final 
&ryst of 20.1% and Rye of 28.2%. The final refinement statistics are given in Table 
3.13. It should be noted that the two binary chains (B and D) correlate to the substrate 
binding domains which could only be found during the final Phaser search. A detailed 
description of the structure is given in the discussion and the quality of the electron 
density maps can be seen in Figure 3.22b. 
Chain NADPH Occupancy D-glycerate Occupancy State 
A Yes 0.75 Yes 0.75 Ternary 
B Yes 0.50 No n/a Binary 
C Yes 0.75 Yes 0.75 Ternary 
D Yes 0.50 No n/a Binary 
Table 3.11 Presence of ligands for each chain in the "ternary" asymmetric unit of GRHHPR. 
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3.2.7.2 Apo 
Unlike the ternary solution, here the molecular replacement model and the target 
structure were the same protein, resulting in refinement starting at a more advanced 
stage. The density maps produced directly from Phaser were largely complete, 
including side chain density. Initial analysis of these maps and the domain positions 
were carried out in Coot (Emsley and Cowtan, 2004). Continuous difference density 
was present making it possible to add in residues 106,107,298 and 299, connecting the 
coenzyme binding domains to their substrate binding domains. Additionally, at this 
stage it was noted that the 217-223 loop region in all 4 protein chains had very little 
electron density. This region was deleted from subsequent refinement to prevent it 
contributing model bias (stage 1). Tight NCS and high geometry restraints were also 
used. Subsequent model alterations were carried out, including changing the 
occupancy of flexible side chains and some minimal main chain movements. 
Loosening of the NCS restraints resulted in a significant drop in both R, ryst and Rfree of 
2-3% (stage 2). However their complete removal (stage 3) only produced a minimal 
effect. Analysis of the model with the MolProbity web server (Davis et al., 2007) at 
this point indicated a large number of bad rotamers were present. Manual improvement 
of these rotamers, followed by refinement in Refmac5 did not resolve the problem. 
This was likely due to Refmac5 forcing bad geometry in an effort to improve other 
statistics and is due to the poorer quality data in many of these regions. Even though 
the overall geometry weighting was high, it was found that manually tightening the 
torsion restraints, from 1.0 to 5.0, within Refmac5 resulted in an almost immediate 
improvement to the rotamers. Importantly, this brought Rfree below 30%, while the 
corresponding increase in &ryst suggests some amount of model overfitting had been 
eliminated (stage 4). Additionally, a solvent exposed region of the substrate binding 
domain of chain D (residues 45 - 53,61 - 74,88 - 92, and 96 - 100), distant from 
crystal contact sites, showed very poor density and the occupancy of the region was 
reduced. As this region is well ordered in all other chains, tight NCS restraints between 
it and the same region in chain B were used to force it to retain a `likely' structure. The 
use of 10 TLS groups per monomer during refinement resulted in a further I% decrease 
in both R values (stage 5). Interestingly, this had improved the model to a point where 
the extra torsion restraint could be reduced back to the default setting without a 
negative effect. Only 48 waters could be identified and fitted to density compared to 
the 610 of the ternary structure. This lower number is due to the lower resolution of 
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this data set (2.85A). Two additional areas of positive solvent density too large to be 
water molecules were modeled as Mg 2+ ions, which were present as the crystallisation 
salt (stage 6). No significant difference density had appeared for the 217 - 223 loop 
region during the course of refinement and it remained deleted. Finally refinement 
resulted in the reasonable R, iyst value of 21.7% and an Rfree of 27.9%. Further 
refinement statistics are given in Table 3.13. 
In summary, the final model contained two GRHPR dimers, one `horizontal' and the 
other `vertical'. Within the asymmetric unit, interdimeric contacts occur via direct 
hydrogen bonds largely between a substrate binding domain in one dimer and a 
coenzyme binding domain in the other. Each monomer consists of residues 6- 327 (or 
325 in chain D) and lacked density for the coenzyme binding loop 217 - 223, which is 
not present in the final model. This loop is discussed further in section 3.3.2.3. No 
significant density was present in the binding grove in any of the 4 monomers. 
3.2.8 Validation and deposition 
Once refinement had converged and the R-factors stabilised, the structure was validated 
by analysis in SFcheck (Vaguine, Richelle and Wodak, 1999) and/or MolProbity (using 
the all-hydrogen option, Davis et al., 2007). Identified Ramachandran outliers were 
examined and where possible fixed, as were excessive clashes and bad rotamers. The 
structures were re-refined after any changes. The Ramachandran plots from SFcheck 
(ternary) or MolProbity (apo) are shown below (Figure 3.15 and Figure 3.16). The 
final ternary structure coordinates and structure factors were deposited into the Protein 
Data Bank (PDB) on 14/03/2006 and released on 18/07/2006 under the code 2GCG. 
This structure has also been published (Booth et al., 2006). The final models are 
discussed in the following section and are represented in Figure 3.17. It should be 
noted that after this deposition, a structure of human GRHPR was deposited from the 
Center for Eukaryotic Structural Genomics (unpublished, PDB code 2H1S). Despite 
this structure being modeled in the apo state it contains extensive density within the 
active site cleft and has highly similar (rmsd 0.33A over 321 equivalent Ca positions) 
domain positions to the ternary data produced in this thesis. Because of the uncertain 
state of this enzyme it shall not be discussed further. 
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The hinge region between the two domains lies at residues 104 - 107 and 298 - 301 
which coincides with the only significant Ramachandran outlier of the ternary model; 
Asp] 05 (Figure 3.15). This well defined residue is within the disallowed region in all 4 
chains and suggests a deformation of this residue has occurred to facilitate the present 
domain positions. All other significant outliers in both models occur in areas (loop 












Figure 3.14 Graph of the decrease in R values over refinement of the apo GRHPR data. 
R«,,,, and Rfree values after the key refinement steps are included and correspond to the refinement steps 
described in Table 3.12. 
Stage Refinement Summary 
1 Tight mainchain NCS restraints and high weighting on geometric restraints 
2 Loosening of NCS restraints 
3 Removal of NCS 
4 Tightened torsion restraints to fix bad rotamers, NCS restraints on specific 
regions 
5 TLS refinement (10 TLS groups per monomer) 
6 Reduction of torsion restraint to default, 48 H2O and Mg24 
7 Final checks of waters and side chain occupancies 
Table 3.12 Major stages of refinement for the apo GRHPR data. 
Summarised notes describing the key stages involved in the refinement procedure employed for the apo 
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Figure 3.15 Ramachandran plot for the final ternary GRHPR model. 
The plots were generated with SFcheck (Vaguine, Richelle and Wodak, 1999). Plot statistics are given in 
Table 3.13. 
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Figure 3.16 Ramachandran plots for the final apo GRHPR model. 
The plots were generated with MolProbity (Davis et a!., 2007). Plot statistics are given in Table 3.13. 
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Ternary Apo 
tryst (%) 20.1 21.7 
Rfree (%) 28.2 27.9 
RMS deviation for bond 
length (A) 
0.017 0.007 
RMS deviation of bond 
angle (°) 
1.866 1.073 
Ramachandran plot (%) 
Most favoured 88.2 96.0 
Additionally allowed 11.3 3.6 
Disallowed 0.4 0.4 
Table 3.13 Final refinement statistics from both ternary and apo GRHPR data. 
The Rte, and Rft. values indicate a reasonable final model. The good geometry of the model is 
indicated by the low RMS deviation values and low percentage of residues in the disallowed region of 
the Ramachandran plots. 
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3.3 Discussion 
The work presented in the preceding sections details the solution of the first structures 
of human glyoxylate reductase/hydroxypyruvate reductase and the first true ternary 
structure of a D-2-hydroxyacid dehydrogenase family member. Structures were solved 
by X-ray crystallography in an attempt to provide information on the three major states 
(ternary, binary and apo) of this enzyme. Fortuitously, one crystal structure provided 
information for both the ternary and binary states, with a second being solely apo. 
In the following, the general GRHPR structure will be described and differences 
between the three states discussed. The details of both coenzyme and substrate binding 
will be described, the latter having added importance as it is the first time the structure 
of a true ternary complex has been observed for this enzyme family. Where 
appropriate comparisons to other family members will be made and finally, a structural 
explanation will be provided for why observed mutations give rise to PH2. 
3.3.1 General structure 
The dimeric nature of human GRHPR, as expected in this enzyme family and indicated 
earlier by the gel filtration results, is apparent in the crystal structures where two dimers 
are present in each asymmetric unit. Each dimer is formed by a staggered, "back-to- 
back" arrangement of monomers, forming an elongated ellipsoid with dimensions of 
approximately 100A x 57A x 44A and displaying 2-fold rotational symmetry (Figure 
3.17a). Each monomer has a dumb-bell shape, consisting of two compact domains 
separated by a deep cleft which contains the coenzyme binding site and, at the bottom, 
the catalytic site and hinge region (Figure 3.17b). This is the expected D-2- 
hydroxyacid dehydrogenase fold as seen in previous structures from this family (Figure 
1.3). 
Both domains are a/p/a structures and represent variations on the Rossmann 
nucleotide-binding fold (Rao and Rossmann, 1973). The smaller substrate binding 
domain comprises residues 5 (the first 4 residues are disordered in all crystal structures) 
to 106 and 299 to 328 (the C-terminus). This domain includes a central 5 stranded 
parallel ß-sheet which runs perpendicular to the binding cleft flanked on one side by 2 
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Figure 3.18 Schematic of a GRHPR monomer. 
ß-strands are represented by arrows, a-helices by circles. Labelling is based on that of Goldberg, 
Yoshida and Brick, (1994). 
The smaller domain is classified as a formate/glycerate dehydrogenase substrate- 
binding domain (Structural Classification of Proteins (SCOP); Murzin et al., 1995). 
The larger, coenzyme binding domain is grossly similar to the substrate binding domain 
with a rmsd of 2.5A over 62 Ca atoms. It is formed by residues 107 - 298 and 
comprises a core 7 stranded parallel ß-sheet flanked on one side by 3 helices and by 4 
on the other (Figure 3.17b and Figure 3.18). This is defined as a NAD(P)-binding 
Rossmann-fold (SCOP; Murzin et al., 1995) but is interrupted between residues 123 
and 149 by the insertion of a helix and loop which enlarges the dimer interface (Figure 
3.17b). This dimerisation loop wraps over the opposing monomer and, unlike non- 
GRHPR D-2-hydroxyacid dehydrogenases, extends to the active site of the opposite 
monomer. Here it contributes an important residue to the active site, Trpl41 (Figure 
3.17a), further discussed in section 3.3.7. The separate domains are effectively 
identical between the monomers within each asymmetric unit and in the three states 
represented in the crystal structures, with rmsd values of 0.3A - 0.4A (131 Ca) 
between the substrate binding domains and 0.3A - 0.6A (179 Ca) between coenzyme 
binding domains. 
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Dimerisation has resulted in the burying of 3161A (19%) of solvent-accessible surface 
area between monomers, predominantly due to interactions between the coenzyme 
binding domains. This is very similar to the area buried in the H. methylovorum 
GRHPR structure (3100A; Goldberg, Yoshida and Brick, 1994), but significantly more 
then that buried in the related D-2-hydroyisocaproate dehydrogenase dimer (2365A, 
14.5%; Dengler et al., 1997), a difference likely to be due to the extended dimerisation 
loop present in the GRHPR family. 
As mentioned above, the overall fold is as expected for the D-2-hydroxyacid 
dehydrogenase family, with the coenzyme binding domain particularly homologous to 
that of other family members (rmsds 0.9A - 1.6A: Table 3.14). This is unsurprising as 
all of these domains bind either NADH or NADPH ligands and therefore need to 
maintain a compatible binding site. The greater variation seen between the substrate 
binding domains (rmsd values of 1.1A - 2.5A: Table 3.14) is likely to arise from the 
weaker constraints in this domain which binds a range of substrates across the family. 
Structurally, the domains of human GRHPR is seen to be most similar to T. 
thermophilus GRHPR (unpublished, PDB code: 2CUK) of the known equivalent 
structures (Table 3.14), despite P. horikoshii GRHPR (Yoshikawa et al., 2007) having 
a slightly higher sequence identity (42% verses 39%). However, the latter has a small 
loop insertion in the coenzyme binding domain and a short loop deletion in the 
substrate binding domain which may explain this discrepancy. 
3.3.2 Comparisons between states 
3.3.2.1 Domain position 
While the structure of individual domains changes little between the enzymatic states, 
the spatial relationship between domains has been seen to vary in other D-2- 
hydroxyacid dehydrogenases when different states have been compared (Lamzin et al., 
1994; Razeto et al., 2002). Relative domain movements are facilitated by the hinge 
regions centered on residues 106 and 299 (human GRHPR numbering) and allow the 
enzymes to adopt `open' and `closed' conformations. These movements allow 
substrate access to the active site in the `open' conformation and subsequently shield it 
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from solvent in the `closed' conformation. Despite the "ternary" crystal structure 
containing both ternary and binary monomers there is little variation in the relative 
positions of the substrate binding and coenzyme binding domains (Figure 3.19a and 
Table 3.15). This overall similarity is reflected in the active site where a high degree of 
correlation between residues is apparent when the structures are superimposed (Figure 
3.23a). The two ternary monomer chains (A and C) are effectively identical (Table 
3.15) with the most divergent monomer (D; binary) representing the most `open' 
conformation in comparison to the `closed' conformation of the ternary chains. This 
monomer displayed the poorest quality electron density for bound coenzyme and has a 
substrate binding domain with average temperature (B) factors significantly higher then 
those of the other monomers (Baverage = 43.8A2 versus 30.0A2). This suggests flexibility 
in the position of this domain which is perhaps partly restrained in the structure due to 
crystal packing restraints. Additionally, investigation of an atom space filling model 
(in CCP4mg; Potterton et al., 2002) indicates that despite being the most `open' binary 
state there is insufficient room for subsequent substrate binding. This is likely to 
therefore represent a partially closed conformation that has been `selected' by the 
crystal lattice. 
Greater variation in relative domain positions is observed when the individual apo 
GRHPR monomers are compared (Figure 3.19b, Figure 3.20 and Table 3.16). This 
implies there is greater inherent flexibility in the unliganded enzyme. Luzzati plots 
(Sf Check; Vaguine, Richelle and Wodak, 1999) indicate an average coordinate error of 
0.40 A in the apo structure compared to 0.30 A in the ternary structure. This provides 
an indication of the upper limit of error in atomic positions in the models: the rmsd 
values in Table 3.17 generally exceed these errors indicating that the displacements 
observed are likely to be real. The packing restrictions of the similar crystal lattices, 
obtained under similar crystallisation conditions (Figure 3.7), would be expected to 
restrain movement between the domains and hence reduce the observable variation. 
Determination of the crystal structure of the apo state under highly divergent 
crystallisation conditions might show a greater variation in the inter-domain 
arrangement, although no satisfactory data from alternative crystals was ever produced 
during this work. It is worth noting however that D-LDH produced two distinctly 
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Table 3.14 (Legend) 'Goldberg, Yoshida and Brick, 1994; 2 T. thermophilus, 2CUK; 'Yoshikawa et 
al., 2007; 4Razeto et al., 2002, chain A; 5Razeto et al., 2002, chain B; 6Dengler et al., 1997; 7Kumar et 
al., 2002; 8 and 9Lamzin et al., 1994; 1°Martins et al., 2004; "Schuller, Grant and Banaszak, 1995. 
aAngle required to overlay substrate binding domains of `apo' and 'holo/temary' structures after pre- 
alignment of the two co-enzyme binding domains. This was calculated using DynDom (Hayward and 
Lee, 2002), rmsd values are in angstroms (A) and were calculated with CCP4mg (Potterton et al., 2002). 
A) 
Figure 3.19 Overlay of GRHPR monomers. 
B) 
A) Ca trace of the 4 subunits present in the ternary asymmetric unit. The ternary subunits are A (blue) 
and C (red), while the binary subunits are B (green) and D (cyan). B) Ca trace of the 4 subunits present 
in the apo asymmetric unit, subunits are coloured the same as in (A). The position of the 217 - 223 loop 





Figure 3.20 Displacement of the apo substrate binding domain. 
The co-enzyme binding domains (108 - 293, indicated by the solid line) of the apo monomers were 
superposed onto that of ternary chain A using CCP4mg (Potterton et a/., 2002) and the resulting rmsd 
(A) at each Ca measured with LSQMAN (Kleywegt and Jones, 1994). 
Altcri B(bin) ýftcrl CD(mix) 
0.33 
C(tcr) 0.25 0.36 
D(bin) 0.57 0.60 0.60 
AB(mix) 0.62 
Table 3.15 Comparison of GRHPR ternary/binar) monomers and dimers within the same 
asymmetric unit. 
The rmsd values in A for a comparison of 323 equivalent Ca positions between each monomer. 
A(apo) B(apo) C(apo) CD(apo) 
B(apo) 0.48 
Capo) 0.37 0.49 
D(apo) 0.83 0.60 0.70 
A BF,,,, 0.55 
Table 3.16 Comparison of GRHPR apo monomers and dimers within the same asymmetric unit. 
The rmsd values in A for a comparison of 311 equivalent Ca positions between each monomer. 
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0 
0 50 100 150 200 250 300 
Residue Number 
Ternary Binary Ternary Binary 
Global rmsd Rotation required 
A 0.50 0.63 2.7 - 
B 0.64 0.56 4.0 - 
C 0.59 0.64 3.2 - 
D 1.02 0.77 6.1 3.5 
Table 3.17 Global rmsd values for each apo GRHPR chain versus ternary and binary examples. 
Subunit A is used as an example of a ternary subunit, and subunit D as an example of a binary subunit. 
The rotation required for apo chains A-C onto the binary subunit was below detectable limits (ratio of 
interdomain to intradomain displacement must be <1; Hayward and Berendsen, 1998). RMSD values 
are in A and rotation required is in degrees. 
By superimposing two coenzyme binding domains it is possible to measure the rotation 
required to map one substrate binding domain onto the other, giving a measure of how 
`open' the binding cleft is. This was done using the DynDom server 
(www. sys. uea. ac. uk/dyndom; Hayward and Berendsen, 1998; Hayward and Lee, 2002) 
and comparisons across the 3 different states show the rotation required to go from apo 
to ternary vary between 2.7° and 6.10 depending on the apo monomer used (Table 
3.17). For three of the apo chains the movements are small and only marginally exceed 
the Luzatti errors of the structures, whereas a significant change is observed for apo 
chain D which represents the most `open' human GRHPR structure. This can be seen 
graphically in Figure 3.20 (and Figure 3.21) where equivalent positions in the substrate 
binding domain of apo chain D are displaced on average 2.5A from their positions in 
the ternary structure, while the other chains show a displacement of around 1. OA. This 
is a smaller amount than is apparent for apo H. methylovorum GRHPR (approximately 
6.5A, with a 18.5° rotation; Table 3.14 and Figure 3.21). A restricted domain 
conformation has previously been seen in the related D-2-hydroxisocaproate 
dehydrogenase (D-HicDH) structure which, despite binding both coenzyme and 
substrate, unexpectedly remains in a fully `open' conformation (Dengler et al., 1997). 
Here it was suggested that crystal contacts constrained the conformation that could be 
accommodated. Subsequently, both the open and closed domain conformations were 
observed in the same asymmetric unit for D-LDH (Razeto et al., 2002). These 
observations lead Razeto et al., (2002) to propose that the energetic barrier between the 
two conformations (open and closed) is low allowing the weak crystal contacts to 
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effectively compete and dominate the overall structure, a proposal supported by the 
relatively closed conformation of the GRHPR apo monomers presented here (Figure 
3.21 and Figure 3.23b). Complete closure does however, appear to require both 
substrate and coenzyme ligands as neither the apo nor binary monomers are as closed 
as the ternary subunits (Table 3.15 and Table 3.17). The formation of multiple 
hydrogen bonds between the substrate binding domain and the coenzyme binding 
domain appears to be facilitated by binding of the substrate (described in following 
sections) and would be expected to stabilise this fully closed conformation. The altered 
spatial relationship between domains in the different states contributes to the entire 
ternary human GRHPR monomer most closely matching the recently determined holo 
(closed) P. horikoshii GRHPR structure (Yoshikawa et al., 2007, rmsd 1.2A) whereas 
the apo human GRHPR monomer is most similar to the apo (open) T. thermophilus 
GRHPR structure (rmsd 1.2A) (Table 3.14). In general terms, the human apo state 
shows lower rmsd values against other apo conformations then the human ternary state, 
and vice versa (Table 3.14). The exception to this is the apo formate dehydrogenase, 
which is minimally more like the human ternary state (rmsd 1.9A) then the human apo 
(rmsd 2. OA) (Table 3.14). This is likely to be due to the relatively small domain 
movement seen between the formate dehydrogenase states (Lamzin et al., 1994). 
However, it should be noted that these are generally small changes overall and care 
needs to be taken in comparing these crystal structures that have been determined to 
different resolutions and at different times. 
Rigid domain movements have previously been noted when comparing apo and holo 
states of enzymes from this family. Formate dehydrogenase, for example, has a 8.9° 
rigid body rotation of the substrate binding domain towards the coenzyme binding 
domain occurs between the apo and holo (NADH + azide) states (Lamzin et al., 1994). 
This is significantly smaller then the 15.4° rotation seen between the binary and holo 
(NADH + sulphate) structures of D-LDH (Razeto et al., 2002). This larger rotation has 
been thought to be required for the larger substrates utilised be D-LDH in comparison 
to FDH (Razeto et al., 2002). The rotation seen between the FDH structures is 
comparable to the largest rotation seen between human GRHPR apo and ternary 
monomers (6.1°; Table 3.17 and Figure 3.21). A low energetic barrier between open 
and closed conformations could be an alternative explanation for the small FDH 
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rotation, with the apo structure not representing a completely open state but a midway 
conformation selected by crystal packing restraints. 
Due to the similar substrate size between GRHPR and LDH it might be expected that a 
comparable degree of opening of the binding cleft is required. A comparison between 
the human ternary GRHPR structure and the two available bacterial apo GRHPR 
structures, H. methylovorum (Goldberg, Yoshida and Brick, 1994) and T. thermophilus 
(PDB code 2CUK), indicates a required closing rotation of 18.5° and 11.7° respectively 
(Table 3.14), comparable to that seen for D-LDH (Razeto et al., 2002). This range 
gives an indication of the potential variations that might be possible in the absence of 
the restraints of a crystal lattice. Interpretation of crystallographic structures requires a 
recognition of the non-physiological environment in which the protein has be 
crystallised and any packing constraints that may have been imposed. Consequently, 
individual structures should be treated with a certain level of caution. In this case, the 
ability to compare structures across a range of family members in various states has 
allowed aberrant conformations to be identified and also suggests there is a low 
energetic barrier between open and closed conformations. 
Figure 3.21 Stereo view of domain rotation. 
Comparison between the human GRHPR ternary (subunit A; blue) and apo (subunit D; green) structures 
with the apo structure of H. methvlovorum (red; Goldberg, Yoshida and Brick, 1994). Co-enzyme 
domains have been overlaid and the star indicates the position of the 217 - 223 loop disordered in the 
apo structures. 
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3.3.2.2 Position of the active site arginine 
Apart from the slight opening of the active site cleft, two significant differences are 
apparent between the ternary/binary states and the apo state. In all ternary monomers 
the Arg245 side chain is ordered and directed towards the substrate binding site where 
it forms hydrogen bonds with D-glycerate (Figure 3.22a). The same conformation is 
seen in the binary monomers (Figure 3.23a) where Arg245 makes ternary-like 
interactions with nearby waters and the OD 1 of Asp86, despite there being no substrate 
present. In comparison, Arg245 within the human apo GRHPR monomers is largely 
disordered and appears to be pointing away from the active site, similar to the 
orientation seen in the apo bacterial GRHPR structure (Figure 3.23b). This movement 
is likely to be necessary, along with cleft opening, to allow product to leave and make 
the active site accessible to substrate. This differs from the structure of formate 
dehydrogenase (Lamzin ei al., 1994) in which the active site directionality of the 
equivalent arginine is retained between the apo and holo (ternary-like) structures. 
3.3.2.3 Co-enzyme binding loop 
The second significant difference is a lack of electron density for the 217 - 223 loop in 
the apo state (ßD-aE loop; Figure 3.18). In the ternary/binary state this loop forms part 
of the coenzyme binding pocket, although (apart from Ser217) not directly interacting 
with but packing around the adenine moiety of the NADPH. The sequence of this loop 
region and that of the equivalent loop in related enzymes (where an apo structure is 
available) is given in Table 3.18. The Ser217 residue is at position 2 of the ß-turn 
leading into this loop and normally makes two hydrogen bonds to the coenzyme 
(Figure 3.24). The lack of these interactions in the apo state may destabilise the 
following loop region, accounting for the observed lack of electron density and 
potentially opening the adenine pocket to allow more ready binding of new coenzyme. 
In all other D-2-hydroxyacid dehydrogenase apo structures, however, this loop region 
shows little movement when compared to its equivalent holo/binary state (where 
available) and is in a similar position to that of the human ternary/binary state. 
However, the distantly related hexameric L-Alanine dehydrogenase, which consists of 
monomers with a D-2-hydroxyacid dehydrogenase fold, contains an equivalent loop 
modeled with high B factors in the apo state and moves by up to 6A between the 
NADH bound and unbound states (Baker et al., 1998). Interestingly, in those structures 
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where minimal movement is observed the equivalent Ser217 position is occupied by a 
proline (Table 3.18). Proline cannot make the hydrogen bond interactions serine does, 
but due to its restricted configuration it is known to increase loop stability, particularly 
when present at position 2 of a ß-turn as it is here (reviewed in Vieille and Zeikus, 
2001). Thus, it is likely the presence of this proline residue in the majority of current 
structures is associated with stabilisation of this loop in the apo state. Investigation of 
the structure of a Ser217Pro mutant of human GRHPR and other related enzymes that 
do not contain this proline would potentially provide more information regarding the 
extent of this loops movement. 
Enzyme 
Human GRHPR 
H. methylovorum GRHPR 







D-Hydroxyglutarate dehydrogenase HVPGIEQNTHI 
L-Alanine dehydrogenase AVLVPGRRAPI 
Table 3.18 Coenzyme loop sequence. 
The sequence of the disordered region in the structure of Human Apo GRHPR (residues 217 - 223) is 
shown in bold. The equivalent sequences from related enzymes with available Apo structures are also 
listed. Enzymes are the same as those referenced in Table 3.14 except L-Alanine dehydrogenase from 
Baker et at, 1998. 
3.3.3 Active site density 
As noted in the results (3.2.7.1), "substrate-like" density within the active site was 
initially modeled as the dicarboxylic acid oxalate with which the protein had been 
incubated prior to crystallisation. However the presence of continuous density 
extending beyond the oxalate 01 position and into a pocket within the active site 
suggested an alternative explanation was required. The identification of an 
approximately 5% contamination by the GRHPR substrate hydroxypyruvate within the 
purchased oxalate lead to this 2-oxo keto acid being successful modeled into the 
available density, producing logical hydrogen bonds (Figure 3.22a). Furthermore a 
significant steric clash would be produced between the 01 of oxalate and the side chain 
of Leu59, indicating why it could not be present (Figure 3.22c). 
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While hydroxypyruvate was initially refined into the density it seems unlikely that this 
GRHPR substrate would remain non-reduced during the incubation period prior to 
crystallisation, particularly as NADPH was present at a 10-fold excess. Moreover, 
inhibition by the product of hydroxypyruvate reduction, D-glycerate, has been 
previously noted for a bacterial GRHPR (Izumi et al., 1990). Consequently D- 
glycerate was modeled to explain the "substrate" density. Theoretically it is possible to 
tell the difference between hydroxypyruvate and D-glycerate based on the geometry at 
the C2 position: hydroxypyruvate is trigonal, D-glycerate is tetrahedral. However, at 
2.2A the structural resolution is insufficient to definitively ascertain this geometry. 
Nonetheless, in the final model an abortive complex containing reduced coenzyme 
(NADPH) and reduced substrate (D-glycerate) was included, as this seems the most 
likely combination to remain trapped. 
3.3.4 Ligand occupancy 
Within each GRHPR dimer of the final model of the "ternary" crystal only one 
monomer represents a ternary complex, with both D-glycerate and NADPH present. 
These have been included in the model with 75% occupancy, which was found to be 
optimal for the refinement (Table 3.11). The other monomer within the dimer contains 
only NADPH (included at 50% occupancy), making it a binary complex. As 
previously discussed there is no significant conformational difference between the main 
chains of the ternary and binary complexes. Single site occupancy has previously been 
observed in the L. bulgaricus D-LDH structure. Unlike the human GRHPR, here there 
are significant (1.8A for 315 Ca) differences between the structures of the closed holo 
(ternary-like) monomer and the open binary monomer (Razeto et al., 2002). While the 
extension of the dimerisation loop in GRHPR may allow the opposing monomer to 
`sense' substrate occupancy, it is difficult to see how this information could be 
transmitted and converted into an `empty' closure. A more feasible explanation is 
provided by looking at the apo GRHPR structure, where a lack of any ligand still 
results in effectively the same "ternary-like" closed relationship between domains 
(particularly chains A-Q. This suggests the potential importance of crystal lattice 
restraints in fixing the conformation with the sub-saturation concentration of the 
substrate contaminant resulting in only one substrate site being occupied per dimer. 
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The conformational similarity of the human apo GRHPR structure also suggests why 
no ligand occupancy could be modeled at 100%. The crystal lattice could be made up 
of a certain proportion of apo monomers as their ability to crystalise in a `closed' 
conformation would not have required a disruption to the crystal packing but would 
result in a lower average presence of coenzyme and substrate. Another possibility is 
that, as binding of substrate brings an entropic cost (cf. B-factors), it is energetically 
unfeasible to have both active sites fully closed in a dimer at the same time. 
3.3.5 Previous models of substrate binding 
The identities of the residues involved in the catalytic activity of the D-2-hydroxyacid 
dehydrogenase family have long been established by mutational and chemical 
modification studies (Kochhar, Chuard and Hottinger, 1992; Kochhar et al., 1992a; 
Taguchi and Ohta, 1993,1994). These residues have subsequently been confirmed in 
the previous structural work (Goldberg, Yoshida and Brick, 1994; Dengler et al, 1997; 
Razeto et al, 2002) and correspond to Arg245, His293 and G1u274 in human GRHPR. 
Despite this the exact mode of substrate binding has been unclear. This was 
predominantly due to the lack of protein structures of a true ternary complex from this 
family. Previous models of binding have gathered support based on holo (ternary-like) 
structures, which contain coenzyme and an anion at the active site; such as FDH + 
azide (Lamzin et al., 1994), D-LDH + sulphate (Razeto et al., 2002) and CtBPI + 
acetate/formate (Kumar et al, 2002; Nardini et al, 2003). Prior to the human GRHPR 
structure, the only ternary structure was that of D-HicDH in complex with an in vitro 
substrate (ketoisocaproate). However, the usefulness of this structure is limited as the 
substrate competes with a sulphate in the active site and, crucially, by having its 
domains in the open "apo" conformation (Dengler et al., 1997). 
Based on various structures two models have been proposed to describe the mode of 
substrate binding in the D-2-hydroxyacid dehydrogenase family, predominantly 
differing in their prescribed role for the single active site arginine (Figure 1.4). Both 
models explain the stereospecificity of this family by positioning the substrate in a 
manner that presents its si face to the nicotinamide NC4 hydrogen, rather then the re 
face as in L-LDH (Figure 3.23c). Hydride transfer to the si face of the substrate results 
















Figure 3.22 Arrangement of the active site of human GRHPR. 
R302 
A) Stereoview showing D-glycerate (cyan), a fragment of NADPH (pink), and active site residues from 
subunit A (green) and subunit B (yellow). Hydrogen bonds are shown as dashed lines. B) As for (A), 
but with the addition of 2F,, b, - FCac electron density contoured at approximately 2 ß. C) Stereoview of 
active site rotated 90° in relation to (A), viewing from the position of Arg245 with residues (Arg245, 




























A) Stereoview of overlay of active site residues (as in Figure 3.22) for binary and ternary GRHPR 
complexes: ternary subunits A (blue) and C (green), binary subunits B (red) and D (yellow). B) 
Stereoview of overlay of active site residues (as in Figure 3.22) for human GRHPR ternary subunit A 
(blue), human GRHPR apo subunit D (green) and H. methvlovorum GRHPR apo subunit (red). D- 
glycerate and a fragment of NADPH are shown in cyan. C) Stereoview in similar orientation to Figure 
3.22a showing the conserved active site residues from human A L-LDH (Read et al., 2001). 
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The original model was proposed based on comparisons with L-LDH structures, the 
holo structure (NADH + azide) of FDH (Lamzin et al., 1994) and the apo structure of 
H. methylovorum GDH (Goldberg, Yoshida and Brick, 1994). In this model the 
substrate carboxylate group interacts with the active site arginine via bifurcated 
hydrogen bonds (Figure 1.4a), as seen with Argl7l in L-LDH (Figure 3.23c). This 
model was supported by the unpublished L. heleveticus D-LDH NADH/oxamate 
complex (released on the PDB in 1996, access code: 2DLD). However this model fails 
to suggest a residue capable of polarising the substrate carbonyl bond, an important 
mechanism enhancing hydride transfer and performed by a second arginine (109) in L- 
LDH (Clarke et al., 1986). 
An alternative binding mode was subsequently proposed, initially based on a structural 
model of L. bulgaricus D-LDH (Vinals et al., 1995) and again when the crystal 
structure of D-LDH from L. pentosus was found to closely match this (Stoll, Kimber 
and Pai, 1996). In this model, as also observed in the human ternary GRHPR structure 
in this study, the single conserved arginine in the active site of D-2-hydroxyacid 
dehydrogenases (Arg245 in GRHPR numbering) forms bifurcated charged hydrogen 
bonds to a single carboxylate oxygen of the substrate and also its keto oxygen (Figure 
3.22a). This allows the single active site arginine to act in both substrate binding and 
catalysis via the polarisation of the substrate carbonyl bond. This is supported by 
kinetic data where mutation of the corresponding arginine in D-LDH resulted in a large 
increase in the substrate binding constant (KM) and a decrease in the catalytic rate 
constant (kt) of the enzyme, indicating its bifunctional role (Taguchi and Ohta, 1994). 
Further mutationaly work has also supported the ability of this arginine to stimulate the 
hydrogen transfer step (Taguchi, Ohta and Matsuzawa, 1997). 
This second model appeared to be corroborated by structural data from D-HicDH, 
where the in vitro substrate ketoisocaproate is modeled in this conformation (Dengler et 
al., 1997). However, the sulphate ion (present at partial occupancy) competing with the 
substrate for the active site made this inconclusive. The structure of the transcription 
factor CtBPI in complex with NAD(H) and acetate (Kumar et al., 2002) or formate 
(Nardini et al., 2003) also support this second model. However, as these are not chiral 
substrates and CtBPI contains a second arginine participating in their binding, these 
structures were also inconclusive. 
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Therefore, despite the second model of substrate binding being generally accepted, the 
ternary structure of human GRHPR presented here is the first structure to contain an 
actual substrate analog bound in a `closed' conformation, and finally confirms the 
orientation of substrate binding within the D-2-hydroxyacid dehydrogenase family. 
The position of the bound D-glycerate can be used to provide a good estimate for the 
binding position of related molecules. More recently, the unpublished Aquifex aeolicus 
D-LDH NAD(H)/lactate ternary complex (released on the PDB in 2007, access code: 
2PI1) also replicates the substrate binding mode revealed here for human GRHPR. 
3.3.6 General D-2-hydroxyacid dehydrogenase substrate binding 
The fundamental interactions between GRHPR and D-glycerate are consistent with 
those described for the D-HicDH/ketoisocaproate complex (Dengler et al., 1997) and 
modeled for pyruvate in D-LDH (Razeto et al., 2002). The conserved active site 
arginine (Arg245) forms a bidentate hydrogen bond to D-glycerate, with one bond to 
the carboxylate oxygen (2.9A) and the second to the keto oxygen (2.9A, Figure 3.22a). 
This assists in the orientation of substrate and allows Arg245 to polarise the carbonyl 
bond (of the keto oxygen), lowering the energetic barrier for hydride transfer. Thus it 
performs the two functions that require Arg171 and Arg109 in L-LDH. 
Additional hydrogen bonds are made between the D-glycerate carboxylate group and 
the substrate binding loop, specifically the main chain amines of Va183 (2.8A) and 
G1y84 (2.8A) further stabilising this substrate orientation (Figure 3.22). The 
importance in substrate binding of this loop region has been indicated by mutational 
studies on an adjacent residue in L. pentosus D-LDH. The D-LDH residue Asn97 
forms a hydrogen bond to its equivalent substrate binding loop. By mutating this 
residue to an aspartate and consequently breaking this interaction, the affinity of the 
enzyme for pyruvate was drastically decreased (Shinoda, Arai and Taguchi, 2007). The 
equivalent residue in human GRHPR is Tyr102 and was proposed to make a similar 
interaction to that of Asn97 (Shinoda, Arai and Taguchi, 2007). However the Tyr102 
side-chain is now seen to point away from the substrate binding loop and the equivalent 
bond is formed by a water mediated link to the coenzyme (NO3*, Figure 3.24). This 
would indicate a potential dependence of correct substrate binding on coenzyme 
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presence. The only change to the active site between the human and H. methylovorum 
GRHPR occurs on this loop, replacing the conserved Va183 position with an isoleucine 
(Goldberg, Yoshida and Brick, 1994). This seems to be the only thing that could 
account for the low binding constant (10.8mM) the bacterial form displays for 
glyoxylate (Izumi et al., 1990) compared to the human form (0.24mM as will be 
described in Chapter 4) and P. horikoshii GRHPR (0.015mM, Yoshikawa et al., 2007). 
The importance of the positioning of this loop also forms part of the discussion 
regarding subsequent mutational studies (Chapter 4). 
The combination of Arg245 and Leu83-G1y84 position the D-glycerate si face (and, by 
analogy, substrate) parallel to the nicotinamide group of NADPH, placing the C2 of the 
substrate within 2.9A of the coenzyme NC4 and hence facilitating hydride transfer 
(Figure 3.22). Further substrate interactions are made to the catalytic histidine 
(His293), which forms a 2.7A hydrogen bond from its NE2 nitrogen to the ketone 
oxygen of the D-glycerate substrate (Figure 3.22). This histidine interacts with the 
OE1 of G1u274 which is 2.8A distant and both stabilises and orientates the imidazole 
ring. The negative charge of G1u274 would be expected to stabilise the protonated state 
of His293, thus raising its pKa as has been demonstrated for the equivalent residue in 
D-LDH (Kochhar, Chuard and Hottinger, 1992; Kochhar et al., 1992a). 
3.3.7 Specific GRHPR substrate interactions 
Unusually, all four monomers of human GRHPR - both binary and ternary states - 
contain a single water molecule within the active site. It is generally considered that 
solvent needs to be excluded from the active site of oxidoreductases, thus lowering the 
dielectric environment and assisting the hydride transfer reaction (Clarke and Dafforn, 
1998; Antoniou et al., 2002). However, within the active site this water makes multiple 
hydrogen bonds (Figure 3.22): to the side chains of Trp14l' (3.0A), Arg302 (3.0A), the 
carbonyl oxygen of His293 (2.9A) and the nicotinamide moiety (2.6A). The multiple 
interactions made by the water may compensate for its potentially unfavorable presence 
and could provide the enzyme with a level of flexibility, allowing the active site to 
adjust to substrates of different sizes. A similarly placed water is present in the active 
site of Bacillus stearothermophilus L-LDH and also makes multiple protein contacts 
(Wigley et al., 1992). 
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The orientation of the substrate imposed by Arg245 and Leu83-Gly84 positions the C2 
substituent in a pocket formed by Leu59, Leul07, His293, Ser296, Met305 and 
Trpl4l'. These residues are all well conserved across the GRHPR family (Figure 1.2) 
and limit the possible size of substituents on the substrate. The H. methylovorum 
GRHPR has been tested for activity towards a large number of potential keto acid 
substrates with only glyoxylate and hydroxypyruvate showing activity (Izumi et al., 
1990). From the human structure it is clear that a larger, or branched, C2 substituent 
would be unable to fit in this pocket. The D-glycerate (and by analogy, 
hydroxypyruvate) hydroxyl group makes a hydrogen bond to that of Ser296 (2.8A) 
(Figure 3.22) and any non-hydrogen bonding substituent at this position would clearly 
cause a steric clash. Any additional length in substrate would also collide with Leu107 
and Met305. Furthermore, a different substituent (or branch) at the C3 position would 
severely clash with Leu59, His293 and Trpl4l' (Figure 3.22). A key constriction 
occurs with the Leu59 side chain which comes within 3.2A of the C3 carbon of D- 
glycerate (Figure 3.22c). This is within van der Waals distance and the unfavorable 
proximity is likely to be compensated for by the hydrogen bond to Ser296. It can be 
seen in Figure 3.23b that this active site opens slightly in the human apo form with the 
substrate binding loop, Arg245 and Leu59 all moving in a way that would make the site 
more accessible for substrate, although again this movement is more pronounced in the 
H. methylovorum structure. This opening would allow hydroxypyruvate to form a 
number of interactions prior to being exposed to the full Leu59 constriction which 
would occur upon full closure. This also shows how oxalate could have bound initially 
in the active site (via Arg245 and His293), thus blocking access for other substrates and 
acting as a competitive inhibitor. However it would prevent full closure by clashing 
with Leu59 and thus be rejected from the active site and consequently not present in the 
crystal structure despite being present in 20-fold excess relative to the hydroxypyruvate 
contamination. The importance of this Leu59 restriction and the compensation 
provided by Ser295 are ideas further explored in Chapter 4 where the catalytic activity 
of human GRHPR is investigated. 
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3.3.8 Coenzyme binding 
The NADPH coenzyme is bound in the cleft between the two domains, and 
predominantly makes contacts with residues from the coenzyme binding domain 
(Figure 3.24). The elongated conformation is consistent with that seen in other 
dehydrogenases (Carugo and Argos, 1997) and many of the same interactions 
previously described for NADH in other D-2-hydroxyacid dehydrogenases are 
conserved (Lamzin et al., 1994; Dengler et al., 1997; Razeto et al., 2002). 
Adenine 
The adenine end of the coenzyme binds in a predominantly hydrophobic pocket created 
by the side chains of Ile 159, Thr183, Cys216, A1a221, Thr222 and Leu225 provided by 
ßA, ßB, ßD and aE (Figure 3.18). A number of these residues form part of the loop 
(217 - 223) that is disordered in the apo state structure (as discussed in 3.3.2.3), 
suggesting this pocket is not preformed (at least not in the human enzyme) awaiting 
coenzyme but coalesces around the adenine region upon binding, burying the 
hydrophobic side chains. The adenine moiety forms no consistent hydrogen bonds with 
either the protein or conserved waters. This is in contrast to other family members 
which contain a direct hydrogen bond to a glutamine or asparagine, residues with no 
equivalent present in human GRHPR. The higher resolution (2.05A) holo FDH 
structure also contains a water network linking the adenine moiety to nearby side 
chains (Lamzin et al., 1994). A similar network could potentially be present in the 
human form, but is not visible at the resolution and quality of this structure. Overall, it 
is assumed that van der Waals contacts account for most of the interactions between the 
adenine and enzyme. 
Adenine 2' phosphoribose 
As this is the first structure of a D-2-hydroxyacid dehydrogenase in complex with 
NADPH the interaction of the protein with the 2'-phosphate is of particular interest. 
The phosphate is situated within a pocket, surrounded on three sides by the side-chains 
of Arg185, Arg188 and G1n186, and below by G1y184. Members of this family with 
strict dependence on NADH contain an aspartate in place of this glycine (Asp 175 in D- 
LDH, Razeto et al., 2002) which would sterically clash with and electrostatically repel 
the phosphate moiety. Residues Arg185 and Arg188 provide a number of salt bridges 
to the 2'-phosphate (Arg185) and a charged hydrogen bond to the 3'-hydroxyl (Arg188, 
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Figure 3.24). Together they act as an "electrostatic clamp", sandwiching the 2'- 
phosphate. Unsurprisingly the side chains of these residues are largely disordered in 
the apo enzyme structure. A similar arrangement of positively charged residues is seen 
in other NADPH dehydrogenases, including the E. coli NADPH dependent shikimate 
dehydrogenase AroE, where the two structurally equivalent arginines (150 and 154) 
perform this function (Michel et al., 2003), and in enzymes from the NADPH 
dependent short-chain dehydrogenase family (Tanaka et al., 1996) where a lysine and 
arginine, more distant in sequence (residues 17 and 39 respectively), are used. This 
pocket is further discussed in 4.3.1.1 in relation to the determined coenzyme specificity 
of the human enzyme. 
Pyrophosphate 
Consistent with other structures, the pyrophosphate part of NADPH is positioned near 
the G-X-G-X-X-G motif (residues 160 - 165 in human GRHPR) which functions to 
help create an a-helix dipole at the end of aB (Figure 3.18), endowing this region with 
a slight positive change to neutralise the positive pyrophosphate (Wierenga, Demaeyer 
and Hol, 1985). A number of interactions between this region and water molecules in 
the ternary state are lost in the (most open) binary state subunit (chain D). These 
include a conserved water that tetrahedrally coordinates NO1 of the coenzyme to main- 
chain atoms and the link from NADPH (N02) to the hinge region of the enzyme 
(Asp105 and Thr108) (Figure 3.24). The loss of these interactions potentially explains 
the reduced coenzyme occupancy seen in the binary state structures. The water 
mediated link to the hinge region is a conserved feature amongst ternary and holo D-2- 
hydroxyacid dehydrogenase structures (Lamzin et al., 1994; Dengler et al., 1997; 
Razeto et al., 2002) and has previously been proposed to be an important contributor to 
the hydrogen bond network that stabilises the closed domain conformation (Razeto et 
al., 2002). 
Nicotinamide ribose 
The nicotinamide ribose 2' and 3' oxygens make a number of interesting interactions. 
Firstly, alone amongst the current structures, N03* interacts with the side chain of 
Ser217 which also binds the adenine ribose (A04*) (Figure 3.24). This interaction, 
which is described in section 3.3.2.3, is likely to assist in the stabilisation of the 
subsequent loop. Also, both N03* and N02* make water mediated interactions with 
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regions of the substrate binding loop (Va183 and Asp86 respectively) with the Va183 
interaction only being made in the ternary state monomers (Figure 3.24). These bonds 
are likely to be involved in stabilising the closed domain conformation and helping to 
correctly position this loop and, consequently, the substrate. 
Nicotinamide 
Hydrogen bonding interactions with G1y295, Asp269, I1e242 and the active site water 
result in a 33° twist (average of the 4 bound coenzymes) of the carboxamide group out 
of the pyridine plane. A similar degree of twist is seen in other family members. This 
places the carboxamide oxygen (N07) in the cis-orientation relative to NC4 (Figure 
3.24), consistent with other dehydrogenases, and has been proposed to activate the NC4 
atom for hydride transfer (Li and Goldstein, 1992). These interactions, and those of the 
nicotinamide ribose, position the nicotinamide A face for hydride transfer, with 2.9A 
between NC4 and the C2 position of the substrate/product, a suitable distance for 
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Figure 3.24 Hydrogen bonding interactions with NADPH. 
The bonds formed between human GRHPR and the co-enzyme are shown as dashed lines with the atoms 
involved labelled. Water molecules (w) are included with their coordinating residues where appropriate. 
The active site water (indicated by *) makes the further interactions shown in Figure 3.22, which are not 
repeated here. Interactions shown in red only occur in the ternary monomers. The NADPH atom 
labelling is based on Carugo and Argos, 1997. 
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3.3.9 PH2 causing mutations 
Primary hyperoxaluria type 2 is the result of a deficiency in GRHPR activity, resulting 
in glyoxylate and hydroxypyruvate being alternatively converted to oxalate and L- 
glycerate respectively (Williams and Smith, 1968b). A small number of mutations 
have been identified within the human GRHPR gene of PH2 patients and shown, 
through expression and activity trials, to be the genetic cause of the disorder (Cramer et 
al., 1999; Webster et al., 2000; Cregeen et al., 2003; Takayama et al., 2007 reviewed in 
Danpure and Rumsby, 2004). The majority of these mutations (approximately 80%) 
are small deletions or single base substitutions that result in a truncated peptide due to 
the creation of termination codons. The GRHPR enzyme may be particularly exposed 
to the effect of truncation mutations as the coding sequence for the coenzyme binding 
domain is inserted within that of the substrate binding domain, meaning without full 
length expression no stable domain can fold. Further identified mutations include 
missplicing events and 7 missense mutations: Glyl65Asp and Met322Arg (Webster et 
al., 2000), Asn3l2Asp (personal communication D. Dinour, Israel), G1ull3Lys 
(Takayama et al., 2007), Glyl60Arg and Arg302His (personal communication Dr G. 
Rumsby, London) and Arg302Cys (Cregeen et al., 2003). These are indicated in the 
sequence alignment shown in Figure 1.2 and mostly occur at highly conserved residues. 
The elucidation of the GRHPR crystal structure allows the mechanism by which these 
substitution mutations affect the catalytic ability to be interpreted. 
Two of these mutations cause obvious problems for the binding of the coenzyme to 
GRHPR: Glyl60Arg and Gly165Asp. The Gly160 residue lies at the bottom of the 
adenine ribose binding pocket and is highly conserved across not only the D-2- 
hydroxyacid dehydrogenase family but all NAD(P)H binding enzymes, being 
substituted only rarely for an alanine (Carugo and Argos, 1997). The inclusion of the 
bulky arginine side chain at this position would clearly inhibit the ability of the 
coenzyme to bind. This glycine is also at position 1 of the nucleotide-binding ßaß 
`fingerprint', Gly-X-Gly-X-X-Gly (Wierenga and Hol, 1983), where it facilitates the 
required sharp turn in the polypeptide allowing subsequent interactions with the 
pyrophosphate region of the coenzyme. The glycine at position 165 is again highly 
conserved across all NAD(P)H binding enzymes (Carugo and Argos, 1997) as it 
constitutes the third glycine of the Pap `fingerprint'. Here this small residue is required 
to allow the close interaction between the P-strands and a-helix of this fold (Wierenga 
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and Hol, 1983), an interaction the mutation to aspartate would be expected to disrupt 
resulting in the reported loss of catalytic ability (Webster et al., 2000). 
Both the Met322Arg and Asn3l2Asp mutation result in a loss of GRHPR activity 
(Webster et al., 2000 and personal communication D. Dinour, Israel) and investigation 
of the structure suggests this may result from the same mechanism: destabilisation of 
the C-terminus. The C-terminus of human GRHPR lies at the edge of the 
substrate/coenzyme binding cleft (Figure 3.17) and its destabilisation may inhibit 
binding and domain closure or may target the enzyme for degradation. The Met322Arg 
mutation may cause this by the larger arginine side chain not being accommodated in 
the hydrophobic pocket which accommodates the original methionine in this position, 
resulting in distortion of the main chain. It seems unlikely that the positive charge of 
the arginine would be readily accommodated in this hydrophobic region which is 
central to the core of the domain, and hence folding is likely to be disrupted. Similarly, 
substitution of Asn312 -a fairly well conserved residue - with a charged aspartate side 
chain also introduces a charged group close to the same hydrophobic core region, and 
again is likely to disrupt the domain folding. 
The recently reported Glu113Lys mutation (Takayama et al., 2007) occurs at the 
dimerisation interface. The Glu113 residue normally forms a hydrogen bond from the 
dimerisation loop to the coenzyme binding domain of the opposite monomer. As 
suggested by Takayama et al., (2007) this mutation represents a change in side chain 
size and charge and may destabilise the dimer interface. This is likely to be particularly 
deleterious as Trpl4l at the tip of the dimerisation loop participates in the active site of 
the opposing monomer. 
Two PH2 causing amino acid substitutes have been identified for Arg302, one to a 
histidine (personal communication Dr G. Rumsby, London) and one to a cysteine 
(Cregeen et al., 2003). As discussed in section 3.3.7, the arginine residue is in close 
proximity to the GRHPR active site and participates in a hydrogen bonding network 
involved in the stabilisation of the hydroxypyruvate substrate (via Ser296) and the 
dimerisation loop/Trpl4l' (via H2O and Prol40') (Figure 3.22c). Neither of the 
substitute amino acids, while theoretically being a reasonable chemical fit, would be 
able to facilitate the multiple interactions that the native arginine residue performs. The 
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loss of these hydrogen bonds could be expected to affect dimerisation and substrate 
binding of GRHPR. Interestingly the Arg302Cys mutation has been shown to 
completely lack hydroxypyruvate reductase activity but retains some (5.6% wild type) 
glyoxylate reductase activity (Cregeen et al., 2003). This indicates the hydrogen 
bonding network is of particular importance for the enzymes substrate specificity and is 
further discussed in Chapter 4. 
These explanations for how these mutations reduce GRHPR activity hence leading to 
PH2 leads to the question of whether drugs could be designed to overcome this 
problem. The mutations that are thought to decrease protein stability (Met322Arg and 
Asn3l2Asp) or dimerisation (G1u113Lys) might potentially be rescued by 
pharmacological chaperones, small molecules selected to enhance protein stability. 
This would allow the GRHPR to regain some functionality and reduce the pathology of 
PH2. Research into the potential of pharmacological chaperones as a class of drugs is 
still at an early stage and is largely focused on cell surface and exported proteins (Loo 
and Clarke, 2007). This rescue mechanism has been suggested to have potential in 
stabilising certain mutants of AGT, the cause of the more common PHI (Danpure, 
2005). However, due to the general rareness of PH2 and the further infrequency of 
these `destabilising' mutations it seems unlikely that this would become a target of 
specific drug design. This does not preclude alternative approaches discussed 
elsewhere in this thesis such as gene therapy (inducing expression of wild-type 
GRHPR) or the (partial) inhibition of L-LDH in order to reduce levels of oxalate, 
which appears to be responsible for most morbidity associated with PH2. 
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Chapter 4 Kinetic studies of human GRHPR 
4.1 Chapter overview 
The work presented in the following chapter was done in collaboration with Dr G. 
Rumsby (UCL Hospitals, London) and, where necessary for completeness, work 
carried out by her laboratory will be included and noted as such. The kinetics 
parameters of recombinant human lactate dehydrogenase (LDH) A, LDHB and 
GRHPR have been determined with a number of substrates in both the reductive and 
oxidative reactions. This has provided the first detailed kinetic information on human 
GRHPR and has allowed the relative roles of LDH and GRHPR in the removal of the 
reactive glyoxylate species and the production of oxalate under physiological 
conditions to be investigated. The mechanisms by which the `healthy' GRHPR route is 
selected over LDH will be discussed. Additionally, using the structures described in 
Chapter 3, the specificity results presented in this chapter can be interpreted from a 
structural perspective. Accordingly a structure based model is proposed to explain the 
coenzyme and substrate specificity of this enzyme. 
The kinetic analysis of recombinant GRHPR produced during this thesis and its 
comparison to the kinetics of human LDHA and B as discussed in the following 
chapter has been published (Mdluli et al., 2005. The herein described model of 
GRPHR substrate specificity has also been published (Booth et al., 2006). 
4.2 Results 
4.2.1 Expression and purification 
In keeping with work already undertaken by the Rumsby Group (UCL Hospitals, 
London), protein from the unmodified pTrcHisB-HPR construct was prepared and used 
for the kinetic experiments. Expression from this construct proceeded identically to 
that described for the thrombin modified form. Within the methods chapter (2.3.11 - 
2.3.14), the purification procedure is described for the production of GRHPR used for 
crystallisation. The procedure used to purify protein for the kinetic studies varies 
slightly in that the nickel column buffers used a 20mM potassium phosphate buffer pH 
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7.5 and 500mM NaCl and the gel filtration buffer was changed to 20mM potassium 
phosphate buffer pH 7.5,100mM NaCl. This was to retain a consistency with work 
carried out in the Rumsby lab. Also due to the use of the pTrcHisB-HPR construct, the 
GRHPR retained the poly-His tag and the benzamidine column step was not carried 
out. 
Selected fractions from the Ni2affinity step were pooled and buffered exchanged into 
20mM potassium phosphate buffer pH 7.5,100mM NaCI in preparation for purification 
via Superdex 75 gel filtration chromatography. The resulting A280 trace (not shown) 
consisted of a single, large, symmetrical peak that corresponds to purified GRHPR 
eluting at a volume of 52.7ml. The conversion equation (logMr = -1.4758(Ve]t; o/Vv,; od) 
+ 6.8879, where V,; w = 41) indicates a molecular weight for the GRHPR of 
approximately 98kDa, slightly bigger then the expected 8OkDa tagged GRHPR dimer. 
This purification procedure resulted in pure protein (Figure 4.1) which was dialysed 
into 20mM potassium phosphate buffer pH 7.5 overnight. Protein concentration was 
determined by A280 (MW = 40,027 Da, s= 29450 M-'. cm') and this pure protein was 
then used for all kinetic studies. The GRHPR used in this section retained its poly-His 
tag, a number of studies have shown that the presence of a terminal His-tag does not 
significantly affect the kinetics of an enzyme (Schmitt, Hess and Stunnenberg, 1993; 
Ma and Kovacs, 2000; Shoemark ei al., 2007). Additionally, due to the extended 
distance of the N-terminus from the active site of GRHPR this seemed unlikely. 
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Figure 4.1 SDS-PAGE gel of GRHPR used for kinetics. 
Pooled GRHPR after final purification by size exclusion chromatography showing greater the 95% 
purity. 
99 
4.2.2 Kinetic values to be determined 
Calculation of the Vmax and KM parameters for each enzyme: substrate: coenzyme 
combination were done in the same manner, by following the decrease in absorbance as 
NAD(P)H was converted to NAD(P)+for the reduction reactions. An increase in 
absorbance is seen during the oxidation reactions, as NAD+ is converted to NADH. 
The values of these parameters were calculated as described in the methods (2.3.22) 
from the double reciprocal Lineweaver-Burk plots, where KM is equivalent to -1/x- 
intercept (1Napp = 0) and Vmax to 1/y-intercept (1/[S] = 0). The KM parameter is 
independent of enzyme concentration and is presented in , while the Vmax value was 
used in the calculation of the rate constant as described below. 
4.2.2.1 Calculation of rate and specificity constants 
The catalytic rate constant (kcat) is a function of the first-order rate constants for the 
conversion of the enzyme-substrate (ES) complex to the enzyme-product (EP) complex 
and subsequent dissociation (E + P), assuming initial binding steps are fast (Fersht, 
1985). This value represents the maximum number of substrate molecules converted to 
product per active site per unit of time, providing the "turnover number" of the enzyme. 
The kcat for the reactions were calculated using the equation (Vmax/60)/[Etotai] and is 
therefore independent of the assay enzyme concentration and is reported in units of per 
second (s-1). The kcat/KM ratio, an apparent second-order rate constant for the reaction 
as the rate varies with how often enzyme encounters substrate (Fersht, 1985), was also 
calculated. The keat/KM value can be used as an indication of enzymatic specificity in 
the sense of an enzyme's preference for one or other competing substrates, ie 
glyoxylate or hydroxypyruvate, or one substrates `preference' between two enzymes, ie 
GRHPR or LDH. The kcat/KM value are therefore also referred to as specificity 
constants (Fersht, 1985). 
The calculated kinetic parameters are shown in and the relevant graphs are presented 
below. The focus of the work carried out during this thesis was on the turnover of 
hydroxypyruvate by recombinant GRHPR. These results shall be discussed in 
combination with those produced by Dr G. Rumbsy to produce a complete picture of 
the metabolism of substrates relevant to PH2. 
100 
4.2.3 Confirming kinetic constants for glyoxylate and NADPH 
Initial work undertaken in the Rumbsy lab had varied NADPH or NADH (0.00625mM 
- 0.3mM) and glyoxylate (0.125mM - 1mM) concentrations, measuring the reaction 
rates at an enzyme concentration of 12nM (Figure 4.2). The kinetic parameters 
calculated from this by both curve fitting and secondary plots were the same and are 
given in . Also calculated were the 
KM values for GRHPR with NADPH and NADH 
0- 
In order to confirm that comparable work was carried out during this thesis, this assay 
was partially repeated in our laboratory. Using an excess of NADPH (0.3mM), the 
concentration of glyoxylate was varied (0.02mM - 0.125mM). An enzyme 
concentration of 12.5nM was used and the change in absorbance as NADPH was 
consumed was measured. A Lineweaver-Burk double reciprocal plot (Figure 4.3) was 
used to calculate the kinetic parameters (b). This produced very similar values to those 
of Dr Rumbsy (a), indicating the enzyme preparations and methodology undertaken 
were comparable to those of our collaborators. Additionally, it was shown that even in 
the presence of very high concentrations of pyruvate (up to 50mM) no GRHPR 










Figure 4.2 GRHPR reduction of glyoxylate with NADPH from the Rumsby lab. 
Effect of variation of NADPH on reaction rate at 
fixed glyoxylate concentrations of 0.125mM (A), 
0.25mM (Q), 0.55mM (") and 1mM (o). Values are mean ± standard deviation, n=3. Reproduced from 
Mdluli et at., (2005). 
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Figure 4.3 Secondary plot of GRHPR catalysed glyoxylate reduction with NADPII. 
Secondary plot of I/V'P4' vs. 1/glyoxylate for determination of KM for GRHPR for glyoxylate reduction. 
4.2.4 Establishing kinetic constants. for hvdroxvpvruvate and NADPH 
The kinetic parameters for GRHPR catalysed reduction of hydroxypyruvate with 
NADPH as the coenzyme were attempted by the Rumbsy lab in a similar manner to 
those for glyoxylate. The NADPH concentration was varied (0.00625mM - 0.3mM) as 
was the hydroxypyruvate (0.125mM - 2mM) (Figure 4.4). It became apparent that as 
the substrate concentration was increased the reaction rate decreased, indicative of 
substrate inhibition. Accurate kinetic parameters could not therefore be calculated 
from these data. 
By methodically lowering the amount of hydroxypyruvate it was possible to observe 
approximately at what concentration inhibition occurred. Kinetic assays were run with 
12.5nM GRHPR, excess NADPH (0.3mM) and hydroxypyruvate ranging between 
0.02mM and 0.5mM (Figure 4.5) to determine the substrate concentrations best suited 
for study. It can be seen that the reaction rate, measuring the use of NADPH, decreases 
as the hydroxypyruvate concentration was increased above 0.07mM (Figure 4.5). 
Additionally, measurements taken at low substrate concentrations (0.02mM and 
0.03mM) could not be accurately measured due to the signal to noise ratio. Data from 
0.04mM to 0.07mM hydroxypyruvate was subsequently plotted on a Lineweaver-Burk 
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Figure 4.4 Initial plot of CRHPR catalysed hydroxypyruvate reduction with NADPH. 
Effect of variation of NADPH on reaction rate at fixed hydroxypyruvate concentrations of 0.125mM 
(A), 0.25mM (o), 0.55mM (. ), 1mM (o) and 2mM ( ). Values are mean ± standard deveiation. n-3. 
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Figure 4.5 Primary plot of CRHPR catalysed hydroxypyruvate reduction with NADPII. 
Effect of variation of hydroxypyruvate concentration at a fixed NADPI I concentration (0.3mM). Values 
















Figure 4.6 Secondary plot of GRHPR catalysed hydroxypyruvate reduction with NADPH. 
Secondary plot of 1/Vary vs. 1/hydroxypyruvate for determination of KM for GRHPR for 
hydroxypyruvate reduction. 
4.2.5 Establishing kinetic constants. for hydroxypyruvate and NADH 
Similar hydroxypyruvate inhibition was seen when NADH was used as the coenzyme 
for GRHPR catalysed reduction. Here 25nM GRHPR was used with excess NADH 
(0.3mM). The hydroxypyruvate concentration was varied from 0.02mM to 0.08mM 
and a decrease in the reaction rate (V`PP) can clearly be seen above 0.05mM 
hydroxypyruvate (Figure 4.7). Data from 0.05mM and below was used to construct a 
Lineweaver-Burk plot (Figure 4.8), from which the kinetic parameters were calculated 
(a). 
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Figure 4.7 Primary plot of GRHPR catalysed hydroxypyruvate reduction with NADH 
Effect of variation of hydroxypyruvate concentration at a fixed NADH concentration (0.3mM). Values 
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Figure 4.8 Secondary plot of GRHPR catalysed hydroxypyruvate reduction with NADH. 
Secondary plot of 1/V'Pr vs. 1/hydroxypyruvate for determination of KM for GRHPR for 
hydroxypyruvate reduction with NADH. 
v=0.0019x + 0.0102 
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4.2.6 Summary of LDH work carried out by the Rumsby group 
It has been proposed that LDH is responsible for the cellular production of oxalate from 
glyoxylate and is responsible for the increase in oxalate seen in the primary 
hyperoxalurias (Williams and Smith, 1971). Liver expresses predominantly the LDHA 
isoform (Brooks et al., 1999) and this could therefore be considered the isoform most 
likely responsible for the production of the excess oxalate seen in PH2. The Rumbsy 
lab carried out work determining the kinetic parameters for the two LDH isoforms in an 
identical manner and under identical "physiological" conditions to those described for 
the GRHPR enzyme, allowing their direct comparison. An example of the primary and 
secondary plots relating to the reduction and oxidation of glyoxylate by LDHA are 
































Figure 4.9 Glyoxylate reduction and oxidation by LDHA. 
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Figure 4.9 Primary and relevant secondary plots for glyoxylate reduction and oxidation by human L- 
LDHA. Reduction of glyoxylate. (a) Effect of variation of NADH concentration on reaction rate at fixed 
glyoxylate concentrations of 1.25mM (A), 2.55mM (o), 5mM (") and 10mM (0). Values are mean ± 
standard deviation, n=3. (b) KM and Vm. were derived from the secondary plot. Oxidation of 
glyoxylate. (c) Effect of variation of NAD concentration on reaction rate at fixed glyoxylate 
concentrations of 0.5mM (A), 1 mM (Q), 2mM (") and 4mM (. ). Values are mean ± standard deviation, 
n=3. For the oxidation of glyoxylate, the KM was determined from the intercept on the ordinate of the 
secondary plot (d) and V from a plot of 1fV "vs. 1/NAD (not shown). Reproduced from Mdluli et al., 
(2005). 
4.2.7 Results summary 
4.2.7.1 GRHPR overview 
The values produced in the Rumbsy lab for GRHPR catalysed glyoxylate reduction 
(with NADPH as coenzyme) shall be the values used for further discussion, although 
they are effectively the same as those produced in this thesis (110s'. mM-1 against 157s" 
1. mM"', ). This is for consistency with the publication arising from these results 
(Mdluli et al., 2005). The reduction of both hydroxypyruvate and glyoxylate could be 
performed by GRHPR utilising either NADPH or NADH as the coenzyme, although 
the specificity constants for both substrates show a preference for NADPH, reflecting 
the lower substrate KM values produced when this coenzyme is used 0. Potential 
structural reasons for this coenzyme specificity will be discussed later (4.3.1.1). With 
either NADPH or NADH as the coenzyme, hydroxypyruvate (specificity constants 
670s"l. mM-' and 344s"'. mM-1 respectively) was the preferred substrate over glyoxylate 
(1lOs"'. mM-' and 67s-'. mM-'). Substrate inhibition of GRHPR was clearly present 
when hydroxypyruvate was used as the substrate, with either NADPH or NADH as the 
coenzyme. Inhibition occurred above 0.07mM with NADPH and 0.05mM with NADH 
(Figure 4.5 and Figure 4.7). Consequently kinetics parameters were calculated from 
data collected at hydroxypyruvate concentrations below those that had an inhibitory 
effect. As with the other characterised GRHPRs, from H. methylovorum (Izumi et al., 
1990), Methylobacterium extorquens (Chistoserdova and Lidstrom, 1991) and rat 
(Dawkins and Dickens, 1965), the human form shows no activity towards pyruvate. 
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4.2.7.2 LDH overview 
Examination of the specificity constants 0 for the reduction reaction of the LDH 
isoforms, indicates a clear substrate preference order of 
pyruvate>hydroxypyruvate>glyoxylate. In the case of LDHA the specificity constants 
decrease from 2200s 1. mM-' for the preferred substrate pyruvate, to 430s"'. mM-l and 
22s"l. mM-1 for hydroxypyruvate and glyoxylate respectively. Both LDH isoforms 
show very similar specificity constants for oxidation reactions involving lactate (52 - 
1lOs'. mM-) and glyoxylate (30 - 100s 
1. mM'') indicating no inherent substrate 
preference. No activity for glycolate as a substrate was evident. As expected, when 
NADPH was utilised as the coenzyme any activity was beyond the sensitivity of the 
assay used for both LDHA and LDHB indicating a very high KM value 0. 
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Table 4.1 (Legend) 
Values in bold determined by M. Booth during the course of this thesis. Letters in parenthesis are 
directly referenced in the main results text. Values in parenthesis are the outcome of curve fitting pre- 
inhibition data to the Michaels-Mention equation (GraphPad Prism version 4.03, GraphPad Software 
Inc. ). GRHPR KM vaules for coenzyme (NADPH and NADH) were calculated with glyoxylate as the 
substrate. The specificity constant data is also summarised schematically in Figure 4.10. Values are ± 
standard deviation, n=3. 
4.3 Kinetics discussion 
Prior to the work presented above, no significant kinetic characterisation of human 
GRHPR had been undertaken. An important factor in this work is that it was 
undertaken under identical, near physiological conditions for all enzymes, substrates 
and cofactors rather then optimised conditions to for reduction and oxidation reactions. 
This has allowed the preferred route of cytosolic glyoxylate and hydroxypyruvate 
metabolism to be established along with its likely causes. Additionally, the recently 
completed ternary structure of human GRHPR allows the determined specificity to be 
interpreted structurally. 
4.3.1 Specificity as explained by the protein structure 
The ternary structure of human GRHPR elucidated during this thesis, described in 
Chapter 3 and since published (Booth et al., 2006), allows for various aspects of the 
above presented kinetic results to be explained from a structural perspective. While the 
kinetics show which substrates and coenzymes are utilised by human GRHPR, the 
crystallographic structure allows the mechanisms by which these specificities are 
determined to be proposed. 
4.3.1.1 Coenzyme specificity 
The kinetic data given in indicates that reduction of both glyoxylate and 
hydroxypyruvate catalysed by human GRHPR proceeds with a similar efficiency 
immaterial of which coenzyme, NADPH or NADH, is included. A slight preference 
for NADPH is apparent, with an approximately 2-fold increase in specificity constants 
when this coenzyme is used. Additionally, the Michaelis constant (KM) values of 
0.011mM and 2.42mM for NADPH and NADH respectively indicate a 200-fold tighter 
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binding of NADPH to human GRHPR, calculated when glyoxylate is used a the 
substrate. A similar NADPH preference is also seen in the rat GRHPR (van 
Schaftingen, Draye and van Hoof, 1989) but is in contrast to the bacterial homolog 
from H. methylovorum, which is strictly NADH dependent (Izumi et al., 1990). The 
investigation of the human GRHPR ternary structure, the first crystal structure of a 
member of the D-2-hydroxyacid dehydrogenase family that utilises NADPH, indicates 
the potential reasons for this preference. 
A survey of (then available) NAD(P)H-protein complex structures by Carugo and 
Argos (1997) indicated coenzyme specificity is not a product a few specific residues, 
but a function of the entire adenosine ribose binding pocket. However, specificity for 
NADH over NADPH in dehydrogenases is usually considered to be largely determined 
by an aspartate or glutamate residue within this pocket. This bulky, negatively charged 
side chain produces an electrostatic and steric repulsion effect on the 2'-phosphate of 
NADPH, while providing hydrogen bonds to the 2'- and 3'-hydroxyl groups of NADH. 
Within the NADH specific D-2-hydroxacid dehydrogenases this is provided by Asp 177 
in H. methylovorum GRHPR (Goldberg, Yoshida and Brick, 1994) and Asp175 in L. 
bulgaricus D-LDH (Bernard et at, 1995). The structurally equivalent position in 
human and other mammalian GRHPRs is a glycine (184), resulting in no steric clash 
for NADPH. The single mutation of Aspl75Ala in L. bulgaricus D-LDH has been 
shown to result in lower, but approximately equivalent, affinities for NADH and 
NADPH (Bernard et al., 1995). This suggests that the lack of the aspartate residue, 
while important, is insufficient to determine specificity of NADPH over NADH. 
As previously stated (section 3.3.8) the 2'-phosphate of NADPH in the human GRHPR 
structure is situated within a pocket, surrounded on 3 sides by the side-chains of 
Arg185 and 188 and G1n186. Residues Arg185 and 188 provide a number of hydrogen 
bonds to the 2'-phosphate (Arg185) and 3'-hydroxyl (Arg188) (Figure 3.24). Together 
they sandwich the 2'-phosphate and are likely to be responsible for the higher affinity 
of the NADPH coenzyme. This binding region sequence is completely conserved in 
the NADPH-dependent GRHPR from the rat (MGC project team, 2004). 
The ability of human GRHPR to utilize NADH with an affinity (KM) of 2.42mM is 
potentially due to the position of 
Arg188, which would be able to make hydrogen 
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bonds to the 2'- and 3'-hydroxyl groups of this coenzyme (Figure 3.24). Conversely, 
the equivalent arginine in the strictly NADPH-dependent AroE (Arg154) is not in a 
position to make any NADH interactions (Michel et al., 2003). The importance of this 
coenzyme preference shall be discussed in later sections. 
4.3.1.2 Substrate specificity 
The ability of human GRHPR to catalysis the reduction of glyoxylate (specificity 
constant of 110s-l. mM") and hydroxypyruvate (670s-'. mM"'), while remaining inactive 
towards pyruvate shows the human form maintains the unusual substrate selectivity 
seen across the GRHPR family (Dawkins and Dickens, 1965; Izumi et al., 1990; 
Chistoserdova and Lidstrom, 1991). These 3 substrates can be seen schematically in 
Figure 4.10 to differ by the substituent of the C2 carbonyl group. Glyoxylate contains a 
small (H-), pyruvate a medium (CH3-) and hydroxypyruvate a large (HOCH2-) 
substituent, with GRHPR enzymatic activity only being observed with the two 
extremes. The ternary structure of GRHPR presented in this thesis contains a product 
molecule (D-glycerate) and confirms the proposed mode of substrate binding in the D- 
2-hydroxyacid dehydrogenase family (described in Chapter 3). The position of the 
bound D-glycerate can be used to provide a good estimate for the binding position of 
related molecules. By investigating the atomic environment surrounding the substrate 
binding site, and noting the conserved residues of the GRHPR family, it becomes 
possible to propose an explanation for the unusual substrate specificity. 
Figure 3.22 in the preceding chapter displays the key residues within the substrate 
binding site, all of which are highly conserved across the GRHPR family (Figure 1.2). 
It can be seen that the CD2 methyl group of the Leu59 side chain comes within 3.2A of 
the substrates "C3" position (assuming equivalent binding as D-glycerate). This 
produces a steric restraint on the substituent at the "C3" position due to potential van 
der Waals radii clashes, with the carbon atoms of two methyl groups requiring 
approximately 4A separation (Mathews, van Holde and Ahern, 2000). Consequently, 
the inclusion of a methyl group at this position (as in pyruvate) would result in a 
significant clash with the leucine side chain, reflected in a lack of activity towards this 
substrate (KM > 100mM). This steric restraint also explains why oxalate was not seen 
in the crystal structure despite being included in the initial conditions, as the oxygen at 
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the equivalent position would also clash. The small substituent of glyoxylate (H-) 
however would produce no such clash, and as a result can be bound (KM = 0.24mM) 
and reduced (11Os l. mM"') effectively. 
The Leu59 side chain could be considered a "steric gate" blocking the larger pyruvate 
(and similar) substrates but the ability of hydroxypyruvate, with an even bigger 
hydroxymethyl constituent, to bind more tightly then glyoxylate (KM = 0.058mM) 
suggests it acts more selectively. The tight binding of hydroxypyruvate indicates the 
apparent steric clash of its CH2 group with the CD2 methyl group of Leu59 can be 
overcome. A likely mechanism for this is via the hydrogen bonding of the hydroxyl 
group of this substrate to that of the Ser296 side chain 2.8A distant. This bond links 
hydroxypyruvate into a hydrogen bonding network involving Arg302, a conserved 
water molecule, the backbone carbonyl of the catalytic histidine (293) and the 
imidazole nitrogen of Trp 141' (Figure 3.22). The final residue, Trpl4l', is provided by 
the dimersiation loop of the second monomer which, penetrates further into GRHPR 
then other D-2-hydroxyacid dehydrogenases. The high level of conservation of these 
residues (Leu59, Ser296, Arg302 and Trpl4l) in known GRHPR sequences (Figure 
1.2), but not the D-2-hydroxyacid dehydrogenase family, further supports their role in 
substrate specificity. 
A number of mutants of GRHPR were designed and constructed in efforts to test this 
hypothesis (section 2.3.21). However, two of these mutants aggregated during 
purification and could not be further utilized; the double mutant: Leu59Val/Ser296A1a 
and the single mutant: Ser296A1a. The Ser296A1a mutation was designed to confirm 
that the hydrogen bond between this residue and hydroxypyruvate is essential to the 
ability of GRHPR to catalyse its reduction and thereby indirectly confirm the 
importance of the Leu59 steric gate. It is tempting to speculate that the instability of 
these two mutants is due to a loss of Ser296 in its role to coordinate the active site 
water and correctly position Arg302 to do so (Figure 3.22). This water is involved with 
the dimer interface due to Trpl4l' and a destabilisation of its position may affect this 
interface and consequently the stability of the enzyme. 
The two remaining mutations; Leu59Val and Leu59Ala, were both designed in an 
attempt to reduce the suspected Leu59: substrate steric clash and as a result provide 
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human GRHPR with a certain degree of activity towards pyruvate. While these 
mutations could be successfully purified they showed no detectable activity towards 
any substrate (glyoxylate, hydroxypyruvate or pyruvate) despite concentrations of up to 
100mM being tested. The abolition of the activity of the Leu59Ala mutation is perhaps 
due to the large change is space filled by this residue allowing excess solvent molecules 
to remain in the substrate binding cavity upon domain closure, negatively affecting the 
hydride transfer reaction (Clarke and Dafforn, 1998; Antoniou et al., 2002). A close 
examination of the active site suggests a structural mechanism by with the activity of 
the Leu59Val mutant has been negatively affected. If the new valine residue 
maintained the orientation seen for Leu59 in the native structure it would result in a 
clash with the Ser82 side chain of the substrate binding loop (Figure 3.22). This loop 
(Ser82 - G1y84) forms one end of the substrate binding site and would be critical in 
correctly positioning the C2 of any substrate over the C4 of the nicotinamide ring, due 
to the hydrogen bonds it forms to the carboxylate group tethering one end. Additional 
rotamers available to a valine at this position (as analysed in Coot; Emsley and Cowtan, 
2004) would also result in significant steric clashes, including with the substrate 
binding residue Arg245. 
While the mutations created in this study have not proved useful in examining the 
substrate specificity hypothesis, the PH2 causing mutation Arg302Cys has been 
enzymatically studied (Cregeen et al., 2003) and provides support for the importance of 
the hydrogen bonding network. Like the Arg302His mutation discussed in section 
3.3.9, this Arg302Cys mutation would result in a side chain which is unable to 
participate in the network of hydrogen bonding interactions with Ser296, the conserved 
water and Trpl4l' observed within the native enzyme (Figure 3.22). The Arg302Cys 
mutant has been shown to retain some ability to reduce glyoxylate (5.6% of wild type 
activity) but displays a complete loss of hydroxypyruvate reductase activity (Cregeen et 
al., 2003). This would corroborate the argument that this hydrogen bond network is 
essential for assisting hydroxypyruvate to overcome the steric barrier presented by 
Leu59, but is not required specifically for glyoxylate reduction. The reduction in 
glyoxylate functionality in this mutant may be a consequence of a relaxation in the 
dimerisation due to a disruption of the Trpl4l' positioning (as this residue also relies 
on the hydrogen bonding network, Figure 3.22) or the loss of the water mediated 
interaction with the N07 atom of the co-enzyme (Figure 3.22 and Figure 3.24). Like 
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the Ser295Ala mutation investigated here, the Arg302Cys mutation was also found to 
be unstable upon purification (Cregeen et al., 2003) indicating the importance of the 
active site hydrogen bonding network to protein stability. 
4.3.2 Kinetic comparisons 
The enzyme L-LDH is known to be multi functional, catalysing the reduction of both 
hydroxypyruvate (Meister, 1952) and glyoxylate (Meister, 1952; Sawaki and Yamada, 
1966), the oxidation of glyoxylate to oxalate (Sawaki, Hattori and Yamada, 1967), as 
well as its usual reactions with pyruvate and lactate. Consequently the role of L-LDH 
in the increased production of oxalate seen in the primary hyperoxalurias, and the L- 
glyceric aciduria of PH2 has long been hypothesised (Williams and Smith, 1968a, 
1971). 
The activity of L-LDH towards glyoxylate and hydroxypyruvate has been widely 
studied using preparations purified from various animals and tissues (Duncan and 
Tipton, 1969; Romano and Cerra, 1969; Warren, 1970; Gibbs and Watts, 1973; Lluis 
and Bozal, 1977). These studies were performed under a range of pH conditions with 
preparations that may have contained a mixture of L-LDH isoforms not relevant to a 
liver specific disease such as PH2, where LDHA is the principal isoform (Brooks et al., 
1999). Additionally, published work undertaken on recombinantly produced, 
individual human isoforms has concentrated on the pyruvate/lactate functionality of L- 
LDH (Eszes et al., 1996; Hewitt et al., 1999), with only a small amount of work 
including hydroxypyruvate (Gomez et al., 1997). This previous work does however 
allow some scope for comparison. 
The KM parameters of the LDH isoforms utilising pyruvate (LDHA; 0.16mM, LDHB; 
0.063mM), produced by Dr G. Rumsby and presented in , match closely previous 
results performed under similar buffer conditions (pH 6-7.5). The data regarding 
lactate is more difficult to compare as all previous work has been completed under high 
pH (8.7 - 9.2), where reduction 
is preferred (Nisselbaum and Bodansky, 1963; Gomez 
et al., 1997). However, the observed pattern of weaker binding by lactate then 
pyruvate, represented by a higher KM value has been reproduced. 
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Despite extensive previous L-LDH work the kinetic constants presented here allow, for 
the first time, direct comparison of the glyoxylate and hydroxypyruvate reductase 
ability of the individual human LDH isoforms with those of GRHPR. Importantly the 
parameters have all been produced under the same, near physiological pH (7.5) and 
temperature (37°C). While the buffer conditions may not perfectly represent a 
physiological environment, the 3 enzymes can now be compared and their relative roles 
relating to glyoxylate and hydroxypyruvate metabolism, and consequently the 
pathology of PH2, explored. The important reactions in regard to PH2 are the 
reduction of hydroxypyruvate and the oxidation and reduction of glyoxalate. It should 
be remembered that to fully understand the relative role of LDH and GRHPR in the 
liver metabolism of these substrates, an understanding of their relative expression 
levels would be useful. This data is not available for GRHPR and consequently this 
effect cannot be taken into account. At the physiological pH and temperature used in 
this study, the oxidation of glycolate was not observed and shall not be further 
discussed. 
4.3.2.1 Reduction of hydroxypyruvate 
Hydroxypyruvate can be reduced in vitro by both GRHPR and LDH, producing D- 
glycerate when catalysed by GRHPR or L-glycerate when utilised by L-LDH (Figure 
4.10). Under normal conditions L-glycerate is not detected as a component of urine 
but, during the course of PH2, its production results in L-glycericaciduria, with L-LDH 
being implicated (Williams and Smith, 1968b). 
The generation of D-glycerate by GRHPR is more favorable in the presence of NADPH 
(specificity constant 670s'. mM-' vs. 344 s"'. mM"1 with NADH), resulting from tighter 
binding of hydroxypyruvate in the company of this coenzyme. This reaction is 
inhibited in the presence of high levels of hydroxypyruvate, with similar levels of 
inhibition being seen in the presence of either coenzyme (Figure 4.5 and Figure 4.7). 
The GRHPR from both Rat liver (van Schaftingen, Draye and van Hoof, 1989) and M 
extorquens (Chistoserdova and Lidstrom, 1991) also display substrate inhibition, with 
the predominant effect being seen with their favoured coenzyme. It is worth noting that 
as the physiological concentration of hydroxypyruvate (approximately 5µM, van 
Schaftingen, Draye and van Hoof, 1989) is far below that at which inhibition is seen, 
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this effect may not be applicable in the cytosol. Product (D-glycerate) inhibition has 
been observed with H. methylovorum GRHPR (Izumi et al., 1990) and the proposed 
presence of D-glycerate in the ternary structure (Chapter 3) suggests it may potentially 
occur in the human enzyme. Substrate inhibition has been observed in many 
dehydrogenases, including both D- and L-LDHs, which react via a compulsory order 
mechanism where NADH binds first and NAD+ leaves last (Denicola-Seoane and 
Anderson, 1990; Kochhar et al., 1992a; Hewitt et al., 1999). In L-LDH this inhibition 
is known to be the result of the formation of a covalent adduct between pyruvate and 
oxidised coenzyme (NAD) prior to its release from the enzyme (Coulson and Rabin, 
1969). This adduct has not been demonstrated in GRHPR (or D-LDH) but may be 
responsible for the inhibition observed. The ability of substrate or product to inhibit 
GRHPR may provide some level of in vivo regulation and have been incorporated into 
the proposed reaction scheme given in Figure 4.11. 
The KM values for the LDH isoforms and hydroxypyruvate (LDHA: 0.75mM, LDHB: 
0.38mM) are similar to those reported previously at pH 7.4 for both human isoforms 
(Gomez et al., 1997) and chicken LDHA (Lluis and Bozal, 1977), although kCet values 
(and consequently kkt/KM) differ, potentially due to the lower temperature (25°C) used. 
The specificity constants produced here show a similar level of activity between 
GRHPR and the dominant liver isoform LDHA, which is only active in the presence of 
NADH (430s'l. mM"1). Although the LDHB isoform shows an appreciably higher 
specificity constant (2100s"'. mM"'), it lacks a significant presence in the liver (Brooks 
et al., 1999) and would therefore be less relevant in normal hydroxypyruvate (and 
glyoxylate) metabolism. 
These specificity constants would suggest that there is no significant inherent 
preference for hydroxypyruvate between GRHPR (670s-'. mM'') and LDHA (430s" 
'. mM"1), shown schematically in Figure 4.10. Therefore, as L-glycerate is not produced 
in healthy individuals (Williams and Smith, 1968a) cellular conditions must themselves 
favour reduction via GRHPR. The mechanism for this is likely to be the difference 
between coenzyme choice: GRHPR can exploit NADPH while LDH cannot. It is 
known that within the liver cytosol the NAD+/NADH concentration ratio is 
approximately 1000: 1, while the NADP+/NADPH ratio is 1: 100 (Newsholme and 
Leech, 1983), with the actual concentration of NADP(H) (0.41imol. g"') being similar to 
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that of NAD(H) (0.9µmol. g 1) (van Schaftingen, Draye and van Hoof, 1989). 
Accordingly, there is a higher proportion of NADPH relative to NADH within the cell, 
favouring reductive reactions that involve NADPH such as that of hydroxypyruvate to 
D-glycerate. 
Hydroxypyruvate has been proposed to have a number of effects on the production of 
oxalate during the pathology of PH2. The reduction of hydroxypyruvate by LDH was 
suggested to produce a shift in the NAD+/NADH ratio, resulting in conditions that 
favour the oxidation of glyoxylate by LDH (Williams and Smith, 1971). Conversely, 
the presence of hydroxypyruvate was shown to have an inhibitory effect on LDH 
catalysed glyoxylate oxidation (Warren, 1970; Raghavan and Richardson, 1983a; 
Raghavan et al., 1997). Hydroxypyruvate has also been suggested to autoxidise to 
oxalate after 48-72 hours at physiological pH and additionally induce the non- 
enzymatic decarboxylation of glyoxylate (Raghavan and Richardson, 1983b; Raghavan 
et al., 1997). However, hydroxypyruvate does not accumulate during the course of 
PH2, likely being swiftly converted to L-glycerate (Danpure and Purdue, 1995). This 
would imply its inhibitory effect on glyoxylate oxidation and potential for non- 
enzymatic conversions are not relevant in vivo 
4.3.2.2 Utilisation of glyoxylate 
The source of glyoxylate in human cells has long been unclear, but recent work 
suggests the majority is derived from hydroxyproline metabolism in hepatocyte 
mitochondria (Knight et al., 2006b). Within a healthy individual this glyoxylate is 
predominantly reduced to glycolate by GRHPR and only a small amount of oxalate is 
formed, while during PH2 the lack of GRHPR results in the predominance of its 
oxidation to oxalate. Up until now it has been unclear how a healthy cell favors the 
useful reduction route over the undesired oxidation. Additionally, the ability of the 
human LDH isoforms to participate in glyoxylate metabolism, while long demonstrated 
(Gibbs and Watts, 1973), has never been studied in detail. 
Reduction of glyoxylate 
Both GRHPR and LDH can catalysis the reduction of glyoxylate to glycolate (Figure 
4.10 and Dawkins and Dickens, 1965; Sawaki and Yamada, 1966). Under the same, 
118 
near physiological conditions used in this study, GRHPR catalyses this reduction with 
similar specificity constants using either NADPH or NADH as coenzyme (110/157s 
'mM"' and 67s'mM"' respectively). This is despite the 200-fold tighter binding of 
NADPH (KM 0.011mM vs. 2.42mM). The Michaelis constant seen with glyoxylate 
and NADPH of 0.24mM is similar to that of the Rat form (KM 0.5mM at pH 6.0, 
Dawkins and Dickens, 1965). However, the affinity for glyoxylate during reduction 
has been shown to vary greatly across the characterised bacterial GRHPRs (KM values 
of 0.015mM - 10.8mM), likely due to their divergent metabolic requirements (Izumi et 
al., 1990; Yoshikawa et al., 2007). Unlike the human form, the rat GRHPR shows 
substrate inhibition with glyoxylate (van Schaftingen, Draye and van Hoof, 1989). 
Alternatively, the reduction of glyoxylate by the LDH isoforms proceeds only in the 
company of NADH, with the resulting specificity constants (22 - 75s"'mM-') again 
very similar to those of GRHPR catalysed reduction (67 - 110s"1mM"1). This similarity 
is despite the tighter affinity of glyoxylate to GRHPR and is due to the greater turnover 
number (kcat) of the LDH isoforms (- 700s"1 vs. - 30-70s'1). Consequently, as with the 
reduction of hydroxypyruvate, there is no inherent preference for glyoxylate reduction 
to occur with GRHPR rather then LDH (Figure 4.10). As reduction by either enzyme 
produces the same product it is difficult to comment on their actual contribution within 
the cell. However, once again the critical difference of coenzyme selectivity is likely to 
result in GRHPR being preferred. The higher proportion of NADPH compared to 
NADH within the cytosol favours reduction reactions that use NADPH (Newsholme 
and Leech, 1983). Of the two enzymes studied here only GRHPR can utilise NADPH 
as the coenzyme indicating, as with hydroxypyruvate reduction to D-glycerate, cellular 
conditions themselves are likely to favor GRHPR. 
The striking difference between the specificity constants of LDH catalysed glyoxylate 
and pyruvate reduction is worth noting considering their structural similarity (22-75s 
'mM-1 vs. 2200-7000s-'fM-'). In an aqueous solution glyoxylate is known to exist in 
two states, a non-hydrated form and the more common hydrated gem-diol form 
(Rendina, Hermes and Cleland, 1984). The hydrated form is considered a structural 
analogue of lactate while the non-hydrated 
form an analogue of pyruvate, with this 
second form the favored substrate 
for reduction by LDH (Duncan and Tipton, 1969; 
Meany and Pocker, 1991). The non-hydrated form is likely to be favoured for GRHPR 
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catalysed reduction also, as not only would the extra hydroxyl group be likely to create 
a steric clash with Leu59 (as described in section 4.3.1.2) but nucleophilic acyl addition 
reactions are usually preferential to the nucleophilic displacement of hydroxide (Meany 
and Pocker, 1991). The fraction of non-hydrated glyoxylate under similar experimental 
conditions to ours has been calculated to be 0.0038 (Meany and Pocker, 1991). 
Consequently the amount of non-hydrated glyoxylate, the reduction substrate, present 
will be markedly lower than the total glyoxylate concentration. This would result in 
actual KM values significantly lower then those given in and as a result, specificity 
constants markedly higher. Applying a similar correction to that in Meany and Pocker 
(1991), would result in approximate specificity constants for LDH of 7800s-'mM"' and 
GRHPR of 14500s 'mM"' for glyoxylate reduction, similar to those of LDH catalysed 
pyruvate reduction. The cytosolic hydrated: non-hydrated ratio is unknown and may be 
different to that reported as the dehydration reaction was shown to be susceptible to 
various metal and buffer ions (Meany and Pocker, 1991). However, the correction to 
KM values would be the same for both LDH and GRHPR, resulting in the similarity of 
their specificity constants remaining. 
Oxidation of glyoxylate 
The most important reaction regarding the pathology of PH2 is the oxidation of 
glyoxylate to oxalate, a reaction that GRHPR cannot catalyse but for which LDH has 
been implicated (Gibbs and Watts, 1973). Pig LDHB has previously been 
demonstrated to maximally catalyse this reaction at the non-physiological pH of 9.3 - 
10 and to have either very low, or no activity at physiological pH (Sawaki, Hattori and 
Yamada, 1967; Warren, 1970). This is in contrast to the results of human LDH 
presented here at pH 7.5, where notable activity was observed. As described above, the 
hydrated form of glyoxylate is likely to be the favored substrate for oxidation. As this 
is by far the dominant form in aqueous solution, no substrate concentration correction 
has been considered. Additionally, the KM values reported here of - 0.2mM are 
significantly lower then those reported at higher pH values for rabbit LDHA (3mM at 
pH 9.1, Duncan and Tipton, 1969) and pig LDHB (2.5mM at pH 9.4, Warren, 1970), 
although similar KM variation with pH has been noted with LDH and pyruvate (Read et 
al., 2001). 
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Under the "physiological" conditions used in this study, the human LDH isoforms are 
clearly able to catalyse the reduction of glyoxylate to oxalate ( and Figure 4.10). 
Interestingly this oxidative ability, as measured by the specificity constants in (30 - 
100s-1mM-'), is effectively identical to the reductive reaction when catalysed by either 
LDH (22 - 75s"'mM"1) or GRHPR (67 - 11Os"'m1V1"'), shown schematically in Figure 
4.10. This would suggest that in themselves, there is no preference for reduction over 
oxidation and the control is likely to rest with conditions within the cytosol. It should 
be noted that oxalate is known to be an inhibitor of LDH (Heilands, 1954) and may 
consequently limit the amount that this enzyme can produce. However, as the oxalate 
is being continuously excreted and sequestered as calcium oxalate it may not build up 
to a cytosolic concentration where its inhibitory effect becomes relevant. 
Demonstrating the ability of ambient cellular conditions to enact control, a 5-fold 
excess of lactate over glyoxylate was shown to inhibit rabbit LDHA catalysed 
glyoxylate oxidation by 50% (Poore et al., 1997), likely as a result of competitive 
binding at the active site. Under normal conditions lactate is present in hepatic tissue at 
levels two orders of magnitude greater then glyoxylate (Holmes et al., 1995), therefore 
this inhibitory effect may help explain the low oxalate production of a healthy liver. 
Additionally, pig LDHB is known to significantly favor glyoxylate reduction over 
oxidation at pH 7 (Warren, 1970) and even in the presence of a 20-fold excess of 
NAD+, NADH has been shown to almost completely inhibit glyoxylate oxidation by 
rabbit LDHA (Holmes et al., 1995). While it should be remembered that cellular 
NAD+ exceeds NADH by 1000-fold (Newsholme and Leech, 1983) these competition 
effects show that the specific conditions and metabolic state within the liver have the 
potential themselves to regulate LDH. Consequently, due to cellular conditions 
particularly the amount of lactate present it seems unlikely the LDH is responsible for 
oxalate production in the presence of GRHPR, only coming to the fore upon the build 
up of glyoxylate due to PH2 (and likely PH1). The lack of a role for LDH in healthy 
patients is supported by the observation that LDH subunit deficient patients have an 
ordinary level of oxalate excretion (Yanagawa et al., 1990). The enzyme(s) responsible 
for this normal level of oxalate production are unknown. 
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The activity of human GRHPR and L-LDHA on the related substrates glyoxylate, pyruvate and 
hydroxypyruvate at physiological pH. Values given are specificity constants as reported in and 
published in Mdluli et al., (2005). 
Figure is adapted from Booth et al., (2006). 
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4.3.3 Kinetic summary 
Primary hyperoxaluria type 2 is caused by the loss of functional GRHPR enzyme, 
which results in a build up of both hydroxypyruvate and glyoxylate (Williams and 
Smith, 1968b). Both of these blockage points could be overcome by LDH, converting 
hydroxypyruvate to L-glycerate and glyoxylate to oxalate. It has therefore been 
proposed that LDH is responsible for producing the signature feature of PH2, L- 
glyceric aciduria, and the primary pathology it shares with PHI, hyperoxaluria (Figure 
1.1). 
In the work presented in this Chapter and published in Mdluli et al., (2005) the initial 
kinetic parameters of recombinant human LDHA, B and GRHPR in relation to the 
substrates of relevance to PH2 have been presented. By investigating these enzymes 
under identical "physiological" conditions, it has become possible for the first time to 
directly compare their activities and discuss their in vivo relevance. A healthy person 
produces no L-glycerate and only a small amount of oxalate, so somewhat surprisingly 
the results indicate that in isolation under an approximation of physiological conditions, 
substrate use by GRHPR is not particularly favored over L-LDH ( and Figure 4.10). 
The critical difference discovered was in coenzyme specificity: GRHPR can utilise 
NADPH whereas LDH cannot. The kinetic preference of GRHPR for NADPH was 
supported by the structural data where the identified 2'-phosphate binding pocket 
created by Arg185 and Arg188 is characteristic of NADPH-dependent enzymes. This 
ability to use NADPH, the more prevalent cytoplasmic reductive coenzyme, is likely to 
be the decisive factor that leads to the dominance of GRHPR catalysed reduction over 
that of LDH within the cell towards both glyoxylate and hydroxypyruvate. The lack of 
a physiological role for glyoxylate oxidation by LDH is probably due to the cellular 
predominance of its other substrates, particularly lactate. As this work shows, LDH is 
capable of oxidizing glyoxylate to oxalate at physiological pH. It is this reaction that 
causes the hyperoxaluria pathology seen 
in PH2 and while it is tempting to consider the 
moderation of L-LDH activity in order to reduce 
levels of oxalate during PH2, this 
would require a complete understanding of the many metabolic pathways to which 
L- 
LDH contributes. The substrate inhibition of GRHPR seen with hydroxypyruvate and 
the potential for product inhibition as 
displayed in the crystal structure, show how this 
enzyme can also, like L-LDH, 
be regulated by ambient concentration of its substrates 
and products. 
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A hypothetical reaction scheme for GRHPR is presented in Figure 4.11, and is based on 
a similar proposed scheme for D- and L-LDH (Denicola-Seoane and Anderson, 1990; 
Hewitt et al., 1999). More work needs to be done to fully kinetically characterise 
human GRHPR and clarify this scheme, such as determining potential inhibition 
constants for substrates and products. However the work presented in this thesis has 
helped in the understanding of hydroxypyruvate/glyoxylate flux through the liver. 










Figure 4.11 Proposed reaction scheme for GRHPR. 
Hyp 





[E. NAD(P)+. DGL] 
(1) product inhibition, as seen in crystal structure (Chapter 3), (2) binding of substrate induces domain 
closure (comparison between apo and ternary structures; Chapter 3), (3) potential mode of substrate 
inhibition, by analog with L-LDH. Hyp = hydroxypyruvate, D-gl = D-glycerate. Adapted from the 
reaction scheme for L-LDH in Hewitt et al., (1999). 
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Chapter 5 Sorting Nexin 1 
5.1 Introduction 
The protein sorting nexin 1 (SNX1) is a member of the large sorting nexin family of 
proteins identified in mammals and yeast, and which have roles in cellular processes 
including endosomal sorting and signaling and endocytosis (reviewed in Worby and 
Dixon, 2002; Carlton et al., 2005a; Seet and Hong, 2006; Cullen, 2008). Mammalian 
SNX1 is the founding member of this family (Kurten, Cadena and Gill, 1996) and the 
most widely studied due to its likely role in the mammalian retromer and subsequent 
endosomal sorting (Haft et al., 2000). No crystal structures of either the whole SNX1 
protein or parts thereof are available, limiting the structural knowledge of this 
important protein to a single NMR structure of the phox-homology (PX) domain 
(Zhong et al., 2005). Consequently work was initiated during the course of this thesis 
with the aim of establishing soluble expression and purification procedures to facilitate 
the production of SNX 1 and, where necessary, truncated forms in quantities sufficient 
and suitable for crystallographic studies. 
5.1.1 Endosomal sorting 
The endosomal system within eukaryotic cells acts to sort and deliver internalised 
proteins, such as various nutrient and signalling receptors, to their correct destinations 
(Figure 5.1). After internalisation at the plasma membrane, often via clathrin-coated 
vesicles, these proteins are delivered to the sorting endosome from where their 
trafficking decisions are made (Lemmon and Traub, 2000). Here, the transferrin 
receptor and many other nutrient receptors release their ligands and are recycled back 
to the plasma membrane. Internalised signalling receptors such as epidermal growth 
factor receptor (EGFR) follow the degradative path, as the final mechanism to switch 
off signalling. These receptors are retained within the endosome as it matures to a "late 
endosome", which subsequently fuses with the lysosome resulting in degradation. A 
further trafficking pathway is that between the early endosome and the trans-Golgi 
network (TGN). The mannose 
6-phosphate receptor (MPR) is recycled between the 
TGN (where it binds lysosomal hydrolases) and the early endosome (where it releases 
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them) allowing multiple rounds of delivery. The retrieval of the MPR to the TGN 
appears to be directed by the mammalian retromer (Arighi et al., 2004). 
The exact mechanism by which different trafficking decisions are made, and the 
identity, function and structure of many of the proteins and protein complexes 
involved, have only recently begun to be elucidated. Key components of many of these 
trafficking pathways are members of the diverse sorting nexin family of proteins 
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Figure 5.1 Diagram of endosomal sorting in mammalian cells. 
Representation of the possible trafficking pathways undertaken by various components. Figure from 
Carlton et al., (2005a). 
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5.1.2 The sorting nexin family and their important domains 
Currently 33 members of the mammalian sorting nexin family and 10 in yeast have 
been identified (Cullen, 2008). However the functions of many of these proteins are 
unknown, despite many being implicated in endosomal sorting pathways. From a 
structural perspective the crystallographic information available is limited to the yeast 
homolog of SNX3 (Grdl9p) which consists solely of a phox-homology (PX) domain 
(Zhou et al., 2003) and, more recently, a truncated form of SNX9 which is involved in 
plasma membrane remodeling events (Pylypenko et al., 2007). Additionally, only two 
NMR structures of PX domains from the sorting nexins have been reported (Zhong et 
al., 2005; Song et al., 2007) but provide little information on critical features such as 
ligand specificity and the spatial arrangements between domains (as discussed below). 
The sorting nexin family of proteins is grouped together on the basis of inclusion of a 
particular subgroup of the PX domain superfamily, now known as SNX-PX (Teasdale 
et al., 2001). The PX domain is a binding domain for the phosphoinositide head group 
of certain phospholipids (phosphatidylinositol phosphates; PtdlnsP) and as such plays 
an important role in localising proteins to specific membranes. Many SNX-PX 
domains, including that in SNXI, have an affinity for Ptdlns(3)P (Cozier et al., 2002), 
which is enriched on sorting endosomal membranes (Gillooly et al., 2000). SNX1-PX 
has also been shown to bind PtdIns(3,5)P2 (Cozier et al., 2002) which is implicated in 
protein trafficking, particularly involving the endosome to lysosome transition and is 
enriched on late endosomes (Gillooly et al., 2000). The specificity of SNX9 for 
PtdIns(4,5)P2, which is enriched (under certain stimuli) at the plasma membrane, is 
consistent with its role in clathrin-mediated endocytosis (Pylypenko et al., 2007). The 
presence of these membrane specific domains in all sorting nexins suggests a role for 
all of these proteins in membrane trafficking events. It is not yet possible to predict 
phosphoinositide specificity of a PX domain from sequence data alone, but this might 
be facilitated through knowledge of the three-dimensional structure of these domains. 
This would permit the assignment of potential localisations for poorly studied sorting 
nexins, assisting with the study of this entire protein family. 
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While the presence of a SNX-PX domain is the defining feature of this family, a variety 
of different lipid binding and protein interacting domains are also present and often 
determine the various roles for separate sorting nexins. For the current work the most 
important is the Bin/Amphiphysis/Rvs (Bar) domain, but other domains including SH3 
(Src-homology-3) and RGS (regulators of G-protein signalling) domains are present on 
various sorting nexins, suggesting (poorly understood) potential roles in integrating 
sorting and signalling (Cullen, 2008). 
A large subset of the mammalian sorting nexins (12 of the 33) combine the PX domain 
with a C-terminal Bar domain. This subset includes those sorting nexins implicated in 
the retromer (SNX1, -2, -5 and -6, section 5.1.3) and those closely related to SNX9 and 
concerned with endocytosis (SNX18 and -30, Pylypenko et al., 2007). The Bar domain 
represents a dimerisation motif which produces a curved binding surface with which 
the associated protein can bind membranes of high curvature, or in some cases, induce 
the production of curved membranes (Carlton et al., 2004; Peter et al., 2004 and 
reviewed in Habermann, 2004; Gallop and McMahon, 2005). The curvature of this 
dimerised domain has been seen to vary amongst the published Bar structures, with the 
predicted membrane diameter that it would fit varying from 150 A in arfaptin 2 
(Tarricone et al., 2001) to 600 A in PHC-F-Bar (Shimada et al., 2007), with many 
expected to bind a diameter of around 220A (Peter et al., 2004; Weissenhorn, 2005; 
Casal et al., 2006). The recent structure of SNX9 included its PX and Bar domains and 
is to date the only sorting nexin Bar domain structure known. In this structure a 
curvature equivalent to a membrane diameter of 400A was seen (Pylypenko et al., 
2007). The sequence homology between SNX 1 and SNX9 is only around 14% and 
therefore it is unclear whether these dimensions also apply to SNX1. More critically, 
while the SNX9 Bar domain has been seen to be largely insensitive to the curvature of 
liposomes, an indication taken to suggest its efficient tubulating ability (Pylypenko et 
al., 2007), the SNX1 Bar domain is highly sensitive, only binding liposomes below a 
certain size (Carlton, 2004). The SNX1 Bar domain appears novel in its high 
sensitivity to curvature and yet it retains some ability to tubulate membranes (Carlton et 
al., 2004) whereas the closely related 
SNX2 Bar domain can only sense but not induce 
curvature (Carlton et al., 2005b). The exact mechanism and structural requirements by 
which these domains cause tubulation 
is unclear, with some Bar domains requiring a N- 
terminal amphipathic helix (N-Bar, McMahon and Gallop, 2005) which the Bar 
128 
domains of the sorting nexins are not predicted to contain. Consequently this will only 
fully be understood when a variety of Bar domain structures from the sorting nexins are 
known. 
Other then the role of SNX9 in clathrin-dependent endocytosis (Soulet et al., 2005) and 
SNX1 in the retromer (Griffin, Trejo and Magnuson, 2005) little is know about the 
functions of the many other members of this family. Consistent with the central 
importance of endosomal sorting and signalling pathways, evidence is growing for a 
role for SNX proteins in a range of diseases, including in the trafficking of prion 
protein (Heiseke et al., 2008) and the amyloid precursor protein (Lee et al., 2008). 
However, sorting nexins have been most comprehensively studied as the targeting 
component within the retromer, where both the PX and Bar domain are essential. 
5.1.3 Retromer 
The retromer is a large, multimeric complex identified in yeast to be essential for the 
endosome-to-Golgi retrieval of vacuolar protein sorting receptor VpsIOp, the functional 
homolog of the mammalian MPR (Seaman, McCaffery and Emr, 1998). The retromer 
is thought to act as a vesicle coat complex, and has been shown to interact directly with 
the endosomal membrane. In yeast, this complex is formed from two subcomplexes: 
Vps35p, Vps29p, and Vps26p, the cargo selection complex and Vps5p and Vpsl7p, as 
a complex with a structural role (Seaman et al., 1997; Seaman, McCaffery and Emr, 
1998). Human orthologs of all components have been identified, and h(uman)Vps35p, 
hVps29p, and hVps26p shown to form multimeric complexes (Haft et al., 2000). The 
human functional orthologs of Vps5p and Vps17 are all members of the sorting nexin 
family, with SNX1 and SNX2 corresponding to Vps5p (Griffin, Trejo and Magnuson, 
2005) and SNX5 and SNX6 to Vps17 (Liu et al., 2006; Wassmer et al., 2007), although 
the exact sorting nexin composition within the retromer is unclear. Yeast-2-hybrid 
studies have also shown the expected interaction between hVps35p (the putative `core' 
of the retromer) and SNX1 (Haft et al., 2000). The SNX dimer is considered the 
targeting/structural component of the retromer and is required to recruit the rest of the 
retromer to the endosome. This interaction has been shown to occur between Vps35p 
and the N-terminus of Vps5p (Seaman and Williams, 2002). The same region is 
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involved between SNX 1 and hVps35p (Gullapalli et al., 2004) and corresponds to the 
largely unstructured region in SNX 1 (Figure 5.3). 
The structures of two retromer components, hVps29p (Collins et al., 2005; Wang et al., 
2005) and hVps26p (Shi et al., 2006; Collins et al., 2008) have been solved 
individually. The crystal structure of a truncated hVps35p: hVps29p complex (Hierro et 
al., 2007) provides further insights into retromer formation and lead to the current 
model of the retromer (Figure 5.2). The ability of the SNX dimer to interact with either 
end of the Vps26/29/35 subcomplex has lead to the suggestion that two complexes may 
lie next to one another, forming a coat on a tubular vesicle structure. The structure of a 
relevant retromer associated sorting nexin is critical in building the entire picture of this 
macromolecular assembly. Further structures of individual retromer components, 
complexes of interacting partners and ultimately the entire retromer complex itself 
would be of great interest and use in furthering understanding of endosome-to-Golgi 
retrieval. Sufficient production of soluble SNX 1 is essential in this process. 
Vps26/29/35 
complex 
Figure 5.2 Schematic of the retromer complex. 
A representation of the retromer components bound to membrane (black line). The coloured SNX 
monomer may be SNXI or SNX2, while the grey monomer may consist of SNX1, SNX2, SNX5 or 
SNX6. PX domains (red) are shown interacting with phosphoinositide (triangles) and curved membrane 
is seen interacting with the Bar (blue) dimer interface. Cargo (dark green) interacts predominantly with 
Vps35 (light green). Vps29 (purple) binds at one end of Vps35, while Vps26 (orange) binds nearer the 
other. Adapted from Cullen. 2008. 
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5.1.4 Sorting nexin I 
Sorting nexin 1 is the most widely studied member of the sorting nexin family due to 
its role in the mammalian retromer (as described in 5.1.3). It does, however, also 
function in other trafficking processes independent of the retromer, although these are 
less well understood (Gullapalli et al., 2006). 
Both the BAR and PX domains (Figure 5.3) are required for the correct localisation of 
SNX I to the early endosome, with the BAR domain providing specificity for highly 
curved membranes and the PX domain for Ptdlns(3)P, both features of the early 
endosome (Carlton et al., 2004). It is these features that also provide the targeting 




Figure 5.3 Domain structure of SNX1. 
BAR -C 
11 1 
267 306 496 
Schematic of SNXI showing relative positions of the PX and BAR domains along with amino acid 
boundaries. SNXI is 522 amino acids in length. Adapted from Carlton, (2004). A similar domain 
structure is seen in SNX2, while SNX5 and SNX6 lack the large N-terminal region (Carlton et a!., 
2005a). 
A crystal structure of SNX I would help answer a number of questions, including the 
physical relationship between the PX and BAR domains, the nature of SNX 1-PX novel 
dual specificity for both Ptdlns(3)P and PtdIns(3,5)P1 and why the SNX 1-BAR domain 
appears to be highly sensitive to changes in curvature, whereas many other solved BAR 
domains are markedly less sensitive. Comparative studies with the SNX2 BAR domain 
would also be valuable, as only SNX 1 induces membrane tubulation despite 69% 
sequence identity in this region (Carlton et al., 2005b). A crystal structure of SNX 1 
would also form another important addition to the composite structure of components 
of the mammalian retromer. To initiate this structural work, the following experiments 
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where aimed at establishing soluble expression and purification procedures for SNX1 
and important sub-regions within it. The production of crystallographic quality and 




The methods used in the study of SNXI are presented below. Some methods from 
Chapter 2 were also used and will not be repeated here, but referenced by their section 
numbering where appropriate. 
5.2.1 Full length SNXJ 
The pGEX-4T-3 vector containing the entire human SNX1 coding sequence (pGEX- 
SNX1) was supplied by Prof. P. Cullen (University of Bristol) as a glycerol stock of 
previously transformed E. coli BL21 (DE3). The pGEX-4T vector system adds a N- 
terminal GST tag followed by a thrombin cleavage sequence to the recombinant 
protein. The use of a GST tag is recognised to produce the soluble expression of 
proteins normally poorly soluble when poly-His tags are used (Braun et al., 2002). The 
pGEX vector contains the ampicillin resistant gene, therefore 50µg. m1-1 of ampicillin 
was always present for selection pressure. 
5.2.1.1 Expression 
Expression was undertaken as previously optimised by Dr Gyles Cozier, University of 
Bristol. A single colony was used to inoculate 10ml LB (with ampicillin) and grown 
overnight at 37°C with shaking (300rmp). This was then used to inoculate 1L of LB 
and grown at 37°C to an OD600 of approximately 0.6. The culture was then transferred 
to a 16°C water bath to cool. Once chilled, the cultures were induced with 0.1mM 
IPTG and further grown at 16°C in a refrigerated incubator (Innova4230, New 
Brunswick Scientific). Expression occurred overnight (approximately 16hrs) and the 
resulting cells were pelleted by centrifugation at 10,000g, 4°C for 10 min, resuspended 
in 40m1 PBS and re-centrifuged at 5000g, 4°C for 5 min. Cell pellets were frozen at - 
20°C until required. 
5.2.1.2 GST column purification 
The initial purification of GST tagged SNX1 was performed by resuspending a cell 
pellet in 30ml of GST Binding Buffer 
(50mM HEPES pH 8.0,200mM NaCl, 1mM 
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EDTA, 1mM dithiothreitol (DTT), 10% glycerol). This also contained an EDTA-free 
protease inhibitor (Roche). Cell disruption was performed as described for GRHPR 
(section 2.3.11). Resulting cell debris and insoluble proteins were pelleted by 
centrifugation at 15,000g for 25 minutes. 
The GST tag allows for protein purification via binding to the glutathione ligand. In 
this work, lml GSTrap FF columns (Amersham Biosciences) which contain glutathione 
immobilised on cross-linked 4% agarose were used. The GSTrap FF column was 
equilibrated in GST Binding Buffer and the clarified supernatant loaded onto the 
column with a peristaltic pump at 0.3ml. min 1. The flow through was collected and the 
column washed to a flat A280 baseline. A gradient into 20mM reduced glutathione was 
run at 0.3ml. mii ' over 10 CV to elute bound protein, with 0.5ml or lml fractions 
collected. Fractions corresponding to A280nm peaks were analysed by SDS-PAGE and 
those containing recombinant protein pooled. 
The amount of protein was estimated using the predicted molecular weight of GST- 
SNXI (85,459 Da) and theoretical extinction coefficient (90760 M"tcm 1) calculated 
from Protparm. 
5.2.1.3 Removal of the GST tag 
Cleavage trials to remove the GST tag with thrombin were performed. A small aliquot 
of purified protein was mixed with IOU of thrombin per mg of recombinant protein. 
This was left at 18°C and samples taken at various time points, SDS-PAGE sample 
loading buffer added and the sample boiled to halt the cleavage reaction. Cleaved 
samples were then analysed on SDS-PAGE and compared to undigested protein. Prior 
to larger scale digestions, protein was buffer exchanged into the appropriate buffer for 
the subsequent purification step. 
5.2.1.4 Subsequent purification attempts 
Two methods were undertaken to further purify full length SNXI. These were 
attempted both prior to, and after thrombin digestion to remove the uncleaved protein, 
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thrombin and free GST. Generally ion exchange was undertaken first and followed by 
gel filtration, however gel filtration was also attempted alone. 
Ion Exchange 
SNX1 was loaded onto an equilibrated MonoQ column (Amersham Biosciences) in 
binding buffer (50mM HEPES pH 7.0 or 8.0,20mM NaCl, 1mM EDTA, 1mM ß- 
mercaptoethanol) and elution proceeded with a gradient into 1M NaC1 run at lml. min 1. 
Eluted protein was collected in lml fractions and those corresponding to A280ini peaks 
were kept and analysed by SDS-PAGE. 
Gel Filtration 
A Superdex 200 16/60 column (Amersham Biosciences) equilibrated in 50mM HEPES 
pH 7.0 or 8.0,150mM NaCl, 1mM EDTA, 1mM ß-mercaptoethanol was used for gel 
filtration purification. Fractions from ion exchange identified as containing SNX1 
were concentrated to approximated 0.5ml and loaded onto the column. Alternatively, 
cleaved protein was concentrated and loaded directly. Gel filtration was then run at 
0.3ml. min' with 2m1 fractions collected. Those fractions corresponding to A28om 
peaks were kept and analysed by SDS-PAGE. 
5.2.2 SNXI truncation construction 
5.2.2.1 Primer design 
To reduce the size of the protein and potential crystallisation complications, various 
SNX1 truncations were designed and constructed. Firstly, the largely unstructured N- 
terminus of SNX1 was removed and the remaining PX-Bar fragment cloned into both 
GST (pGEX-4T-1, Amersham Biosciences) and poly-His (pET-30b, Novagen) tagged 
expression vectors. Additionally, a poly-His tag was added to the C-terminal of the 
GST-PX-Bar version in an effort to assist with purification. The individual PX and Bar 
domain were also cloned into the poly-His (pET-30b) tagged expression vector. 
Primers were designed with similar features (Table 5.1), including beginning and 
ending in aG or C and having at 
least 21bp of gene specific sequence. Restriction 
enzyme sites were included to 
facilitate ligation into the selected vectors and artificial 
stop codons (UAA) incorporated where required. More specifically, the 
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SXJ_C His reverse primer includes the sequence to create an artificial hexa-His tag at 
the SNX 1 C-terminus. The forward primers for the separate domain constructs 
incorporate a Factor Xa cleavage sequence (IEGR) directly at the protein N-terminus 
and the reverse primers contain an artificial stop codon. These are required as the pET- 
30b vector produces a N-terminal poly-His tag which, after thrombin cleavage, results 
in a 21 amino acid N-terminal extension. Also, this vector would normally include a 
non-cleavable C-terminal His-tag. The sequence of the primers used and their 
individual attributes are given in Table 5.1. All primers were produced and purified by 
Invitrogen and the lyophilised primers resuspended in Elgastat water to a final 




forward (b, c) 
5' CGGAATTCCAGGAGGATCAATTTGATTTGACAG3' 
Full SXI_rev (b) 
5' GCGCGGCCGCTTAGGAGATGGCCTTTGCCTCAGG3' 
SXI C His reverse (c) 
5' GCGCGGCCGCTTAGTGGTGGTGGTGGTGGTGGGAGATGGCCTTTGCCTCAGG3' 
pET-30b 
PX_ forward (d, e) 
5' GCAGATCTGATCGAAGGTCGTCAGGAGGATCAATTTGATTTGACAG3' 
PX reverse (e) 
5' GCGCGGCCGCTTACTCTTCTTTTTCCAAGAACTCTCTGAC3' 
BAR forward (f) 
5' GCAGATCTGATCGAAGGTCGTAGCAAAATGACCATCAAGATGAATG3' 
BAR reverse (d, f) 
5' GCGCGGCCGCTTATGAGTAAAGGAGTGTCTCAAGGTAC3' 
Table 5.1 Primers designed for the cloning of SNX1 truncations. 
The pGEX-4T-1 vector was used for the GST tagged truncations, while pET-30b was used for N- 
terminal poly-His tagged truncations. All primers are given in the 5' to 3' direction. Incorporated 
restriction endonuclease sites are indicated; orange: EcoRI, red: NotI, green: BglII. Sequences for the 
addition of Factor Xa protease sites 
(blue), hexa-His tag (purple) and stop codons (bold) are shown. 
Brackets indicate which truncations they were used to create (Figure 5.8). 
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5.2.2.2 PCR and vector construction 
The pGEX-SNX1 plasmid DNA was extracted from 5m1 of a lOml overnight culture of 
the supplied E. coli BL21 (DE3) strain using the QlAprep Spin Miniprep Kit (Qiagen), 
following manufacturers' instructions. This was used as the template plasmid for the 
PCR of the GST tagged PX-Bar construct (GST-PX-Bar); subsequent PCR used this 
truncated construct as the template. The standard PCR reaction mix was used in all 
cases: 1.75U Expand High Fidelity Polymerase, Ix Expand Buffer + MgC12, both 
primers (as indicated in Table 5.1) at 2µM, dNTPs (50pmol) and lµl of template 
plasmid, in a final volume of 50µl. The PCR cycling protocol varied depending on the 
primers used. The basic protocol, as used in the PCR of the GST-PX-BAR construct, is 
given in Table 5.2 with variations described below. 
Temperature Time No. Rounds 
Initial DNA denaturation 94°C 4 minutes 1 
Denaturation 94°C 1 minute 
Annealing 48°C 45 seconds 25 
Amplification 72°C 90 seconds 
Hold 4°C Indefinite 
Table 5.2 General PCR protocol for SNX1 truncations. 
Due to the GC rich His-tag sequence in the SXI_C His reverse primer it had a much 
higher melting point (Tm = 75°C) then its complement primer (PX SXljorward, Tm 
= 57°C). The difference in Tm of 18°C for this primer pair required a two-step 
annealing process for PCR of the GST-PX-Bar-His construct to be successful. During 
the first 5 rounds of amplification, primer annealing occurred at 48°C thus allowing a 
certain amount of non-specific hybridisation of the reverse primer. During the 
subsequent 20 rounds the annealing temperature was increased to 55°C, with the 
previous amplification in target copy number increasing the chance of the forward 
primer successful binding and raising the stringency of the reverse primer. The 
protocol for the poly-His tagged PX-Bar construct (His-PX-Bar) required primer 
annealing to occur at 55°C across all rounds. The PCR cycle for the His-tagged PX 
(His-PX) and Bar (His-Bar) individual domains was as in Table 5.2 except with an 
amplification time of 60 seconds as 
befits their smaller size. 
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The subsequent purification, cloning, ligation, transformation and sequencing was 
performed largely as described in sections 2.3.3 to 2.3.8 with the substitution of 
appropriate restriction enzymes and expression vectors as indicated in Table 5.1. The 
creation of the expression constructs was done by double digestion of both the 
expression vector and corresponding pGEM-Teasy ligation. The vector pGEX-4T-1 
and the inserts designed for this vector (GST-PX-Bar and GST-PX-Bar-His) were 
cleaved with EcoRI and Noll, while pET-30b and the inserts intended for this (His-PX- 
Bar, His-PX and His-Bar) were digested with Bg1II and Notf. Overnight ligation was 
followed by transformation into E. coli NovaBlue, Rosetta and BL21 (DE3) strains 
with final double digests to confirm the presence of the insert. Plasmid retention 
required ampicillin (50µg. ml-1) for pGEX and kanamycin (50µg. ml-') for pET vectors. 
Correct colonies were then grown for expression trials and long term -80°C storage. 
5.2.3 GST-PX-Bar 
It was hoped that removal of the unstructured N-terminal section would improve the 
purification and stability of the resulting protein. Expression trials were run as 
described in section 2.3.10. Expression temperatures of 16°C and 37°C were 
investigated, with IPTG concentrations of 1mM and 0.1mM. Final large scale 
expression and purification was undertaken as previously described for full length 
SNX1 (section 5.2.1). Thrombin cleavage and further purification was also as above, 
except purification buffers contained 10% v/v glycerol and O. ImM 
phenylmethylsulphonyl fluoride (PMSF). 
5.2.4 Poly-His tagged PX-Bar constructs 
Expression trials were performed as described in section 2.3.10. Expression 
temperatures of 16°C, 30°C and 37°C and IPTG induction concentrations of ImM and 
0.1 mM were trialled. 
5.2.5 Denaturing nickel purification 
Expression of both truncation constructs GST-PX-Bar-His and His-PX-Bar resulted in 
insoluble protein. Cell disruption was done as described for GRHPR (section 2.3.11), 
with the cell pellet resuspended in 30m1 of 50mM HEPES pH 8.0,500mM NaCl, 
20mM imidazole, 10% (v/v) glycerol, 1mM ß-mercaptoethanol and an EDTA-free 
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protease inhibitor (Roche). After centrifugation at 25000g for 30min the recombinant 
protein was present in inclusion bodies. The insoluble pellet was resuspended in 
Denaturing SNX Ni2+ Loading Buffer (50mM HEPES pH 8.0,500mM NaCl, 20mM 
imidazole, 8M urea, 10% (v/v) glycerol and 1mM ß-mercaptoethanol). A sonicating 
water bath was used to assist the resuspension of denatured protein. The denatured 
protein was clarified by centrifugation as above. The solubilised, denatured protein 
was loaded on to a 5ml Ni2+ affinity column equilibrated in the same buffer and washed 
until a flat A280nm reading was achieved. Bound protein was then eluted using a 
gradient to 1M imidazole. The fractions containing denatured protein were identified 
5.2.6 Refolding GST-PX-Bar-His 
In both cases the success of refolding was analysed by solubility and successful 
thrombin cleavage. 
5.2.6.1 Dialysis buttons 
Against a background of 250mM NaCl, 10% glycerol and 1mM ß-mercaptoethanol, a 
range of buffer pHs were trialled to assist refolding of this construct (Table 5.3). A 
small volume (30µl) of purified, denatured GST-PX-Bar-His was added to a dialysis 
button and sealed with a square of dialysis tubing (14,000 Da cutoff). Dialysis was 
undertaken with 50m1 of "refolding buffer" at 4°C. After 16 hrs the sample was 
inspected for precipitation, removed from the button and centrifuged at 18,000g for 
10min. The resulting supernatant was analysed by SDS-PAGE for the presence of 
protein. 
Buffer (50mM) pH 
Sodium Acetate 4.6 
Sodium Citrate 5.6 
BisTris-HCI 6.5 
Potassium phosphate 7.5 
Tris-HC1 8.5 
Ches 9.5 
Table 5.3 Various buffers attempted during GST-PX-Bar-His refolding. 
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5.2.6.2 Refolding screen 
Small scale trials using a commercially available protein refolding screen (MDL) were 
undertaken. This screen contains 15 pre-made buffers containing various combinations 
of the buffer components shown in Table 5.4. Denatured protein (lmg. ml"') was 
diluted 1: 20 into these buffers with rapid mixing. These were then incubated for 1 hr at 
18°C, with continued slow mixing. Protein is initially determined to be soluble (and by 
inference refolded) by its visible presence on an SDS-PAGE gel after centrifugation at 
18000g, 15°C for 30min. Refolding success could then be scored as a comparison to 
the original denatured protein and critical buffer components determined. 
Buffer 50mM MES pH 6.0 
50mM Tris-HC1 pH 8.0 
Salt 9.6mM NaCl, 0.4mM KCl 
240mM NaCl, 10mM KCl 
2mM MgC12,2mM CaC12 
Redox Potential +/- 1mM DTT 
+/- 1mM GSH, 0.1mM GSSH 
Detergent 0.5% Triton X-100 
0.05% polyethylene glycol 3,550 
Solubiliser 0.4M sucrose 
0.5M arginine 
0.75M guanidine HCl 
Table 5.4 Components of the MDL refolding screen. 
Each of the components was present in a number of the pre-made buffers allowing their contribution to 
refolding to be determined. 
5.2.7 Poly-His tagged domain constructs 
5.2.7.1 Expression and purification 
Expression trials were run as described in section 2.3.10 with expression temperatures 
of 30°C and 37°C and IPTG concentrations of 1mM and 0.1mM. Large scale 
expression was undertaken at 37°C with 1mM IPTG for 3-5 hrs and cells pellets 
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prepared using standard procedures. Initial nickel column purifications were also 
performed as for T-GRHPR (section 2.3.11). 
5.2.7.2 His-tag removal 
Prior to protease cleavage, purified protein was buffer exchanged into the appropriate 
buffer for the subsequent purification step. Cleavage trials were performed with both 
thrombin and Factor Xa to determine the most appropriate cleavage site, digestion time 
and temperature. Both proteases were added initially at IOU or 5U per mg of protein. 
After cleavage, the serine protease and uncleaved protein were removed by 
benzamidine and Ni2+ column purification as described in section 2.3.13. 
5.2.7.3 Gel filtration 
Gel filtration was done largely as described in section 2.3.14. Both the PX and Bar 
domains were purified via a HiLoad 16/60 Superdex 75 prep grade column. The PX 
domain was purified in 20mM Ches pH 9.5 and 200mM NaCl buffer and the Bar 
domain in 20mM Ches pH 9.5,200mM NaCl, 10% glycerol and 1mM ß- 
mercaptoethanol buffer. Fractions (1 ml) corresponding to A280 peaks were analysed by 
SDS-PAGE. 
5.2.7.4 Crystallisation 
Purified domains were buffer exchanged into either 20mM Tris-HC1 pH 8.5 (PX) or 
20mM Tris-HCI pH 8.5 and 1mM ß-mercaptoethanol (Bar) and concentrated as 
described previously. A range of final protein concentrations from 2.4 - 16.7mg. ml4 
for the PX domain and 1.5 - 10.2mg. ml'1 for the Bar domain were used in 
crystallisation trials with a number of commercially available screens (Table 5.5). 
Crystallisation screens were set up as sitting drops with the Phoenix nanolitre robot 
using 250n1 drops of mother liquor and 
250n1 drops of protein. Plates were sealed, 
stored at 18°C and inspected 
for indications of crystal growth at regular intervals. In 
addition, JBScreens 3,5,6 and 
7 were set up manually as 500n1 mother liquor + 500n1 
protein hanging drops in pre-greased 
24-well plates as described in section 2.3.15.2. 
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Phosphatidylinositol complex attempt 
The PX domain of SNX1 is thought to bind 2 different phosphatidylinositides (Ptdlns), 
Ptdlns(3)P and Ptdlns(3,5)P2 (Cozier et al., 2002). Solid di-butanoyl- 
phosphatidylinositidol 3-phosphate (di-C4-Ptdlns(3)P) and di-butanoyl- 
phosphatidylinositidol 3,5-bisphosphate (di-C4-Ptdlns(3,5)P2) were supplied by 
Echelon, Utah. The production of these had been discontinued and only a small 
amount could be purchased limiting the screening that could be done. The powder was 
resuspended in water to a concentration of 30mM and stored at -20°C. An aliquot of 
this resuspension (3.3µl) was added to concentrated PX domain (46.7µl, 5. lmg. ml-1) to 
give a final concentration of 2mM PtdlnsP. This was incubated on ice for 30 minutes, 
followed by centrifugation at 18,000g for 5 minutes. The Phoenix robot was then used 
to set up 250n1 of Structure Screen I and II HT-96 with 250n1 of "complex". Plates 
were sealed, stored at 18°C and inspected for crystal growth as usual. 
Crystal Screen Manufacturer No. of conditions 
Structure Screen I and II HT-96 MDL 96 
PACT premier HT-96 MDL 96 
JCSG plus HT-96 MDL 96 
JBScreen 1- 4 Jena Bioscience 96 
JBScreen 5-8 Jena Bioscience 96 
JBScreen 9 and 10 Jena Bioscience 48 




In this chapter work undertaken to purify full length human SNXI will be presented. 
In addition the cloning and expression of a number of SNX I truncation constructs, 
produced in the hope of improving purification and crystallisability is reported. The 
crystallisation trials undertaken on the individual SNXI PX and Bar domains, including 
co-crystallisation with phosphatidylinositides, are also presented. Disappointingly, 
purification complications and a lack of reproducible crystallisation hits prevented 
further progression of this work. However, the establishment of expressing constructs 
and purification procedures will facilitate future work. 
5.3.2 Full length SNXJ 
5.3.2.1 Purification 
The established procedure of expression at 16°C induced with low (0.1mM) IPTG 
concentration resulted in the soluble expression of full length GST-tagged SNX1. 
Initial purification of this protein was via the interaction between the GST tag and 
immobilised glutathione as described in 5.2.1.2. 
Protein bound to the column was washed with a gradient from 0- 20mM glutathione to 
competitively disrupt the GST: resin interaction, with protein elution monitored by A280 
measurements. The only peak eluted at approximately 4mM glutathione corresponding 
to reasonably pure protein as determined by SDS-PAGE (Figure 5.4 and Figure 5.5). 
Although the size of the eluted protein cannot be judged accurately due to it exceeding 
the limit of the molecular weight markers used, the dominant band is likely to 
correspond to the 85kD GST-SNX1 monomer (Figure 5.5). The fractions containing 
the recombinant protein were pooled, yielding less than 2mg of protein from a litre 
culture, as calculated with the extinction coefficients given in Table 5.6. 
A significant amount of the expressed GST-SNX1 did not bind the GST column and 
can be seen in the flow-through 
fraction produced during column loading (Figure 5.5). 
Attempts were made to increase the proportion of GST-SNX1 to bind the column. 
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Temperature, flow rate and buffer pH are all thought to affect the GST-tag/glutathione 
resin interaction (GSTrap FF Troubleshooting, Amersham Biosciences). To investigate 
this, the loading of the GST column was repeated at pH 7.0, the suggested optimal 
loading pH (GSTrap FF Troubleshooting, Amersham Biosciences). Additional binding 
trials were also done at a slow flow rate (0. lml. min-1) and 4°C, both conditions 
suggested to improve binding affinity. No improvement in binding yield was seen with 
























Figure 5.4 Glutathione affinity column chromatography of full-length SNXI. 
Profile of GST-SNX I elution with a glutathione gradient, monitored by UV absorbance at 280nrn. The 
solid line indicates those fractions (0.5ml) ran on the SDS-PAGE gel in Figure 5.5. 
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Figure 5.5 SDS-PACE of purification fractions from GST-SNXI. 
Purification of full length SNX 1. lane 1) molecular weight markers, 2) uninduced total protein, 3) total 
protein after 8hr induction. 4) total protein after overnight induction, 5) soluble protein after overnight 
induction, 6) flow through fraction from glutathione column chromatography. Other lanes correspond to 




5.3.2.2 GST tag cleavage 
The pooled protein from the GST column step was subjected to thrombin digestion 
(l OU/mg) at 18°C in order to remove the GST tag. A time course showed complete 
cleavage had occurred after 19hrs, resulting in an upper SNXI band, running slightly 
higher then its expected 59kDa, and a lower 26kDa GST band (Figure 5.6). Removal 
of the GST tag by thrombin cleavage results in 5 non-native amino acids (GSPNS) 
remaining at the SNX 1 N-terminus. Protein sequencing on the upper band, by the 
University of Bristol Proteomics Facility, produced the sequence GSPNSMAS. This 
corresponds to the expected 5 amino acid tag remnant plus the first 3 residues of native 
SNX 1, confirming the identity of the protein and correct N-terminal cleavage. 
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Figure 5.6 SDS-PAGE gel of thrombin cleavage trial undertaken on GST-SNXI. 
Thrombin cleav age used to remove the GST tag from the full length SNX 1 protein purified in Figure 5.5; 
lane 1) molecular weight markers, 2) GST-SNXI pre-thrombin addition, 3) lhr post thrombin addition, 
4) 2hrs, 5) ihrs, 6) Shrs, 7) l9hrs. Major cleavage products are labelled. 
5.3.2.3 Further purification attempts 
Any attempts to further purify the cleaved full length SNX 1 by either ion exchange or 
gel filtration as described in the methods (5.2.1.4) resulted in complete loss of the 
protein. This suggested that the removal of the GST tag decreased the stability of 
SNXI. Attempts to further purify the uncleaved, GST-tagged form by the same 
methods were also unsuccessful. The protein behaved as large impure aggregates in 
gel filtration chromatography and extensive protein loss was observed in ion exchange 
chromatography, which prevented further progress with this construct (data not shown). 
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5.3.3 SVA'l trul7cation constructs 
While a small amount of the full length GST-SNX1 protein could be produced and 
initially purified, the loss of protein during subsequent purification steps made it 
impossible to carry out further work upon this construct. The domain structure of the 
full length SNX 1 protein had been defined previously (Carlton, 2004) and is 
reproduced in Figure 5.7. This was analysed to determine potential protein truncations 
that could be constructed to improve the chances of crystallisation while still answering 
some of the questions regarding SNX I. Using previously published work including the 
construct design of the SNXI-PX domain by Zhong et al., (2005) used for NMR 
studies and the related dAmphiphysin (dAmp) Bar structure from Peter et al., (2004) 
along with helpful discussions with Dr R. Sessions (University of Bristol), a number of 
truncated constructs were designed (Figure 5.8). The predicted molecular weight and 
extinction coefficients of both the tagged and un-tagged forms of these novel constructs 
are given in Table 5.6. The manufacture of the expression vectors for these truncations 
will be further described in the following section. 
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Figure 5.7 SNXI protein sequence and domain boundaries. 
Small font size depicts the putative N-terminal "unstructured" region. Red delineates PX domain, with 
bold extension included in PX constructs based on Zhong et al., (2005). Blue demarcates the Bar 
domain as determined in Carlton (2004), with bold extensions included in Bar constructs due to 
comparison with the ordered region of the dAmp Bar structure (Peter et al., 2004) and discussion with Dr 
R Sessions (University of Bristol). This also corresponds to the schematic of SNXI in the introduction 
(Figure 5.3). 
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Recombinant protein produced Amino Acid 
GST 11111000- 1- 522 (a) 
- MEMO- (iST 139 - 522 (b) 
GST HHHHHH 139 - 522 (C) 
HHHHHH 139 - 503 (d) 
HIlllllllll   139 - 269 (e) 
HHHHHH 296 - 503 (f) 
Figure 5.8 Schematic of S\\1 truncations including tags. 
The positions of affinity purification tags are indicated; GST: glutathione S-transferase tag, HHHHHH: 
poly-His tag. Colored regions correspond to those in Figure 5.7 (and Figure 5.3) and amino acid numbers 
refers to the native SNX I numbering. Letter codes; a) GST-SNXI, b) GST-PX-Bar, c) GST-PX-Bar-His, 
d) His-PX-Bar. e) His-PX. f) His-Bar. These letter also correspond to the primers used in their creation 
(Table 5.1) 
Protein MW (Da) F (M-tcm-t) 
GST-SNX 1 85459.1 90760 
SNX 1 --------- 59310.7 - ------------------- 47900 
GST-PX-Bar 71261.8 89520 
------ ------------------ PX-Bar ---------------- 45113.4 -- -------------------- 46410 
His-PX 19514.7 5960 
- PX --- ----- 17896.3 
-- -------------------- 5960 
His-Bar 28982.9 33460 
Bar -- -------- 24716.1 
----------------------- 33460 
Table 5.6 Predicted molecular ýýeig hts and extinction coefficients of designed SNXI truncations. 
Values used in all calculation of protein concentration. Calculated with Protparam (Expasy; 
http: //ca. expasy. orL ) 
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5.3.3.1 GST tagged constructs 
The use of a GST tag both provides a mechanism for first step purification and can 
enhance the soluble expression of recombinant proteins (Braun et al., 2002). A GST 
tagged construct was the only one to produce soluble full length SNX1 (personal 
communication Dr G. Cozier). These tags have also been used to assist the expression 
of other Sorting Nexins, including the recently crystallised SNX9 (Pylypenko et al., 
2007; Pylypenko et al., 2008). Constructs including just the PX-Bar segment of SNX1 
(139 - 522) were designed to be cloned into the pGEX-4T-1 expression vector 
(Amersham Biosciences). This vector fuses the GST tag followed by a thrombin 
cleavage sequence to the N-terminus of the protein. 
The PCR reaction to produce the PX-Bar segment was undertaken as described in 
section 5.2.2.2 of the methods. One construct was designed to just have the pGEX 
vector encoded GST tag, therefore PCR was performed using the primers 
PXSXI_forward and Full SXI_rev (Table 5.3, Figure 5.9a). It was found that an 
extended time of 90 seconds was required for successful PCR and this time was used 
for all subsequent PX-Bar reactions. A second construct was designed to include a 
non-cleavable, C-terminal poly-His tag and therefore used primers PXSX1_forward and 
SX1_C His reverse (Table 5.3 and Figure 5.9b). This His-tag was included with the 
hope of improving purification by allowing the use of the tighter affinity nickel column 
purification, without the loss of the GST solubilising effect. Successful PCR for this 
construct required the modification of the annealing step as the two primers had 
significantly different Tm points (75°C and 57°C respectively). The use of lower 
stringency in the first 5 annealing rounds as described in the methods (5.2.2.2) was 
essential for the production of any PCR product, but is likely to be the cause of the 
smearing of DNA product (Figure 5.9b). 
In both cases a PCR product of approximately 1.2 kbp was visualised in a 1% agarose 
gel (Figure 5.9a, b) and purified. Care was taken to avoid as much of the smeared 
region as possible present in Figure 5.9b when excising that product. Following 
ligation in to pGEM-Teasy and transformation into E. cola NovaBlue, a significant 
proportion of colonies were the expected white of successfully ligated plasmid: PCR 
product. A number of white colonies 
for each insert were selected and plasmid DNA 
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was purified. Double digestion using EcoRI and Not! confirmed the presence of the 
PCR product insert, and DNA sequencing verified that no mutations had been created. 
Full digestion of the pGEM-PCR vector with the EcoRI and Noll restriction enzymes 
produced a cleaved product which was then ligated into similarly digested pGEX-4T- I 
as described in 5.2.2. Transformation into the E. coli Rosetta strain and selection on 
chloramphenicol and ampicillin LB agar plates resulted in a small number of colonies. 
Conformation of successful ligation was seen with a double digestion of purified 
plasmid (Figure 5.9c). These constructs are referred to as GST-PX-Bar and GST-PX- 











Figure 5.9 Agarose gels of GST-tagged PX-Bar vector construction. 
I% agarose gels of, Lane 1) DNA ladder A ith relevant sizes indicated, A) PCR product PX-Bar (2), B) 
PCR product PX-Bar-His (2). C) example double vector digestion showing presence of insert (2). All 
show the correct sized insert of approximately 1.2kbp. Linearised pGEX vector is approximately 5kbp. 








5.3.3.2 Poly-His tagged constructs 
Nickel affinity purification with the use of a poly-His tag allows for both faster column 
loading and more stringent on-column washing then GST tag purification, due to the 
increase affinity of the interaction (Schmitt, Hess and Stunnenberg, 1993). As the 
requirement of the SNX1 truncations for the solublising effect of the GST was 
unknown, a further 3 constructs were designed to be cloned into the pET-30b 
expression vector (Novagen). This vector adds a hexa-His tag and thrombin cleavage 
sequence to the N-terminus of the protein via a 18 amino acid linker. Due to the 
particularities of this vector and the truncations to be inserted into it, a number of 
specific additions were made to the primers. Firstly, as these truncations also involved 
a shortening of the C-terminus, an artificial stop codon had to be specifically included 
prior to the restriction sequence in the reverse primers (Table 5.3). Also, since after 
thrombin cleavage a 20 amino acid N-terminal vector encoded extension would remain, 
the Factor Xa cleavage sequence was included in the forward primers, directly prior to 
the initial residue of the SNX 1 truncation (Table 5.3). The resulting modified, vector 
encoded N-terminal sequence is given below in Figure 5.10. 
The PCR reactions were undertaken as described in the methods (5.2.2) with the PX- 
Bar truncation being produced with the PX forward and BAR reverse primers (Table 
5.3). The separate PX and Bar domains were amplified with the PX and Bar primers 
(Table 5.3) respectively. Gels demonstrating the success of these reactions are shown 
in Figure 5.11. Ligation of purified PCR product into pGEM-Teasy followed by 
successful blue-white selection of transformed E. cola NovaBlue successful produced 
initial pGEM-PCR clones, with a lack of mutations confirmed by sequencing. Double 
digestion of the pGEM-PCR vector with BgilI and Nod preceded successful ligation 
into similarly digested pET-30b vector. Conformation of ligation is show in Figure 
5.11, with these constructs being referred to as His-PX-Bar, His-PX and His-Bar 
respectively (Figure 5.8 d, e, f). All constructs were finally transformed into the E. cola 
Rosetta strain for recombinant protein expression. 
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Figure 5.10 N-terminal protein sequence produced by the modified pET-30b vector tag. 
The modified tag sequence included in the forward primers (Table 5.1) encoded a Factor Xa cleavage 
site (IEGR; blue), used for all N-terminally His-tagged SNXI constructs shown in Figure 5.8 (d, e, f). 
Cleavage with this protease occurs directly after `R' in this sequence. Thrombin cleavage occurs 
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Figure 5.11 Aga rose gels of poly-His tagged constructs. 
1% agarose gels of, Lane 1) DNA ladder with relevant sizes 
indicated, A) PCR products of PX (3) and 
Bar (4) domain coding sequence. with final pET vector conformation by double digestion in the second 
gel (PX: 2. Bar: 3). B) PCR product of 
PX-Bar (2, care was taken to only take the upper band), with 
final pET vector conformation by double 
digestion in the second gel. All show the correct sized insert of 
approximately 400pb (PX), 600bp (Bar) and 
l. lkbp (PX-Bar). Linearised pET vector is approximately 
5.4kpb. All inserts were also confirmed by DNA sequencing. 
151 
5.3.4 GST-PX-Bar 
5.3.4.1 Expression test 
To investigate the effect of the removal of the unstructured N-terminal region of SNX I 
on soluble expression, small scale expressions were performed at 16°C and 37°C with 
two different IPTG induction concentrations (0.1mM and 1mM). Soluble expression, 
however, was only achieved with 0.1 mM ITPG induction and expression at 16°C 
(Figure 5.12). the same conditions as for full length GST-SNX 1. Large scale 
expressions were therefore undertaken as described previously (5.2.1.1). 
5.3.4.2 GST column purification 
Initial purification of the soluble recombinant protein via a GST column proceeded as 
for the full length SNX1. A shallow gradient into glutathione was used (0 - 5mM over 
IOCV), resulting in a broader elution peak then that seen for the full length protein 
(Figure 5.4) but no significant improvement in protein purity (Figure 5.13 and Figure 
5.14). Additionally, this truncated form of SNXI, without the N-terminal 138 residues, 
showed no increase in the fraction of soluble protein binding the GST column, with a 
significant proportion flowing straight through during loading (Figure 5.14). Protein 
containing fractions eluted from the column were then pooled and used in subsequent 
steps. 
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Figure 5.12 SDS-PACE gel of 16°C expression of GST-PX-Bar. 
Expression of the GST tagged PX-Bar construct undertaken at 16°C; lane 1) molecular weight markers, 
2) uninduced total protein. 3) uninduced soluble protein. 4) total protein after overnight induction with 
0.1 mM IPTG, 5) soluble protein after overnight 
induction. GST-PX-Bar is produced at around its 





















Figure 5.13 Glutathione affinity column chromatography of SNXI PX-Bar truncation. 
Profile of GST-PX-Bar elution run with a glutathione gradient, monitored by UV absorbance at 280nm. 
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Figure 5.14 SDS-PAGE of glutathione affinity purification fractions for GST-PX-Bar. 
Purification of the GST tagged PX-Bar truncation; lane 1) molecular weight markers, 2) uninduced total 
protein, 3) total protein after 16hr induction, 4) total soluble protein after l6hr induction, 5) flow through 
fraction from glutathione column chromatography. Other lanes correspond to fractions marked with a 
solid line in Figure 5.13. 
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5.3.4.3 Further purification attempts 
Subsequent purification of the uncleaved GST-PX-Bar sample was attempted via 
MonoQ ion exchange and gel filtration. Ion exchange resulted in the protein being 
present in every fraction across the salt gradient and significant loss of protein (data not 
shown). Purification using gel filtration and the Superdex 200 column was only 
slightly more successful, with the GST-PX-Bar eluting from the column within the void 
volume (Figure 5.15). This indicates the presence of a large aggregate, which is 
unlikely to be of use in crystallisation and amounted to only 0.2mg of `purified' protein 
from a litre culture (Figure 5.16). 
5.3.4.4 Cleavage trial 
A time course thrombin cleavage trial was undertaken on the glutathione column 
purified sample at 18°C. This resulted in a number of non-specific cleavage events and 
significant loss of protein, indicating some level of instability had been introduced with 
the removal of the N-terminal 138 amino acids (Figure 5.17). Reducing the 
temperature at which cleavage was undertaken did not improve this. Thrombin 
cleavage was also attempted on the sample from the previous gel filtration (Figure 
5.15), but no evidence for cleavage was seen (data not shown). Again this is consistent 
with aggregation of the protein, making the thrombin site inaccessible. Nothing further 
















Figure 5.15 S200 gel filtration chromatography of GST-PX-Bar. 
Protein elution was monitored by UV absorbance at 280nm. The only peak to contain GST-PX-Bar is 







Figure 5.16 SDS-PACE gel of aggregated GST-PX-Bar. 
SDS-PAGE gel of S200 gel filtration chromatography of the GST tagged PX-Bar truncation; lane 1) 
pooled GST-PX-Bar from Figure 5.14,2) concentrated GST-PX-Bar prior to gel filtration. 3- 8) 
fractions corresponding to the peak indicated in Figure 5.15. 
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Figure 5.17 SUS-PAGE gel of thrombin cleavage trial undertaken on GST-PX-Bar. 
Thrombin cleavage used to remove the GST tag from the PX-Bar SNX I truncation purified in Figure 
5.14, lane 1) molecular weight markers, 2) GST-PX-Bar pre-thrombin addition, 3) 2hrs post thrombin 
addition, 4) 4hrs. 5) 6hrs, 6) Rhrs, 7) 15hrs, 8) 23hrs Major cleavage products are labelled. 
5.3.5 GST-PX-Bar-His and His-Pa"-Bar 
With protein from previous constructs (GST-SNX I and GST-PX-Bar) a large loss of 
soluble protein always occurred at the initial GST column purification stage due to 
apparent low affinity for the glutathione resin. In an effort to combat this, the effect of 
the addition of a poly-His tag to allow for nickel affinity purification, both alone and in 
conjunction with a GST tag, was investigated. 
5.3.5.1 Expression test 
Extensive expression trials at 3 temperatures (16°C, 30°C and 37°C), each with two 
IPTG concentrations (0.1 mM and I mM), were undertaken on both the GST-PX-Bar- 
His and His-PX-Bar constructs. Figure 5.18 shows an example expression trial for His- 
PX-Bar induced with 0.1 mM IPTG at 16°C. At no point was soluble protein seen 
under any condition tested. nor was it during GST-PX-Bar-His expression (data not 
shown). This suggested that not only was the GST tag essential for soluble expression 
of the PX-Bar truncation, but that the addition of the hexa-His tag at the C-terminus 
was enough to destabilise this effect. 
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Figure 5.18 St)S-P: *, GE gel of expression trial for His-PX-Bar at 16°C. 
Expression of the poly-His tagged PX-Bar construct undertaken at 16°C; lane 1) molecular weight 
markers. Each subsequent pair of lanes contains total protein followed by soluble protein at various time 
points after induction with 0.1 m11 IPTG. 2) uninduced, 3) 2hrs, 4) 4hrs, 5) 6hrs, 6) 8hrs, 7) l6hrs. 
Insoluble His-PN-Bar is seen appearing after 6hrs. 
5.3.5.2 Denatured purification 
In an effort to purify protein and allow refolding to be attempted, a denaturing Nie' 
column purification strategy was undertaken. Denatured His-tagged proteins can be 
easily purified, as their affinity for the Ni2f resin is not dependent on a specific 3- 
dimensional structure. Denatured purification and subsequent refolding was only 
attempted on the GST-PX-Bar-His recombinant protein, as this was deemed to be the 
most likely to successfully refold. 
Cell pellets from a GST-PX-Bar-His expression were treated as described in the 
methods, . ith the insoluble protein 
being resuspended in nickel column loading buffer 
containing 8M urea. This denatured protein was loaded onto an appropriately 
equilibrated nickel affinity column and unbound protein washed off. Elution of the 
bound, denatured protein from the column with a shallow imidazole gradient produced 
a reasonable A-,,, (, peak (Figure 5.19). Inspection of the resulting SDS-PAGE gel 
(Figure 5.20) showed GST-PX-Bar-His to be the major constituent of the peak, which 
eluted with approximately 250mM imidazole. Additionally, little recombinant protein 
was present in the flow through fraction and the resulting eluted protein was considered 

























Figure 5.19 Denatured nickel affinity column chromatography of GST-PX-Bar-His. 
The purification was carried out in the presence of 8M urea and monitored by UV absorbance at 280nm. 
Solid line indicates the range of fractions seen in Figure 5.20 
, ýýýý' 
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Figure 5.20 SDS-PAGE of the denatured nickel affinity purification of GST-PX-Bar-His. 
Denatured purification of the dual tagged PX-Bar truncation; 1) molecular weight markers. Other lanes 
(from left to right) correspond to fractions marked with a solid line in Figure 5.19. 
5.3.5.3 Refolding 
Various refolding techniques such as rapid dilution and dialysis were attempted as 
described in 5.2.6. Both the MDL screen, rapid dilution and dialysis buttons gave 
initially encouraging results. Refolding by dialysis into 50 mM CHES pH 9.5 appeared 
to produce soluble protein (as determined by centrifugation), but the addition of 
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soluble aggregates making the thrombin cleavage site inaccessible. The MDL 
refolding screen showed the presence of 0.5M arginine to be important in producing 
`soluble' protein as determined by the protein remaining in the supernatant after 
centrifugation (data not shown). However upon dialysis from the refolding buffer into 
`native buffer' (50 mM CHES pH 9.5,250mM NaCl, 10% glycerol, 1mM ß- 
mercaptoethanol) the protein precipitated, suggesting the solublising ability of arginine 
was merely keeping misfolded and poorly soluble protein in solution. Together these 
perhaps reflect the difficulty in refolding multidomain, oligomeric proteins. 
5.3.6 Individual poly-His tagged domains 
Although it had not proven feasible to purify full-length SNXI in adequate quantities, 
the discrete domains that make up the SNX1 protein are thought to act in a separate, but 
additive, manner to control the specificity of the overall protein (Carlton et al., 2004). 
The structures of the isolated domains should therefore provide a lot of the specificity 
information, while leaving only their spatial relationship unclear. 
5.3.6.1 Expression 
Small scale expression trials of both the His-PX and His-Bar constructs showed that 
their expression from the pET-30b vector resulted in the production of significant 
amounts of soluble protein under all conditions screened (not shown). Subsequent 
large scale expression was undertaken from the E. coif Rosetta strain at 37°C, using 
1mM IPTG to induce expression for 3-5 hrs as these conditions produced the best 
yield. 
5.3.6.2 Nickel column purification 
Purification of the expressed domains proceeded via nickel affinity chromatography 
using standard procedures. This resulted in a large increase in protein purity for both 
the His-PX and His-Bar proteins. The His-PX protein eluted from the Ni2+ column 
with approximately 150mM imidazole (Figure 5.21) and the elution of a large His-Bar 
A280 peak correlated to 300mM imidazole (Figure 5.22). Contaminating proteins 
present in these fractions were far outweighed by the amount of recombinant protein 
and tag cleavage was undertaken 
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Figure 5.21 Nickel affinith purification of His-PX. 
Chromatography trace and resulting SDS-PAGE gel of the nickel affinity purification of His-PX. 
Protein elution from the nickel column was monitored by UV absorbance at 280nm. Within the SDS- 
PAGE gel lanes correspond to. I) molecular weight marker, 2) total protein, 3) total soluble protein, 4) 
flow-through from column loading. The remaining lanes correspond to the solid black line present on 
the chromatography trace. 
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Figure 5.22 Nickel affinity purification of His-Bar. 
Chromatography trace and resulting SDS-PAGE gel of the nickel affinity purification of His-Bar. 
Protein elution from the nickel column was monitored by UV absorbance at 280nm. Within the SDS- 
PAGE gel lanes correspond to: 1) molecular weight marker, and the remaining lanes to the solid black 
line present on the chromatography trace. 
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5.3.6.3 His-tag removal 
Due to the construction of the recombinant protein the His-tag could theoretically be 
removed by the use of either thrombin or Factor Xa, with thrombin leaving a 24aa 
extension and Factor Xa cleavage resulting in no extension (Figure 5.10). 
In order to remove the maximum amount of the N-terminal extension, cleavage trials 
were first undertaken using Factor Xa. The use of either 5 or IOU per milligram of 
His-PX protein resulted in a number of non-specific cleavage events (data not shown). 
Despite the PX domain sequence itself containing no recognised Factor Xa cleavage 
sites (PeptideCutter; Expasy http: //ca. expasy. org), this non-specific cleavage pattern 
was present across all time points attempted. Altering the temperature at which 
cleavage was undertaken from 18°C to either 37°C or 4°C did not modify the 
apparently poor specificity, with the same cleavage pattern occurring (data not shown). 
Efforts were made to N-terminally sequence the aberrant cleavage products to clarify 
where they were occurring. However, despite many attempts, transfer to the 
Polyvinylidene fluoride (PVDF) membrane required for sequencing could not be 
achieved. In contrast, cleavage with thrombin resulted in efficient and reasonably 
specific digestion at 18°C (Figure 5.23). Preceding the final large scale digestions, the 
pooled protein was buffer exchanged into gel filtration buffer and cleavage performed 
overnight (16hrs) at 18°C using 5U of thrombin per milligram of His-PX. 
Alternatively, cleavage of pooled His-Bar protein using IOU of Factor Xa per 
milligram of protein resulted in stable, specific cleavage after 16 hrs at 18°C, although 
a low molecular weight doublet can be seen appearing across the course of digestion 
(Figure 5.24). Again, preceding large scale digestions the protein was buffer 
exchanged into the appropriate gel filtration buffer. 
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Figure 5.23 1 hromhin clcs%mgc of Flic-P\. 
SUS-PAGE gel of timr ourwr Jügc>urm of IIi. -I'\ %%ith 5l thrombin per mg to remove the poly-His tag. 
Lane I) molecular %eight marker. 2) unclea%ed Ht. -PX. 3) Ihr post thrombin addition, 4) 2hrs, 5) 3hrs, 
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Figure 5.24 Factor \a clea%age of 1lis-Bar. 
SI)' -I'A(; I t; rl u( umr . ours 
digestion A' His-Bar Hith IUl Factor Xa per tng to remove the poly-His 
tag. Lane I) molecular weight marker, 2) unclea%ed His-Bar, 3) Ihr post thrombin addition, 4) 2hrs, 5) 
3hrs. 6) Mrs. 7) I6hn Mayor cka%age products are labelled. 
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5.3.6.4 Gel Filtration 
Prior to separation by gel filtration, any uncleaved protein and the serine protease used 
for cleavage was removed via Ni2+ affinity and benzamidine columns connected in 
series. This resulted in a reasonably pure sample of cleaved recombinant protein, with 
any uncleaved protein and free His-tag remaining on the Ni2+ column. However, in the 
case of the Bar domain a reasonable amount of cleaved protein remained bound to the 
benzamidine column and was lost. In neither case were the low molecular weight 
fragments (other then the tag) produced during cleavage removed by this purification 
step. The resulting protein samples for both constructs were concentrated to 
approximately 0.5m1 in preparation for loading onto a Superdex 75 gel filtration 
column. The column was run slowly (0.3ml. min 1) and smaller then normal fractions 
(lml) were collected in order to achieve the degree of resolution required to separate 
the recombinant domains from the smaller contaminating proteins. 
Purified Bar domain eluted from the column as a large symmetrical peak at a volume of 
54.2m1 (Figure 5.25). This corresponds to a molecular weight of 86.5kDa (logMr =- 
1.4758(VelutionNriod) + 6.8879, where Vv; 0d = 41), 1.75 times the size of the expect 
dimer (predicted molecular dimer weight of 49.4kDa). A dimer of dimers might be 
possible, but it seems more likely that the likely elongated nature of the Bar dimer, as 
expected based on published Bar structures, has produced an erroneous elution volume 
making molecular weight calculations based on globular standards inappropriate. The 
purified PX domain also eluted as a symmetrical peak (Figure 5.26). This peak elution 
volume of 68.5ml corresponds to a molecular weight of 26.4kDa, half as big again as 
the expect 18kDa PX monomer. The reasons for this discrepancy are unclear, but 
could be due to the extended tag derived N-terminus or the molecular shape. A similar 
size discrepancy has been seen previously with gel filtration of SNX1-PX (Zhong et al., 
2002) and was shown not to be due to any dimerisation. 
After gel filtration and careful selection of fractions to be combined, approximately 
4mg of each domain was produced and deemed to be of greater then 95% purity by 
SDS-PAGE. Pooled fractions were buffer exchanged into their respective 
crystallisation buffer (5.2.7.4). 
Crystallisation trials were generally attempted 
immediately using `fresh' protein, but the domains seemed stable when stored at -20°C 
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Figure 5.25 Gel filtration purification of cleaved Bar domain. 
Chromatography trace and resulting SDS-PAGE gel of the gel filtration Factor Xa cleaved Rar domain. 
Protein elution from the size exclusion column was monitored by UV absorbance at 280nm. Within the 
SDS-PAGE gel lanes correspond to; I) molecular weight marker, and the remaining lanes to the solid 
black line present on the chromatography trace. 
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Figure 5.26 Gel filtration purification of cleaved PX domain. 
120 140 
f- PX 
Chromatography trace and resulting SDS-PAGE gel of the gel filtration thrombin cleaved PX domain. 
Protein elution from the size exclusion column was monitored by UV absorbance at 280nm. Within the 
SDS-PAGE gel lanes correspond to; I) molecular weight marker, 2) pooled, cleaved PX domain prior to 
size exclusion chromatography. The remaining lanes correspond to the solid black line present on the 
chromatography trace. 
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Extensive screening using commercially available crystallisation screens was 
undertaken with both purified domains. The PX domain was initially concentrated to 
16.7 and 5.5mg. m1-' and crystallisation sitting drops set up across the 288 conditions of 
the 3 MDL screens (Table 5.5). Although no crystallisation hits were detected (or have 
been since), it was noticed that the majority of the higher protein concentration drops 
contained heavy precipitation while approximately half the drops set up with 5.5mg. m1' 
' remained clear. These screens were then set up again, with 5.1 and 3.4mg. ml' to 
investigate the effect of a lower protein concentration. While the lower protein 
concentrations did not greatly alter the proportion of drops containing precipitant, this 
round of screening did provide one of the few crystallisation hits for the PX domain 
(Table 5.7). The spherolites produced occurred at both protein concentrations and took 
approximately 2 months to appear (Figure 5.27a). When previously screened at 
5.5mg. ml' this condition had remained clear, but it seems unlikely that the small drop 
in protein concentration is responsible for this and is more likely due to variation in the 
protein preparation. To investigate whether these were salt or protein crystals, the 
spherolites were frozen in well solution containing 50% w/v glycerol, the 
recommended cryo-solution for this condition (McFerrin and Snell, 2002). Test 
diffraction images were taken at the Daresbury synchrotron by Ms V. Fairweather 
(University of Bristol). Neither salt nor protein diffraction was detected. 
Subsequently, 5 of the remaining spherolites were washed to remove free protein and 
run on SDS-PAGE. Washing occurred by transferring the crystals to a fresh drop of 
reservoir solution and then to a second drop. This final drop, containing all 5 
spherolites, was then pipetted into I Oµ1 of SDS sample loading buffer and boiled for 15 
minutes. The resulting Coomassie stained gel showed no protein present (not shown). 
If these crystals are protein rather then salt, this could be due to there being insufficient 
protein to detect by this method. Finally, the recent purchase of Izit Crystal Dye 
(Hampton Research) allowed this to be employed. This blue dye differentiates salt 
from protein crystals as the latter contains large solvent channels which Izit can 
penetrate, colouring the crystals a 
darker blue then the surrounding solvent. A 1: 10 
dilution of Izit was added (0.5µl) directly to a crystallisation drop containing some 
remaining spherolites. An 
hour later the crystals had become significantly darker then 
their surroundings, suggesting them to 
be protein crystals (Figure 5.27b). 
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Further crystallisation attempts were set up using the JBScreens. All 10 screens were 
set up using the Phoenix robot as sitting drops at 2.4 and 5.5mg. m1-1, or a selection 
(JBScreen 3,5,6 and 7) were also done as hanging drops manually with 3mg. ml-' of 
protein. From both methods, a total of 576 drops, only 3 drops produced a `hit', each 
constituting phase separation (Table 5.7 and Figure 5.27c). A small amount of manual 
screening around the hits presented in Table 5.7 has been attempted as described in 
2.3.15.2. However in no case were the hits reproducible. This could be due to the 
move from a robot set up sitting drop to a larger, manually set up hanging drop or 
simple variation in the protein preparation and source of screen solutions. 
Co-crystallisation of the PX domain at a concentration of 5. lmg. ml-' with the two 
different phosphatidylinositides was also attempted as described in the methods 
(5.2.7.4). As only a small amount of each phosphatidylinositide could be purchased 
only one 96-well screen (SSI and II) could be set up. However, this screen was not 
successful in producing any crystallisation hits to further direct this work. 
In the case of purified Bar domain the Phoenix robot was used to produce 500n1 sitting 
drops. However, despite all 13 screens (Table 5.5) being set up at 3 different protein 
concentrations (1.6,5.2 and 10.2mg. m1"') no crystallisation hit has since been produced 
to direct further optimisation. It was noted that the majority of drops set up at 
10.2mg. ml' contained heavy precipitation, indicating this concentration to be higher 
then desired for nucleation. 
The 3 MDL 96-HT screens (Table 5.5) were also set up using purified domains that 
retained their poly-His tags. The tagged domains were purified in approximately the 
same manner to their cleaved counterparts, the exception being the lack of thrombin 
cleavage step. The purified His-domains were buffer exchanged into the same pre- 
crystallisation buffer as their untagged form, with the inclusion of 100mM imidazole to 
encourage the ordering of the His-tag. Crystallisation trials have been attempted at 
5.5mg. m1'1 for His-PX and 5.2mg. ml' for His-Bar, however neither has yet produced a 
hit. 
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Screen Protein Method Drop Condition Description 
(mg. ml') size 
SS I 3.4 and Sitting SOOnI 0.2 M magnesium Spherolites 
5.1 formate 
JBScrecn 3.4 Hanging 1 PI 0.1 M HEPES pH 7.5, Phase 
6 2°% PEG I K, separation 
1.6 M ammonium 
sulphate 
JBScrecn 2.4 and Sitting 500n1 0.1 M Tris-HCI pH 8.5, Phase 
8 5.5 2° v-/v ios-propanol, separation 
0.1 M magnesium 
sulphate 
Table 5.7 ('rsstallisation conditions producing "hits* for the apo PX domain. 
1he to sitting drop hits Hcre produced during robotic screening and the hanging drop hit by manually 
set up 24-Hell plate Kreenmc. 
AI 
Cº 






Photographs of the hits produced during screening for apo PX domain crystallisation conditions. A) 
corresponds to the sphcrolites produced with the SS I condition in Table 5.7 while B) shows these 
spherolites after Itit treatment. 
The concentration of the lzit dye with these spherolites has made them 
darker and is indicati e of protein crystals. C) the phase separation produced with the JBScreen 6 
condition presented in Table 5.7. 
Similar phase separation %% as produced in the other reported condition. 
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5.4 Discussion 
Despite the sorting nexins forming a large, diverse class of proteins involved in various 
aspects of cellular trafficking (reviewed in Worby and Dixon, 2002) very little 
structural work on these proteins has previously been reported. At the outset of this 
study only one crystal structure had been produced, that of yeast SNX3 with and 
without bound ligand (Zhou et al., 2003). This sorting nexin solely consists of a PX 
domain. Additionally structures of a small number of further, separate PX domains 
were available as NMR structures, including SNX1-PX (Zhong et al., 2005). 
Consequently the scarcity of structural information regarding this important group of 
proteins led us, in collaboration with Prof. P. Cullen (University of Bristol), to 
investigate the feasibility of producing milligram quantities of pure, soluble SNX1 
protein (or parts there of) with the aim of establishing purification procedures and 
initiating crystallisation trials. The progress of this work will be discussed with a focus 
on what can be learnt and applied to any future initiatives. The recently published 
SNX9 PX-Bar structure (Pylypenko et al., 2007; Pylypenko et al., 2008) is also 
mentioned as a potential model for further work on SNX 1. 
5.4.1 Full length SNXI and PX-Bar truncations 
The bacterial expression of full length SNX1 in combination with a GST tag at 16°C 
and with low imidazole concentration (0.1M) was the only procedure to successfully 
produce detectable quantities of soluble protein (personal communication Dr. G. 
Cozier). These requirements are consistent with the bacteria having difficulties 
expressing and folding the protein and were 
indicative of this protein being difficult to 
handle. 
A key problem with the purification of the GST tagged SNX1 constructs (both full 
length and the PX-Bar truncations) was their poor binding to the glutathione column 
(sections 5.3.2.1 and 5.2.3). Despite the use of the supposedly optimum buffer 
conditions and temperature only a small proportion of the produced soluble protein was 
bound and subsequently eluted from the column, suggesting that something was 
inhibiting the interaction or that the interaction of the protein with the column was 
intrinsically weak. It seems feasible that the oligomeric state of the protein could 
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decrease the availability of the GST binding site to the column glutathione. With 
SNX1 forming dimers and potentially higher order oligomers via the Bar domain, along 
with the ability of GST itself to dimerise (Dirr, Reinemer and Huber, 1994), there is the 
potential for large complexes to easily form and these may reduce access to the GST. 
These effects might be partially abrogated by mixing free glutathione resin with the 
protein as has been used recently for SNX9 production (Pylypenko et al., 2008). 
Oligomer formation is consistent with the short retention time seen during subsequent 
size exclusion chromatography where the protein is eluted in the void volume (Figure 
5.15). 
It was noted that the expression and purification of a separate Bar domain used a GST- 
tag to enhance solubility together with a poly-His tag for purification (Weissenhorn, 
2005). In this case the expressed protein comprised an N-terminal His-tag directly 
followed by a GST-tag and finally the domain of interest. This concept was exploited 
with the GST-PX-Bar-His construct although, due to the construction of the vector, the 
His-tag was C-terminal and separated from the GST-tag by the Bar protein. 
Surprisingly, this also resulted in insoluble protein although a similar construct, lacking 
the His-tag, was fully soluble (sections 5.3.4 and 5.3.5). This again reinforces the 
instability of this protein even when lacking the large N-terminal region of SNX1. 
Alternatively, this insolubility could be the result of the C-terminal His-tag disrupting 
the dimerisation of the Bar domains due to its potential position near this interface. 
This would also offer an explanation as to why all attempts at refolding failed. As an 
N-terminal poly-His tag alone also resulted in insoluble protein (Figure 5.18) it may be 
worth investigating an N-terminal poly-His-GST-tag construct, although this may not 
avoid issues of higher order oligomer formation. This would require either the 
modification of the available pGEX vectors or the purchase of other commercial 
versions and was not feasible during the course of this work. 
Upon purification of the GST tagged proteins a second problem developed when 
removal of the tag was attempted. The presence of a 
large tag is likely to add structural 
variability and flexibility with resultant effects on or prevention of crystal packing. 
Consequently the removal of the tag was deemed to be essential; however upon its 
cleavage from the full length 
SNX1 this protein precipitated. The large N-terminal 
region of SNX1 (residues 
I- 138) contains no predicted secondary structure and may 
171 
constitute an intrinsically unfolded region of the protein. Without anything to stabilise 
this region, such as the GST domain or a physiological partner (such as components of 
the retromer, Seaman and Williams, 2002) it may form inappropriate interactions 
leading to the insolubility of the entire protein. Accordingly, it proved very difficult to 
produce full length SNX1 for crystallisation and a focus on truncated forms including 
the PX and Bar domains was therefore deemed appropriate. 
Attempts to cleave the GST tag from the truncated PX-Bar construct resulted in non- 
specific cleavage and no useable protein was obtained. The appearance of multiple 
non-specific cleavage sites within this truncated form may reflect introduced instability 
and misfolding of the protein. The results produced during the cleavage of the poly-His 
tag from the PX domain also indicate that there may not be sufficient space between the 
folded PX domain and the folded GST domain to allow thrombin access. The 
obstruction of this site would liberate thrombin to attack non-specific sites. It may be 
desirable to extend the PX domain by a few residues to provide more space between the 
tag and this domain. This is further discussed in section 5.4.2.2 in relation to the His- 
PX construct. 
Although it has not proved possible to purify either full-length SNX1 or the truncated 
SNX1 PX-Bar in adequate quantities for crystallisation trials during the course of this 
thesis, progress has been made that can be used to direct future lines of inquiry. The 
use of a GST-tag to produce soluble PX-Bar provides a starting point from which the 
linker between the PX domain and tag can be increased to improve protease 
accessibility, or the incorporation of an intein mechanism to remove this requirement. 
Additionally, the inclusion of an N-terminal poly-His tag to improve purification may 
be worth exploring. The use of other large tags that may enhance solubility, such as 
Maltose Binding Protein (MBP), may also help avoid the aggregation issue, although 
may ultimately prove fruitless if the SNX1 proteins itself is poorly folded. 
5.4.2 Individual domains 
The discrete PX and Bar domains of SNXI act in a separate, but additive, manner to 
direct the membrane specificity of the entire protein (Carlton et al., 2004). 
Consequently, the structural investigation of these regions independently is worth 
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pursuing as it would provide a lot of information on their separate specificity 
determinants, leaving only their spatial relationship unclear. 
5.4.2.1 BAR domain 
The localisation of SNXI on highly curved membranes and the ability of its 
overexpression to induce (and stabilise) the tubulation of membranes from the early 
endosome is dependent on the Bar domain (Carlton et a!., 2004). This class of 
dimerisation domain forms a banana-shaped dimer, which binds to negatively charged 
membranes via its positively charged concave surface (Gallop and McMahon, 2005). 
The curvature of this dimer is partly due to the way in which the monomers intersect 
and has been seen to vary widely across the published Bar structures (Tarricone et a!., 
2001; Shimada et a!., 2007). Knowledge of the structure of the SNXI Bar domain 
would show its level of curvature and provide a useful comparison (and model) for 
other SNX Bar domains, particularly as the SNX1 Bar domain is especially sensitive to 
membrane curvature (Carlton, 2004). It may also provide further information on the 
mechanism of membrane tubulation. 
The SNX1 Bar domain has been predicted to comprise residues 306 to 496 (Carlton, 
2004). It was decided, in discussion with Dr R. Sessions (University of Bristol), to 
express a construct from residue 296 to 503. This corresponds, at the N-terminus, to 
the ordered region seen in the dAMP Bar domain structure (Peter et al., 2004) and, at 
the C-terminus, to a short extension prior to a charged region (Figure 5.7). Previously, 
most individual Bar domains have been expressed as a GST-tag fusion product (Peter et 
al., 2004; Weissenhorn, 2005; Masuda et al., 2006), but as there was precedent for 
soluble Bar expression using a poly-His tag (Casal et al., 2006) this was attempted, and 
succeeded in producing large quantities of soluble SNX1 Bar domain that could be 
readily purified. 
Disappointingly, despite screening 3 protein concentrations across 528 crystallisation 
conditions no crystals were obtained. 
A number of structures from individual Bar 
domains have been published (Peter et al., 2004; Weissenhorn, 2005; Casal et al., 
2006; Masuda et al., 2006) suggesting that despite its elongated, curved nature it is a 
domain that can be crystallised using standard techniques. Further, the inclusion of a 
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Factor Xa protease site allowed removal of all extraneous vector encoded amino acids 
indicating that it is perhaps the Bar domain boundaries used that are preventing 
crystallisation. Adjustment of these boundaries may be required to produce protein 
crystals. The soluble expression system and a purification procedure developed during 
the course of this work will, hopefully, facilitate production of these future variants. It 
should also be noted that time did not allow a screen of crystallisation temperatures or a 
complete range of protein concentrations, both of which are variables that could be 
further explored in future work. 
It is possible that this Bar domain was prematurely truncated despite the C-terminal 
residue (503) extending beyond the predicted domain boundaries although the 
production of soluble, stable protein suggests the protein is well folded and should be 
amenable to crystallisation. The size of the SNXI Bar domain used here matches that 
seen in the SNX9 structure where this domain continues to the C-terminus (Pylypenko 
et al., 2007), again supporting the choice of the domain boundaries. 
5.4.2.2 PX domain 
The PX domain is a small domain known to bind various phosphatidylinositol 
phosphates (PtdlnsP) and to be involved in targeting various proteins to specific 
membranes (reviewed in Seet and Hong, 2006). The PtdlnsP binding specificity varies 
across the SNX family, with SNXI binding Ptdlns(3)P and Ptdlns(3,5)P2 (Cozier et al., 
2002). However, the extra requirement for the Bar domain in membrane binding 
indicates this as a low affinity PX domain (Zhong et a!., 2002; Carlton et a!., 2004). 
Although there is an existing NMR structure of this domain (Zhong et a!., 2005), its 
classification as a low affinity PX domain with dual PtdlnsP specificity makes further 
structural study appropriate. 
As previously mentioned, the boundaries of the SNX1 PX domain construct (residues 
139 - 269) were based on those successfully shown by Zhong et al., (2005) to be 
produce soluble and stable protein. This range of residues ensured the entire predicted 
PX domain was included without the addition of potentially flexible termini which may 
interfere with crystallisation and also avoided the stretch of charged glutamate residues 
at the N-terminal (Figure 5.7). 
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As with the Bar domain construct, the PX domain was designed to include a Factor Xa 
cleavage site directly at the N-terminus of the domain to allow the removal of the entire 
tag and hence minimise potential protein flexibility during crystallisation. However, 
unlike the Bar domain, the addition of Factor Xa resulted in non-specific proteolysis 
requiring instead the use of the secondary thrombin site to remove the poly-His section 
of the tag. This resulted in the PX domain having 24 extra N-terminal residues which, 
while not optimal, was deemed reasonable to move into initial crystal trials. The 
production of apo PX crystals was targeted with the aim of allowing ligand soaking 
experiments to take place. These crystallisation trials have so far produced 3 
identifiable hits (Table 5.7 and Figure 5.27), one of which was crystalline but failed to 
diffract. Co-crystallisation of SNX1 PX with Ptdlns ligands failed to produce any hits, 
but due to the poor availability of the commercial di-C4-Ptdlns this can not be 
considered an in depth screening. A number of high affinity PX domains have been co- 
crystallised in complex with di-C4-Ptdlns(3)P (Bravo et al., 2001; Zhou et al., 2003), 
while this ligand was successfully soaked into the SNX9 PX-Bar crystals (a low 
affinity PX domain, Pylypenko et al., 2007). The lack of co-crystallisation hits may be 
due to the intrinsic low affinity of the SNX1 PX domain for its Ptdlns ligand but further 
screening is required. If no further source of the di-C4-Ptdlns ligands can be found it 
may be necessary to use versions with longer "tails" such as C8 which is still water 
soluble or the phosphoinositide head group itself, both commercially available from 
Echelon (Utah, USA). 
The small number of identified crystallisation conditions may also be due to the 
construct used. The excess amino acids retained at the N-terminus due to the use of the 
thrombin cleavage site may have added a region high in flexibility which makes crystal 
packing more difficult. The apparent inability of the Factor Xa protease to access its 
cleavage site may be indicative of this site being shielded by the structure. The NMR 
SNXI-PX structure indicates that the constructs N-terminus is flexible, but its position 
at the end of a ß-strand and potential to pack against other secondary structures may 
result in poor accessibility for the proteases. This would be particularly true when the 
GST domain is attached as in the previous, larger constructs. As Zhong et al., (2005) 
used self-cleavage by an incorporated intein to remove the tag from their SNXI PX 
construct they did not require access by a secondary factor, negating this structural 
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factor. The structure of SNX9 is 34 residues longer at the N-terminus then the PX 
boundary used in these studies (Pylypenko et al., 2007). Although these extra residues 
largely fold back on to the Bar domain it may be possibly to significantly extend the N- 
terminus and still retain a compact domain. This would be worth investigating, with an 
N-terminal extension to the region of residue 121 being a potential starting point, as 
this would avoid the string of charged residues and the inclusion of prolines near the 
beginning (start at ATN, Figure 5.7). This would also be an appropriate extension to 
trial for the expression of the entire PX-Bar region, particularly as these N-terminal 
residues may be involved in interactions with the Bar domain, as seen for SNX9 
(Pylypenko et al., 2007). The expression and purification procedures established in this 
thesis will hopefully assist in this process once the constructs have been made. It 
would also be potentially useful to determine the domain boundaries (of both the PX 
and Bar domains) via limited proteolysis, this however would require improved 
production of the full length SNX1 protein. 
Additionally, the NMR structure shows a large amount of flexibility in a loop region 
that forms part of the PtdlnsP binding pocket (Zhong et al., 2005). This flexibility may 
make the production of an apo crystal form significantly more difficult then if it was 
stabilised. As this region is expected to become more ordered when bound to its ligand 
(Zhong et al., 2005) it might be appropriate to focus future work on co-crystallisation 
with Ptdlns(3)P and Ptdlns(3,5)P2, although the success of soaking ligand as seen in the 
SNX9 structure (Pylypenko et al., 2007) indicates that the production of apo crystals is 
still a worthwhile aim. 
While the recent structure of SNX9 PX-Bar has provided fresh insight into the 
mechanism by which membrane specificity is achieved in this sorting nexin, there are 
significant differences between the function and specificity of SNX9 compared with 
SNX1. Consequently, the importance of structural studies on SNX1 has not been 
diminished but may, as described above, be advanced by the knowledge gained from 
the successful SNX9 structure. 
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Chapter 6 Investigation of Binding Partners for 
TFLl and FT 
6.1 Introduction 
The Arabidopsis proteins produced by the genes TERMINAL FLOWER 1 (TFL1) and 
FLOWERING LOCUS T (FT) act antagonistically to control the timing of floral 
meristem formation. These closely related proteins are members of the 
phosphatidylethanolamine-binding protein (PEBP) family, the most highly studied of 
which is the Raf kinase inhibitor protein (RKIP). The crystal structures of both TFLI 
and FT have been produced previously (Ahn et al., 2006), and in this study phospho- 
amino acid soaking and co-crystallisation experiments have been undertaken as an 
initial extension of these structural studies towards complexes with their binding 
partners. 
6.1.1 RKIP/PEBP family 
The RKJP/PEBP family is a widespread, highly conserved protein family found in 
many organisms, including humans (Tohdoh et al., 1995), flowering plants (Bradley et 
al., 1997), Drosophila (Pikielny et al., 1994) and E. coli (Serre et al., 2001). They 
were initially named as phosphatidylethanolamine binding proteins (PEBP), due to an 
in vitro affinity for PE (Bernier, Tresca and Jolles, 1986). Now, they are more 
commonly referred to as Raf kinase inhibitor proteins (RKIP, Yeung et al., 1999), due 
to the action of a rat form as described shortly. In general however, the mode of action 
of this ubiquitous family is unclear. 
A number of RKIP/PEBP family members have had their structures solved, including 3 
mammalian forms (human, bovine and mouse: Banfield et al., 1998; Serre et al., 1998; 
Simister, Banfield and Brady, 2002), 3 plant forms (Antirrhinum CEN, Arabidopsis 
TFL1 and FT, Banfield and Brady, 2000; Miller, 2004; Ahn et al., 2006) and two E. 
coli members (Serre et al., 2001). All structures show a high level of similarity with a 
large central ß-sheet, an anion binding site at one end and an external loop likely to be 
involved in determining some of the specificity for each protein (Figure 6.1). 
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The anion binding site is created from a number of highly conserved residues which 
together form a surface exposed pocket (Figure 6.5). A number of crystal structures of 
PEBP/RKIP members contain phosphorylated ligands (ie PF), the phosphate analogue 
cacodylate or an acetate ion bound in this pocket (Banfield et al., 1998; Serre et u1., 
1998), indicating a potential role in binding phosphorylated ligands. Moreover, 
mutations within this binding pocket have been shown to have a significant negative 
effect on the ability of RKIP to interact with the Raf-1 kinase, an interaction normally 
facilitated by the phosphorylation of Raf-1 (Rath et al., 2008). The (non peer 
reviewed) crystal structure of human RKIP containing a phospho-tyrosinc ligand bound 
in this pocket (Simister, 2004), strongly supports the hypothesis that this pocket 
represents a phospho-amino acid binding site. 
Anionic binding 
pocket 
Specificity loop ? 
4 
Figure 6.1 Overlay of TFLI, FT and human RKIP with salient features indicated. 
Cartoon representation of TFLI (cyan), FT (red) and human RKIP (green). PDB access codes are 
I WKO, I WKP and 2QYQ respectively. 
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6.1.2 Role in kinase signalling pathrtwavs 
Evidence is accumulating that indicates a general role for the RKIP/PEBP fitmily in the 
regulation of various signalling pathways. The correct growth and development of 
multicellular organisms is often dependent on the appropriate response to an 
extracellular stimulus such as growth factors, hormones and stress. This response often 
involves the induction or inhibition of a particular transcription event, requiring an 
extracellular stimulus to be converted into an event at the nucleus. This is often 
facilitated by the sequential activation of one kinase by another (a kinase cascade). 
culminating with the activation of a transcription factor or regulator. 
Many studies now indicate the importance of some mammalian forms of the RKIP 
family in inhibiting the Raf/MEK/ERK mitogen activated protein kinase (MAPK) 
pathway (Yeung et al., 1999; Yeung et al., 2000). This pathway is involved in 
controlling cell growth in response to hormones and growth factors. Additional kinase 
pathways are also affected by RKIP, including the NFKcß pathway (Chen, Deniers and 
Shi, 2002) and the G-protein coupled receptor kinase 2 pathway (Lorenz, Lohse and 
Quitterer, 2003) demonstrating a widespread role. RKIP functions in the 
Raf/MEK/ERK pathway to inhibit the interaction between Raf-1 kinase and M I: K by 
competing for Raf-1 binding (Yeung et a/., 1999). It is this ability of RKIP to out 




Figure 6.2 Simplified RKIP mechanism. 
Iw 
Transcription 
When RKIP is dissociated, Raf-I and MEK can interact, MEK is phosphorylated and activated by Rat=1. 
MEK in turn phosphorylates and activates the transcription factor ERK. RKIP/ERK interaction not 
shown for clarity. Phosphorylation shown as orange balls. 
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Binding to partially phosphorylated Raf-1 kinase allows RKIP to act as a buffer, 
soaking up Raf-1 until full activation is achieved. The level of RKIP can control the 
threshold level at which the Raf/MEK/ERK pathway activates. This inhibition can also 
be relieved by phosphorylation of RKIP itself (Corbit et al., 2003). however molecular 
level details of this mechanism are not fully understood, partially due to the difficulty 
in obtaining the interacting proteins for structural studies. 
Additionally, work on a tomato member of RKIP/PEBP family, SELF-PRUNING (SP), 
also supports a role for SP within a signalling pathway involved in determining the 
growth pattern of tomato plants (Pnueli et al., 2001). SP (a close homologue to TFLI 
and FT) was shown to interact with a serine/threonine kinase (SPAK), a bZIP (basic 
region/leucine zipper) transcription factor (SPGB) and a 14-3-3 isoform (Pnucli et aL, 
2001). The interaction of SP and SPAK was shown to require that SPAK be 
phosphorylated, just as RKIP requires that Raf-1 be phosphorylated for complex 
formation. Moreover, bZIP transcription factors are known to require phosphorylation 
to be transcriptionally activated (Jakoby et al., 2002) and 14-3-3 proteins can act as 
scaffolds for the assembly of signalling complexes (Roberts, 2003; Ferl, 2004). The 
Arabidopsis RKIP/PEBP proteins, TFL1 and FT, can also replace SP in many of these 
interactions in vitro (Pnueli et al., 2001). While not all of these interactions may be 
physiologically relevant, in general these observations are consistent with a primary 
role for RKIP/PEBP proteins as components of signalling pathways. Because of this 
apparent conservation of function for this family of proteins, it was hoped that a general 
mechanism for RKIP/PEBP proteins might be elucidated through structural and binding 
studies on a range of proteins. 
6.1.3 TFL1 and FT function 
The RKIP/PEBP proteins that form the basis of this study are TFLI and FT, both from 
the plant Arabidopsis thaliana where they play a role in the choice between vegetative 
growth and floral development (reproductive growth). The normal pattern of growth in 
Arabidopsis is classified as indeterminate, where the apical meristem grows indefinitely 
and produces floral meristems from the periphery (Figure 6.3). The choice between 
vegetative and reproductive growth is dependent on various environmental signals 
sensed and relayed into the cell by a large number of genes. Under appropriate 
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conditions these result in the formation of an inflorescence, the reproductive structure. 
Mutagenesis and o% er-expression studies suggest these two highly homologous proteins 
(56°° sequence identity. r. m. s. d of 0.77A over 157 Ca atoms) act in a generally 
antagonistic function to control the timing of inflorescence formation. The flowering 
of Jt %t mutants is delayed indicating FT as a floral promoter (Kobayashi et al., 1999), 
while if!! till mutants show early flowering and reduced vegetative growth, indicative 
of TFLI as an inhibitor of inflorescence formation (Bradley et al., 1997, Figure 6.3). 
The respective overexpression studies show a delay in flowering when TFL 1 is 
overexpressed (Bradley et at. 1997) and an enhancement of flowering when FT is 
overexpressed (Kardailsky et ßj1., 1999, Kobayashi et al., 1999), indicative of their 
antagonistic effect. While slight variations in plant phenotypes produced by loss of 
function and over-expression mutants do indicate some independent activities, separate 
FT- and TFL 1-specific binding partners have yet to be identified. 
ýC6 
1/11 mutant Wild Type ft mutant 
Figure 6.3 Phenohpes of TFI. t and FT mutants. 
The r/l till mutation results in much earlier flowering. while the Jt: jr mutant allows TFLI to dominate, 
resulting in far later (lowering. Leases = ellipses, stems/shoots = lines, flowers = circles, and shoot 
meristems - arrows. Adapted from Flanzawa. 
Money and Bradley, 2005. 
TFL I and FT appear to represent a convergence point for the various signals that 
control the timing of the vegetative to reproductive switch. The vernalisation (low 
temperature) pathway controls the level of the floral inhibitor FLOWERING LOCUS C 
(F LC) that in turn prevents the expression of pro-reproductive genes, including FT 
(Henderson and Dean. 2004. Figure 6.4). The photoperiod (day-length) regulates the 
activity of CONSTANS (CO) that, during long days accumulates and activates the 
expression of pro-reproductive genes, with a major effect being the upregulation of FT 
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(Samach et al., 2000, Figure 6.4). TFL1 negatively regulates the floral activator genes 
APETALA I (API) and LEAFY (LFY) (Liljegren et al., 1999) while FT activates them 
(Samach et al., 2000), meaning the balance between these two proteins has a large 
effect on flowering time (Figure 6.4). However, unlike many of the other genes 
regulated by FLC and CO, FT and TFL1 are not transcription factors so the mechanism 
by which they perform their regulatory functions has been unclear until recently. The 
identification of the bZIP transcription factor FD as an interacting partner of both TFL1 
and FT (Abe et al., 2005; Wigge et al., 2005) goes some way to explaining the 
antagonistic relationship of these proteins. The FT: FD interaction was also shown to 
be dependent on the retention of a proposed Cat+-dependent protein kinase (CDPK) 
phosphorylation site (either a threonine or serine) at the C-terminus of FD (Abe et al., 
2005). This is consistent with the observed dependence of RKIP (Rath et al., 2008) 
and SP (Pnueli et al., 2001) on phosphorylation for binding to their respective kinases. 
Immunoprecipitation studies also showed FT is recruited to the AP 1 promoter region in 
an FD-dependent fashion, where it acts to enhance the transcriptional activation activity 
of FD (Wigge et al., 2005). Regions of the "specificity loop", the major region of 
difference between FT and TFL1 (Figure 6.1), may act to recruit different 
transcriptional activators/repressors to the FD element of the AP1 promoter or may 
induce a switch between these two states of the same interacting partner (Ahn et al., 
2006). 
The expression of FT as controlled by CO is restricted to the phloem tissue of leaves 
(Takada and Goto, 2003), while FD appears to be constitutively expressed in the shoot 
apex (Abe et al., 2005; Wigge et al., 2005). Consequently, when FT is expressed in 
response to the increase in day length it must relocate to the shoot apex where FD 
defines the location of its effect. This mobile signal has recently been discovered to be 
the FT protein itself rather then mRNA as previously thought (Corbesier et al., 2007; 
Jaeger and Wigge, 2007; Mathieu et al., 2007). This long range protein movement has 
also be demonstrated for the rice FT homolog (Tamaki et al., 2007) and for TFLI, 






Floral Activator Genes 
Figure 6.4 Simplified mechanism for the control of flower timing in Arabidopsis. 
Floral activator genes include API and LFY. with arrows indicating activation/induction and blunted 
lines indicating repression. 
Close homologues of FT and TFLI with similar roles have been found across the 
flowering plant family including separate homologues in rice (Kojima et al., 2002; 
Nakagawa, Shimamoto and Kyozuka, 2002), and TFLI homologues in the snapdragon 
(CEN, Amaya, Ratcliffe and Bradley, 1999), tomato (SP, Pnueli et at., 1998) and pea 
(DET and LF, Foucher er a1., 2003). The apparent conservation and importance of this 
growth determination mechanism across flowering plants makes the study of this 
pathway of great interest. 
The proposed anion binding pockets of FT and TFLI (and the Antirrhinum homolog 
CEN, Banfield and Brady, 2000) are more accessible then their mammalian 
counterparts, due to the absence of a C-terminal helix that is present in RKIP (Ahn et 
al., 2006, Figure 6.1). Despite being crystallised in the presence of phosphate 
analogues, in the respective crystal structures these regions are observed to only bind 
solvent molecules (Banfield and Brady, 2000; Ahn et al., 2006). Nevertheless, the 
residues within this pocket are consistent with an anion binding function (Figure 6.5), 
with the FT pocket being slightly enlarged compared with TFLI although not 
significantly enough to easily explain their alternative functions. These pockets could 
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not only feasibly bind anionic ligands, but also phosphorylated amino acids such as the 
phospho-tyrosine bound within the pocket of human RKIP (Figure 6.5). Interestingly 
the switch of a single FT residue positioned at the entrance to the anion binding pocket 
(Tyr85, Figure 6.5) to the corresponding TFL1 residue (His88) results in FT with 
largely TFL1-like function, and vice versa (to a lesser extent, Hanzawa, Money and 
Bradley, 2005). The conversion of 12 residues of the FT "specificity loop" to those of 
TFL1 also caused a reversal of function (Ahn et al., 2006). Importantly the residue 
(His88) identified by Hanzawa, Money and Bradley (2005) interacts with those of the 
"specificity loop" (Ahn et al., 2006), indicating that both the anion pocket and this loop 
region are important for the specificity of these proteins. 
The following experiments aimed to probe the specificity determinants in TFL1 and 
FT. Through the study of interactions of TFL1 and FT with individual phospho-amino 
acids, particularly at a structural level, it was hoped to indirectly determine some of the 
features present in their respective protein ligands. This might generally be used to 
further elucidate the role of FT and TFL1 in the timing of flowering in Arabidopsis and 







































































































































































Both TFLI and FT had been previously cloned into the expression vector pET-28a 
(Novagen), which attaches a thrombin cleavable hexa-His tag to the N-terminus 
(Miller, 2004). The FT used throughout this study has had all its cysteines (3) removed 
either by mutagenesis to serine or as the result of a small C-terminal deletion. This 
version has proven to be the most amenable to study (Miller, 2004). The TFL1 used 
has a native sequence. The expression, purification and initial crystallisation of both 
TFLI and FT have been published elsewhere (Miller, 2004 and Ahn et al., 2006) and 
shall be described in brief here. The methods used in this chapter are presented below. 
Some methods from the previous chapters (Chapter 2 and Chapter 5) were also used 
and will not be repeated here, but referenced by their section numbering where 
appropriate. 
6.2.1 Expression 
Both TFL1 and FT constructs were supplied as -80°C stocks of pre-transformed E. coli 
BL21 (DE3) cells. Expression was undertaken as described for GRHPR, except 
expression lasted for 5-6 hours and the resulting cell pellets were washed in 20mM 
Tris-HCI pH 7.4,150mM NaCl, 0.02% w/v sodium azide (NaN3). Cell pellets were 
frozen at -20°C until required. During expression kanamycin (50pg. ml"') was present 
as the pET-28a selector. 
6.2.2 Purification 
For both proteins, cell pellets were resuspended in 20mM BisTris-HCl pH 6.5,100mM 
NaCl, EDTA-free protease inhibitor (Roche) and sonicated on ice. Sonication was 
performed at 40% Ampl, 10sec bursts for a total of 200sec (VibraCell, Sonics). The 
resulting cell lysate was centrifuged at 25000g, 4°C for 30min. 
6.2.2.1 TFL 1 
TFL1 is expressed insolubly and is only present in the pellet after centrifugation. The 
insoluble pellet was resuspended in 20mM BisTris-HC1 pH 6.5,100mM NaCl, 4M 
urea, followed by recentrifugation at 25000g, 15°C for 30min. This wash step was 
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executed twice. The resulting pellet (still containing TFL1) was resuspended in 
Denaturing PEBP Ni2+ Loading Buffer (50mM BisTris-HCI pH 6.5,250mM NaCl, 
50mM imidazole, 20mM ethanolamine, 8M urea, 10% (v/v) glycerol and 0.02% (w/v) 
NaN3). A sonicating water bath was used to assist the resuspension of denatured 
protein. The denatured protein was clarified by centrifugation as above. The 
solubilised, denatured protein was loaded on to a 5ml Ni2+ affinity column and washed 
until a flat baseline was achieved. Bound protein was then eluted using a gradient to 
1M imidazole. The fractions containing denatured TFL 1 were identified, and refolding 
was accomplished by a 50-fold rapid dilution into Native PEBP Ni2+ Loading Buffer 
(50mM BisTris-HC1 pH 6.5,250mM NaCl, 50mM imidazole, 10% (v/v) glycerol and 
0.02% (w/v) NaN3). This was then spun at 25000g, 4°C for 30min and the supernatant 
loaded onto a new non-denatured Ni2+ affinity column, equilibrated in the same buffer. 
Elution of bound protein was again achieved with an imidazole gradient to 1M. 
Fractions predominantly containing TFL1 were pooled and dialysed (14kDa cut-off 
dialysis tubing) at 4°C, using two changes of a 100x volume of MonoS Loading Buffer 
(50mM BisTris-HC1 pH 6.5,20mM NaCI and 0.02% NaN3). The protein concentration 
was determined by A280 (MW = 20158Da, c= 9530M-l. cm') and the His-tag was 
removed by the addition of IOU thrombin per mg of protein with incubation at 18°C for 
16hrs. Cleaved TFLI was purified away from thrombin and uncleaved protein by ion 
exchange chromatography using a cation exchange resin (MonoS, Amersham 
Biosciences). A gradient of 20mM - 500mM NaCI was used to elute protein from the 
MonoS column. Pure, cleaved TFL1 was then used for crystallisation. 
6.2.2.2 FT 
A fraction of the expressed FT is soluble and hence the clarified supernatant was 
loaded directly onto a native Ni2+ affinity column. Bound protein was eluted with a0- 
1M imidazole gradient, pooled and protein concentration determined by A280 (MW = 
19,809Da, c= 20340M"'. cm"'). Cleavage of the His-tag was accomplished by the 
addition of thrombin (10U. mg"1) and incubation for 16hrs at 18°C. Separation of 
cleaved FT from uncleaved protein and thrombin was performed by gel filtration 
(Superdex 75 16/60) in FT Stabilisation Buffer (20mM CHES pH 9.5,100mM NaCl). 




Both TFLI and FT have previously been crystallised (Miller, 2004). The hanging drop 
vapour diffusion method was used to set up crystal trials around those conditions 
previously shown to be successful. 
6.2.3.1 TFL1 crystallisation 
TFL1 was buffer exchanged into 20mM BisTris-HCI pH 6.5 and concentrated to either 
10mg. ml" or 15mg. ml' using a 5kDa cut-off Centricon (Amicon). The published 
crystallisation conditions of TFL1 were; 10mg. ml'' in 0.3M (NH4)2SO4,22% w/v PEG 
5K MME and O. 1M Cacodylate pH 5.0 (Ahn et al., 2006). In addition, quality crystals 
had been produced with 0.1M MES pH 6.5,0.2M (NH4)2SO4 and 30% w/v PEG 5K 
MME (personal communication, Dr D. Miller, University of Bristol). Hanging drop 
vapour diffusion crystallisation trays were set up as described in section 2.3.15.2. A 
range of conditions, given in Table 6.1 were used in order to maximise the chances of 
reproducing the published crystals 
Crystallisation conditions 
0.1M Cacodylate pH 5.0 
18% - 30% PEG 5000 MME 
0.2M or 0.3M (NH4)2S04 
+/- 10mM ammonium phosphate 
0.1M MES pH 6.5 
22% - 32% PEG 5000 MME 
0.2M or 0.3M (NH4)2SO4 
+/- 10mM ammonium phosphate 
Table 6.1 Screening conditions used for TFL1 crystallisation. 
Based on successful conditions determined in Miller, 2004. 
6.2.3.2 FT crystallisation 
FT was retained in the Stabilisation Buffer and concentrated to 10mg. m1-1 using a 
lOkDa cut-off Centricon. The original FT crystallisation was undertaken at 10mg. m1'' 
in 0.14M (NH4)2S04,38% w/v PEG 5K MME and 0.1M MES pH 7.1 (Ahn et al., 
2006) but was poorly reproducible (personal communication Dr D. Miller). Attempts 
were made to reproduce and improve on these crystals by re-optimising around this 
condition (Table 6.2). 
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Buffers 1 0.1M MES pH 7.0,7.1,7.2 
0.1M HEPES pH 7.0,7.1,7.2 
Precipitant 130% - 40% w/v PEG 5K MME 
Salts (0.1 - 0.2M) (NH. )2SO4 
LiSO4 
M92SO4 
Table 6.2 Initial screening conditions for FT crystallisation. 
Based on successful conditions determined in Miller, 2004. 
Additionally, a previously unoptimised crystal screen hit (0.1M sodium acetate pH 4.6, 
14% PEG 4K) was chosen for further screening. It was hoped that the significantly 
different conditions might produce a more stable and reproducible crystal for soaking 
experiments. The additive screen (Hampton Research) was used to attempt to improve 
any conditions were crystals formed (section 2.3.15.2) 
6.2.4 Phospho-amino acid experiments 
6.2.4.1 Soaking 
Visually good quality apo crystals were selected for soaking experiments. As it was 
not clear which phospho-amino acid may bind, all 3 (phospho-serine (p-Ser), -tyrosine 
(p-Tyr), and -threonine (p-Thr)) were attempted. Stock solutions (1M) of each 
phospho-amino acid were made in a buffer as close to that of the protein being 
investigated as possible. Small volumes of mother liquor were made, matching each 
crystal reservoir condition except for the addition of 0.1M phospho-amino acid. High 
concentrations of phospho-amino acid were used as the interaction with the protein was 
expected to be weak. Soaking experiments were implemented in 2 ways; normal and 
gentle. Normal soaking involved the direct transfer of a single crystal to a 2µl 
phospho-amino acid/mother liquor drop on a fresh cover slip. Gentle soaking was used 
to try to reduce the potential "shock" of transfer. Firstly the selected crystal was 
transferred to a fresh 2µl drop of its original mother liquor. Next 1µl of phospho- 
amino acid/mother liquor was added, followed by the removal of an equivalent volume 
from the drop. This was then left for lhr at 18°C and the process repeated (more than 4 
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times), after which it was assumed the crystal was now fully in soak solution. In both 
cases the soaking drop was resealed over mother liquor to prevent the drop drying out. 
Crystals remained in the soak solution for between 24hrs and 2 months, after which 
they were either plunge frozen in liquid nitrogen for storage or directly tested for X-ray 
diffraction. 
6.2.4.2 Co-crystallisation 
Co-crystallisation of FT with the 3 phospho-amino acids was also attempted. Protein 
was concentrated as before to 10mg. ml"' and the phospho-amino acid added to various 
concentrations (15mM, 30mM and 50mM). The solution was stored on ice for 30min 
and centrifuged (18,000g, 5 min) before crystal tray set up. Conditions successful for 
the apo-crystal were trialled, as was the Structure Screen I and II HT-96 (MDL). 
JBScreen 3 was attempted with the hanging drop method after a hit relating to this 
screen was identified in the MDL screen. Further improvements of potential crystals 
have been attempted with the additive screen (Hampton Research) and by lowering the 
crystallisation temperature to 4°C. All were set up by hand as 1µl mother liquor with 
1 pl protein drops. 
6.2.5 Data collection, processing and solving 
Data was collected at the Daresbury SRS, Warrington as described in section 2.3.16. 
Between 5%-20% glycerol was used as a cryoprotectant depending on the well 
conditions of the crystal. These cryoprotectant solutions also contained an equivalent 
concentration of the phospho-amino acid under investigation. 
Data processing, solving and refinement were performed largely as described in 
sections 2.3.17 to 2.3.20. A monomer of each protein was extracted from their PDB 
entry (TFL 1-I WKO and FT -I WKP) and used for molecular replacement. Structures 
were refined to a point where the presence or absence of something in the binding 
pocket could be determined. TLS was not used during the refinement of these 
structures. 
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6 2.6 FD 
6.2.6.1 Expression 
The cloned, full length FD in the expression vector pET-16b (Novagen) was supplied 
by Dr T. Joseph-Home (University of Bristol) and expression of FD from this vector 
results in the attachment of 38 additional (thrombin cleavable) amino acids to the N- 
terminus, including a deca-His tag. Expression was done as for TFL1 and produced 
insoluble protein. 
6.2.6.2 Purification 
The cell pellet of FD expression was resuspended in FD Resuspension Buffer (50mM 
HEPES pH 7.2,200mM NaCl, 20mM imidazole, 10% v/v glycerol) with EDTA-free 
protease inhibitor, sonicated and centrifuged as standard. The resulting pellet was 
resuspended in the same buffer and respun. This washed pellet was finally suspended 
in FD Denaturing Ni2+ Loading Buffer (50mM HEPES pH 7.2,200mM NaCl, 8M 
urea) and centrifuged again. The denatured, solubilised protein was loaded on to a 5m1 
Ni2+ affinity column, washed and bound protein was eluted using an imidazole gradient. 
Fractions containing FD were identified by SDS-PAGE and used in refolding 
experiments 
6.2.6.3 Refolding attempts 
Tests to confirm refolding included concentrating the sample or buffer exchanging into 
Ni2+ column buffer. In both case incorrectly or partially folded protein would be 
expected to aggregate and precipitate. 
Dilution and dialysis 
Refolding was initially attempted using both a 50-fold rapid dilution into 3 different 
`simple' buffers, 50mM Tris-HCI pH 8.0/HEPES pH 7.2/BisTris-HCI pH 6.5,200mM 
NaCl and 10% glycerol, or dialysis into the same buffers. Dialysis was performed both 
at room temperature and 4°C, using dialysis buttons as described in section 5.2.6.1. In 
the case of rapid dilution, successful refolding was monitored by Trichloroacetic acid 
(TCA) precipitation and SDS-PAGE. Briefly, a sample of the refold dilution was 
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mixed with 1/5`h the volume of 3.2M TCA and incubated for 15min. Centrifugation at 
18,000g for 10min was followed by washing the pellet in ethanol and re-centrifugation. 
The resulting pellet was resuspended in SDS sample loading buffer, boiled and run on 
SDS-PAGE. 
Refolding screen 
The commercially available protein refolding screen (MDL) was undertaken as 
described in section 5.2.6.2. 
On-column refolding 
On-column refolding was attempted following the method of Oganesyan, Kim and 
Kim, (2005). Briefly, denatured protein was loaded onto a Ni2+ affinity column as for 
normal denaturing purification. This was then washed, using a shallow gradient, into 
buffer containing 0.1% Triton X-100 and no urea. This detergent wash is designed to 
prevent misfolding upon removal of the denaturant. The Triton was removed by 
quickly washing the column with buffer containing 5mM ß-cyclodextrin to remove the 
detergent and promote correct folding. Finally the column was washed into 100mM 
HEPES pH 7.2,100mM NaCl, 1mM ß-mercaptoethanol. `Refolded' protein could then 




The following describes the attempts to produce crystal structures of TFL1 and FT in 
complex with their potential partners. Apo crystal soaking and co-crystallisation 
experiments with phospho-amino acids are presented. In total 6 data sets were 
collected and solved, none of which contained ligand. The purification and refolding 
efforts carried out on FD, FT's proposed protein interacting partner, are also presented. 
This is followed by a discussion on potential reasons why no complexes could be 
produced and proposals for future work. 
6.3.2 Purification 
6.3.2.1 TFL I 
The expression of TFL1 from the pET-28a vector results in the production of insoluble 
protein, despite past efforts to alter this (Miller, 2004). However, a reasonably simple 
refolding and purification procedure existed and was used in this thesis. 
Initial purification of TFLI exploits the fact that poly-His tags do not rely on a specific 
3-dimensional structure for their affinity, and can therefore be successfully used to 
purify denatured protein. Denaturing the insoluble TFL1 with 8M urea resulted in a 
supernatant that could be loaded onto a Ni2+ affinity column equilibrated in denaturing 
buffers. Bound protein eluted with approximately 200mM imidazole, resulting in a 
significant A280 peak that corresponded to reasonably pure TFL1. Fractions that were 
concurrent with this were pooled and refolded. Refolding was carried out by rapid 
dilution into non-denaturing Ni2+ column buffer. After centrifuging this refolded 
protein, a small pellet was visible, indicating that refolding had not been 100% 
successful. Reloading the resulting supernatant onto a non-denaturing Ni2+ affinity 
column and its subsequent elution both concentrated and further purified the refolded 
protein (Figure 6.6 and Figure 6.7a). Refolded TFLI was eluted by approximately 
0.4M imidazole which had to be removed by dialysis before successful thrombin 
cleavage could be carried out. Cleavage with thrombin at 18°C for 16hrs produced 
entirely cleaved TFL1. Final purification to remove the thrombin was carried out on a 
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MonoS column and resulted in approximately 5mg of pure (greater then 95% as 
visualised by SDS-PAGE), cleaved TFL I per litre of E. co/i culture (Figure 6.7h). 
6.3.2.2 FT 
Approximately a third of FT is expressed in the soluble form allowing fora simple two 
column purification. The FT was initially purified from other soluble proteins by a 
native Nie{ affinity column where it elutes as the main protein in the second peak with 
approximately 0.4M imidazole (Figure 6.8). The FT containing fractions were pooled 
and the His-tag removed by cleavage with thrombin overnight. Separation of the 
thrombin and any remaining contaminating proteins was achieved by gel filtration 
(Figure 6.9) with the elution of the main peak corresponding to a monomeric FT 
weight. This produced approximately 10mg of pure (greater then 95% as visualised by 
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Figure 6.6 Native nickel affinity column chromatography of refolded TFI. I. 
Profile of refolded TFLI elution with an imidazole gradient. monitored by UV absorbance at 2 Onm. 
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Figure 6.7 SDS-PAGE gels of the purification of TFLI. 
A) SDS-PAGE gel of peak fractions containing His tagged TFLI, from the native Ni''-affinity column 
purification. Fractions correspond to solid line in Figure 6.6. B) Final TFL I purification, lane 1) 
molecular size markers, 2) pooled, refolded His-TFLI from (A), 3) TFLI post thrombin cleavage, 4) 
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Figure 6.8 Nickel affinity column chromatography of FT. 
Profile of poly-His tagged FT elution with an imidazole gradient, monitored by UV absorbance at 











Figure 6.9 S75 gel filtration chromatography of cleaved FT. 
Protein elution was monitored by UV absorbance at 280nm. The peak corresponds to monomeric FT and 
the solid line indicates those fractions combined to provide protein for crystallisation. 
)rbance 
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Figure 6.10 SDS-PAGE gel of the purification of FT. 
Summary of FT purification; lane 1) molecular size markers, 2) total expressed protein, 3) total soluble 
protein, 4) pooled His-FT from peak fractions of Figure 6.8,5) pooled FT post gel filtration, from peak 
fractions of Figure 6.9,6) concentrated FT post gel filtration. 
6.3.3 Phospho-amino acid soaking experiments 
6.3.3.1 TFL 1 
Good quality crystals of TFL I grew in a number of the conditions tried. This was 
expected as its crystallisation conditions are well established. The crystals all had a 
similar morphology (half hexagon) were of similar size (100µm - 300µm in length) 
and appeared after 1-2 weeks (Figure 6.11 a) Crystals chosen for data collection were 
soaked in Well solution containing a phospho-amino acid as described in section 
6.2.4.1. In general, all soaking experiments resulted in the appearance of cracks in the 
crystals, but where possible regions of better quality were used for data collection 
(Figure 6.11 b). 
6.3.3.2 FT 
The crystallisation of FT has been less reproducible and many of the conditions tried 
resulted in multiple small, thin plates (Figure 6.12a). By using the Hampton additive 
screen it was possible to achieve a well formed FT crystal (Figure 6.12b). This crystal 
grew in 38% PEG 5K MME, 0.1 M MES pH 7.0,0.14M (NH4)2S04,10mM NH4Pi and 
3% v/v glycerol, but was only around 100µm in length and very thin. This proved 
difficult to reproduce, as did a second reasonable quality apo condition, 0.1 M MES pH 
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7.0,32% w/v PEG 5K MME, 0.15M LiSO4,10mM NH,, Pi. Enough FT crystals of' 
acceptable visual quality were produced to allow a number of soaks to be carried out 
with some expectation of diffraction potential. Optimisation of the novel screen hit 
(OA M sodium acetate pH 4.6,14% PEG 4K) failed to produce any significant 
improvement in crystallisation. 
Soaking experiments were attempted on a number of FT crystals, including the crystal 
shown in Figure 6.12b. Despite using a gentle transfer method into the soak solution 
many soaking attempts resulted in the crystals breaking apart, dissolving or severely 
cracking. Of those crystals where diffraction was tested only one produced analysable 
data, a 24hr soak with 0.1 M p-Ser. As FT crystals are known to be of poor quality 
(personal communication Dr D. Miller, University of Bristol) it is unclear if the lack of 
collectable data sets was due to the crystals being of low quality before soaking or if 
the soaking caused (or enhanced) crystal disorder. 
a. 
Figure 6.11 Example TFLI crystals. 
1l 
A) Apo TFLI crystal. B) Same crystal as in (A) after 72hrs soaking with phospho-amino acid (p-Tyr). 
Arrow indicates region used for data collection. 
a. 
Figure 6.12 Example FT apo crystals. 
b. 
A) Standard morphology of FT crystals produced. B) Example FT crystal produced using additive 
screen. 
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6.3.4 Phospho-amino acid co-crystallisation 
A number of potential conditions have been identified for the production of 
FT/phospho-amino acid co-crystals. The MDL Screens I and II were carried out with 
50mM p-Ser and produced small crystalline plates after a month in 0.1M Na Citrate pH 
5.6,30% w/w PEG 4K, 0.2M ammonium acetate. The JBScreen 3 is a PEG 4K based 
commercial screen and was undertaken with 15mM p-Ser, resulting in small crystalline 
plates in the same condition, but crystal growth only took one week. In addition 
JBScreen 3 showed phase separation at 25% w/w PEG 4K with the same buffer and 
salt, providing an indication of the low range of PEG 4K concentration to use in 
screening. Crystal optimisation was carried out with 15mM p-Ser, p-Tyr and p-Thr, 
26% - 38% PEG 4K, 0.16M - 0.22M ammonium acetate in 0.1M Na Citrate pH 5.6. 
Additional screening was done by taking the best apo condition (0.1M MES pH 7.0, 
32% w/v PEG 5K MME, 0.15M LiSO4,10mM NH4Pi) and using this as a basis for co- 
crystallisation with 30mM of p-Ser or p-Tyr in the set up. The Hampton additive 
screen and incubation at 4°C have both been used in an attempt to improve crystals, 
with neither being successful. Currently, crystalline plates of a similar morphology to 
those in Figure 6.13 have been produced in all 3 phospho-amino acid co-crystallisation 
(Table 6.3). However, none have proved large enough or stable enough to produce a 
usable diffraction pattern. 
6.3.5 Data collection 
In total 5 data sets have been collected for TFL1 phospho-amino acid soaking 
experiments, 2 each for p-Tyr, p-Ser and 1 for p-Thr (Table 6.4). However, only one 
TFLI data set will be presented and discussed hereafter, the 0.1M p-Tyr 72 hour soak, 
as the other 4 data sets were of similar quality, were processed in the same way and 
gave the same result. A single FT data set has been successfully collected and solved, a 
24 hour 0.1M p-Ser soak, and its results are also presented below. 
Diffraction data was collected at the Daresbury SRS, Warrington under cryocooled 
conditions (100K). Test diffraction images were used to optimise exposure time and 
detector distance. Additionally, the strategy program within HKL2000 was used to 
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determine how best to collect complete data sets. The collection parameters are given 
below in Table 6.5 and example diffraction images are given in Figure 6.14. 
Phospho-amino acid (15mM) I Best condition 
p-Ser 0.1 M Sodium Citrate pH 5.6,34% PEG 
4K, 0. I6M Ammonium acetate 
p-Tyr 0.1 M Sodium Citrate pH 5.6,38% PEG 
4K, 0.16M Ammonium acetate 
p-Thr 0.1 M Sodium Citrate pH 5.6,38% PEG 
4K, 0.18M Ammonium acetate 
Table 6.3 Best determined co-crystallisation condition for FT with each phospho-amino acid. 
Figure 6.13 Example F7'/p-tier co-crystals. 
Co-crystals produced in the p-Ser condition give in Table 6.3. These did not produce usable diffraction. 









Table 6.4 Length of phospho-amino acid soaking times used on TFI. I crystals. 
The length of time each data collected TFL I apo crystal was soaked in 0. IM phospho-amino acid prior 
to data collection (or freezing). 
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TFL1 FT 
Crystal Conditions 10mg. m1' , 0.1M MES pH 
6.5,28% PEG 5K MME, 
0.3M (NH4)2SO4 
10mg. m1' , 0.1M MES pH 
7.0,38% PEG 5K MME, 
0.14M (NH4)2SO4,10mM 
NH4Pi and 3% v/v glycerol 
Soak 0.1M p-Tyr, 72 hours 0.1M p-Ser, 24 hours 
Cryoprotectant 20% glycerol, 0.1M p-Tyr 5% glycerol, 0.1M p-Ser 
Station/Wavelength 10.1/1.488 14.1/1.488 
Detector MAR165 CCD detector Quantum 4 CCD detector 
Exposure time (sec) 7 45 
Oscillation per frame (°) 0.5 1 
Detector distance (mm) 100 120 
Degrees of data collected (°) 239 327 
Table 6.5 Data collection parameters for example TFL1 and FT data sets. 





Figure 6.1 4 Images of diffraction pattern from TF1.1 and FT crystals. 
A) I.. anipIc Pubtraction pattern from FFL I crystaI, B) Example diffraction pattern from FT crystal. This 
shows the poor diffraction ability of FT crystals in comparison to TFL 1. Data collect parameters were as 
given in Table 6.5. 
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6.3.6 Data processing, molecular replacement and refinement 
Diffraction data was indexed using Denzo (HKL2000 suite, Otwinowski and Minor, 
1997), initially in P1 with box and spot size adjustments made, followed by multiple 
rounds of refinement. The highest symmetry Bravais Lattice with the lowest distortion 
was then chosen (data not shown) and further rounds of refinement were undertaken. 
The refined unit cell measurements closely matched those previously published as did 
the lattice choice, with TFLI indexed as primitive hexagonal (P3) and FT as primitive 
triclinic (P1). 
Indexing was followed by integration and the data was scaled and merged onto one 
scale with ScalePack (HKL2000 suite). As with the published structure, TFL1 was 
scaled in P321. The processing statistics are shown in Table 6.6. 
The Matthews coefficient was calculated to determine the number of protein monomers 
in the asymmetric unit. This showed TFLI with 2 monomers per AU and a solvent 
content of 55%, while FT contained 4 monomers and a solvent content of 51% (data 
not shown) consistent with previous work (Ahn et al., 2006). 
Molecular replacement was carried out using Phaser (Storoni, McCoy and Read, 2004). 
A single protein chain was extracted from the PDB files, 1WKO and 1WKP for TFLI 
and FT respectively, to act as the search model. A high quality solution was found for 
each and examined in Coot (Emsley and Cowtan, 2004). The maps produced by Phaser 
were of good quality due to the 100% identity of search model and structure. The 
model required very little alteration, indicating that soaking had had little effect on 
side-chain and loop position. Any required changes were made followed by rounds of 
refinement in Refmac5 (Murshudov, Vagin and Dodson, 1997) and subsequent 
inspection of the resulting density maps. Upon examination of the putative phospho- 
amino acid binding pocket no density was observed to indicate the presence of the 
soaked ligand, nor was there evidence for the ligand being present elsewhere in the 
asymmetric unit. Figure 6.15 shows a view of the proposed binding pocket in both 
TFL 1 and FT. This indicates both the quality of the 2Fo-Fc map for the surrounding 




Space group P321 P1 
Unit cell (A) ab= 108.8. c=65.0 
y= 120° 
a= 53.9, b 62.5, c= 67.8 
a= 74.2°, = 72.2°, y= 70.3° 
Resolution ranee (A) 50 - 1.75 (1.81 - 1.75) 50 - 2.70 (2.80 - 2.70 
Number of unique 
reflections 
44926 (4477) 18788 (1279) 
I/a 36.2 (3.7) 8.4 (1.9) 
8.2(38.8) 12.6(42.3 
Completeness (%) 100 (100) 87.1 (59.6) 
Redundancy 14.4 (12.7) 3.1 (2.4) 
Mosalcity (°) 0.414 2.173 
Refinement 
R,,, _, (0/'0) 
24.8 18.3 
Rf«c% 27.0 29.1 
Table 6.6 Final refinement statistics for representative TFLI and FT data sets. 
Values are for the complete dataset. bracketed Values represent the highest resolution shell only. 
FT TFLI 
Figure 6.15 Qualih of electron densit for the pocket forming residues. 
The electron densit> maps (2Fo-Fc) of the residues forming the proposed phospho-amino acid binding 
pocket for FT and TFL 1. This indicates the quality of side-chain electron density and the lack of density 
wthin the pocket. Hic residues sho%Nn are identical to those in Figure 6.5. Maps are contoured at la. 
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6.3.7 FD purification 
The expression of FD occurs from the pET-16b vector and attaches an additional 38 
amino acids to the N-terminus, including a deca-His tag. Small scale expression tests 
were carried out across a range of temperatures and IPTG concentrations, however 
soluble protein was not seen (personal communication Dr T. Joseph-Home, University 
of Bristol), leading to the need to purify the protein from inclusion bodies. A 
denaturing Ni2+ affinity column was carried out as for TFL1 and an imidazole gradient 
resulted in the elution of reasonably pure FD at very low imidazole concentrations 
(Figure 6.16 and Figure 6.17). While some contamination remained these samples 
were deemed pure enough to be useful for refolding experiments. 
6.3.8 Refolding attempts 
Over time urea can break down and cause the carbamylation of lysine and arginine side 
chains. As this may effect folding, only fresh preparations of denatured FD were used 
in all folding experiments. Initial `basic' refolding buffers were made and refolding 
attempted by both rapid dilution and dialysis. Both these methods failed to produce 
any soluble protein as analysed by TCA precipitation and SDS-PAGE. 
The commercial refolding screen contains 15 buffers representing a range of additives 
and their combinations. Comparing the solublising (and by conjecture, refolding) 
ability of each buffer to denatured protein allows the importance of various components 
to be scored. Table 6.7 shows the scoring of components for their apparent 
contribution to refolding lmg. ml"' of FD after a 1: 20 dilution. 
Based on these results various combinations of the positive components (Table 6.7) 
were trialled. EDTA was not used as it would be incompatible with further purification 
by Ni2+ affinity. Additionally, the detergent CHAPS was used to replace Triton X-100 
as this can prove troublesome for crystallisation experiments. A final buffer of 50mM 
MES pH 6.0,250mM NaCl, 10mM KCI, 0.5M L-arginine, 0.5% w/v CHAPS proved 
successful at retaining FD solubility after a 1: 20 dilution. However, upon either buffer 
exchange by centrifugation (Vivaspin, lOkDa cutoff) or dialysis into 50mM MES pH 
6.0,250mM NaCl, the FD precipitated. This suggests that incomplete or incorrect 
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folded versions of FD were being retained in the supernatant by the general soluhilising 
ability of L-arginine and CHAPS rather then actual successful refolding. 
Additionally on-column refolding was attempted. The method used here, "artificial 
chaperone-assisted refolding" was developed by (Oganesyan, Kim and Kim, 2005). 
This uses slow replacement of the denaturant (urea) with a detergent-containing butter 
(in this case Triton X-100) to prevent aggregation, followed by removal of the 
detergent with ß-cyclodextrin. However, this method proved ineffective in the 
refolding of full-length FD and resulted in its elution as an insoluble aggregate after the 



















The nickel column was run in the presence of 8M urea and FD elution monitored by UV absorbance at 
280nm. Solid line indicates the range of fractions ran on the SDS-PAGE gel in Figure 6.17. 
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Figure 6.17 SDS-PAGE gel of the denatured purification of His-FD 
Lanes 1) molecular size markers, 2) total expressed protein, 3) total insoluble protein. The remaining 
lanes correspond to the region indicated by the solid line in Figure 6.16. Those fractions containing the 
majority of FD were pooled for refolding experiments. 
Buffer Component Facilitation of Folding 
50mM MES H 6.0 +++ 









Triton X-100 +++ 
PEG 3550 0 
DTT 0 
GSH/ GSSH 0 
Table 6.7 MDL refolding screen components and their effect on FD folding. 




A number of crystal structures for proteins from the RKIP/PEBP family are known, 
including representatives from mammalian, plant and bacterial members. All of these 
structures show a high level of similarity and contain a distinctive and conserved anion- 
binding pocket which has previously been proposed (Banfield and Brady, 2000) and 
recently shown (Rath et al., 2008) to be the likely recognition site for phosphorylated 
residues on the respective binding partners. The potential physiological interactions 
facilitated by this protein family remain structurally uncharacterised, with the exception 
of the structure of human RK[P bound to phospho-tyrosine (Simister, 2004). This led 
us to investigate if a similar interaction could be observed with the plant proteins TFLI 
and FT. The results of this work are described here, with a focus on possible reasons 
for the lack of success and suggestions for future directions that could be followed. 
The purification and structural details of TFL 1 and FT will not be discussed as they are 
identical to those published elsewhere (Miller, 2004; Ahn et al., 2006). 
6.4.1 Soaking and co-crystallisation experiments 
A large constraint on both the soaking and co-crystallisation experiments was the lack 
of clear knowledge of which (if any) phospho-amino acid binds to the pocket. 
Attempts were made to study the potential phospho-amino acid interactions via ITC. 
However it proved impossible to solubilise the protein and phospho-amino acid in 
identical buffers, a requirement for ITC. Although the related protein (SP) from tomato 
has been reported to interact with a phospho-serine in at least some of its binding 
partners (Pnueli et al., 2001), it was not until after the FT/TFLI work had been initiated 
that a potential interaction dependent on either a (likely phosphorylated) threonine or 
serine was identified between FT and FD (Abe et al., 2005). Consequently, the later 
co-crystallisation work focused on this interaction, assisted by the fact that FT is simple 
to purify in the large quantities needed for extensive screening. If phospho-serine (p- 
Ser) is the appropriate ligand for FT it is disappointing that the crystallographic data 
produced from a 24hr p-Sec soak into a FT crystal (sections 6.3.3.2 and 6.3.6) did not 
contain any discernible density for this ligand. 
All soaking experiments led to deterioration in the visual quality of both TFLI and FT 
crystals, although only FT crystals were seen to totally disintegrate over time while 
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TFL1 crystals remained reasonably intact for at least 2 months. While care was taken 
to minimise the change in buffer condition upon the addition of the phospho-amino 
acid it appears that, due to the known delicate nature of apo FT crystals (Miller, 2004), 
this slight change in conditions has had a significant deleterious effect. Whether this is 
due to a change in buffer conditions or a ligand interaction disrupting crystal packing is 
unclear. 
Successfully soaking a ligand into apo crystals is dependent on a number of factors, 
including the retention of important crystal lattice interactions, the affinity of the 
protein: ligand interaction and, importantly, the presence of solvent channels allowing 
the ligand access to the binding site. Examination of the TFL1 crystal packing 
indicates that one of the two monomers in the asymmetric unit obstructs access to the 
opposing binding pocket. However, that monomer itself retains a pocket apparently 
accessible to solvent. The crystal packing and interactions between the 4 monomers 
within the asymmetric unit of the FT crystal allow all 4 binding pockets to face solvent 
channels. This would suggest that the lack of electron density for a phospho-amino 
acid ligand is not due to its inability to gain access to the interaction site. The RKIP: p- 
Tyr structure resulted from a 72hr, O. 1M soak, with shorter times being unsuccessful 
(Simister, 2004). While this time frame was achieved for the TFL1 soak experiments it 
could not be reproduced with FT due to crystal deterioration. Consequently the 
absence of ligand in the FT binding pocket may be the result of an insufficient soak 
time, although this does not explain its absence in TFL1. 
The use of co-crystallisation avoids the problems of ligand access as it is present prior 
to crystal lattice formation, assuming adequate binding affinity. The 1.4 pH unit shift 
seen between the apo (pH 7.0) and initial co-crystallisation (pH 5.6) conditions (Table 
6.2 and Table 6.3) might be indicative of an altered lattice and, potentially, the presence 
of the ligand. Alternatively the phospho-amino acid could merely be acting as an 
additive within the buffer and not be incorporated into the crystal. However, this seems 
unlikely given the relatively low (15mM) concentration of the ligand. Further work 
need to be undertaken on these co-crystallisation conditions, particularly to establish 
conditions for the formation of a stable protein-ligand complex, with the aim of 
producing diffraction quality crystals. 
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It is possible that the interaction seen in the RIUP: p-Tyr structure is a crystallographic 
artifact and the conditions that favored this simply have not been reproduced with 
TFL1 or FT. There is however mounting experimental evidence that the pocket on this 
family of proteins does indeed bind phosphorylated residues (Pnueli et al., 2001; Abe et 
al., 2005; Rath et al., 2008), and it seems more likely that the lack of ligand within the 
soak experiments indicates a very low affinity interaction. 
6.4.2 Expression of FD 
With the subsequent identification of the potential binding partner, FD (Abe et al., 
2005; Wigge et al., 2005), attempts were made to produce recombinant FD to facilitate 
investigation of the binding interaction. However no soluble full-length protein could 
be produced. The difficulty of obtaining folded (or in refolding) FD may be due to the 
large N-terminal extension from the vector (38 amino acids). Alternatively, the large 
serine and proline rich native N-terminus sequence of FD (residues 1- 207) may 
require particular conditions to assist folding or may be intrinsically unstructured. Co- 
expression with chaperone proteins or expression in a yeast host may be profitable 
avenues for further investigation of the full length form. Work has also been 
undertaken by others in the host laboratory on truncated forms of FD, retaining only the 
C-terminal leucine zipper domain (residues 208 - 285). 
6.4.3 Future work 
While the extensive phospho-amino acid soaking experiments undertaken during the 
course of this work failed to produce a protein: ligand complex structure, the production 
of crystals under co-crystallisation conditions, although of insufficient quality, provide 
a starting point for future screening work. This co-crystallisation work needs to be 
extending to include TFLI which, due to time constraints and the priority placed on 
other projects, could not be achieved during the course of this thesis. Additional 
biophysical techniques such as surface plasmon resonace (Biocore) could be utilised to 
investigate phospho-amino binding. It would be important to confirm the identity of 
the region of FD to which FT binds, which may allow the co-crystallisation of FT with 
an appropriate phospho-peptide constituting the proposed binding region. The use of a 
peptide, rather then a free amino acid, may increase the affinity of the interaction 
sufficiently to allow crystallography to be successful. This method is currently in the 
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early stages of being employed with hRKIP (personal communication Dr N. Burton, 
University of Bristol). Recently, soluble expression of the C-terminus leucine zipper of 
FD (residues 208 - 285) has been achieved (personal communications Dr T. Joseph- 
Home, University of Bristol). This region contains a potential phosphorylation site for 
CDPK, Thr282, that when mutated abolishes the FT: FD interaction (Abe et al., 2005). 
While not possible within the time frame of this thesis, the nature of this interaction 
needs to be further investigated, although it may not constitute a site of direct 
interaction. Various methodologies could be employed including size exclusion 
chromatography, analytical ultra centrifugation (AUC), ITC and, if confirmed, 
crystallography. Other potential FD phosphorlyation sites (many of which are in the 
unstructured N-terminal region; Jakoby et al., 2002) also need to be investigated to 
ascertain their role, if any, in the interaction with FT/TFL1. 
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Chapter 7 General Conclusions 
The different proteins investigated throughout this thesis are involved in a variety of 
cellular processes, from metabolism to trafficking and signaling. Despite this diversity, 
they are linked by a common theme of the structural mechanisms by which ligand 
specificity is determined. 
X-ray crystallography is a powerful technique for the determination of protein 
structures and consequently, their interactions with substrates and ligands. The work 
undertaken during this thesis was aimed at various points along the pathway by which 
protein crystal structures are determined. These ranged from enabling protein 
expression studies at one end to the elucidation of structural complexes at the other, 
with all of these steps being implemented in the study of human GRHPR. 
The production of a structure of the human GRHPR enzyme in complex with both its 
coenzyme (NADPH) and a substrate molecule (D-glycerate) has shown how substrate 
specificity is achieved within the GRHPR family of enzymes (Chapters 3 and 4). The 
elegant use of a steric gate to block unwanted substrates such as pyruvate, combined 
with the deployment of hydrogen bonding potential to allow specific, larger substrates 
(hydroxypyruvate) to overcome this restriction is a mechanism which could not have 
been elucidated without a ternary structure. Additionally, this structure has also 
provided the first structural proof for the manner by which the entire D-2-hydroxyacid 
dehydrogenase protein family are likely to bind their substrates. 
Protein structures are also very important in the process of drug design. As the 
malfunction of human GRHPR ultimately leads to primary hyperoxaluria type 2 (PH2) 
disorder, the structures produced in this thesis may assist in the development of 
therapeutics for the treatment of this condition. The structures have already provided a 
basis from which the reduction in GRHPR activity associated with specific PH2- 
causing missense mutations can be explained, a significant first step when 
contemplating drug design. As some of these changes appear to lead to destabilisation 
of the enzyme structure, a possible route might be to develop compounds that could 
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enhance the GRHPR structure. This concept of molecular chaperones is already being 
explored for mutated forms of AGT, the cause of PHI. A limitation is that the rarity of 
PH2 disease questions the economic viability of developing compounds that would find 
only limited application. As discussed in Chapter 4, a more realistic approach may be 
to moderate the activity of L-LDH in these individuals instead, 'piggybacking' on 
existing campaigns aiming to develop specific L-LDH inhibitors for the treatment of 
cancers. The success of this strategy requires a comprehensive understanding of the 
labyrinthine interactions of the many metabolic pathways to which L-LDH contributes, 
a challenge that needs to be addressed via a `systems biology' approach. 
One of the major limitations of X-ray crystallography is the requirement for well- 
ordered protein crystals from which to collect data. The successful packing of a protein 
into a crystal requires the formation of regular interactions produced by a highly 
consistent molecular conformation. With proteins, this is often difficult to achieve 
because of inherent molecular flexibility, the presence of multiple domains or regions 
of unstructured sequence, and sample heterogeneity. As demonstrated in this thesis for 
sorting nexin 1, even producing a large multi-domain protein in sufficient quantities for 
crystallisation studies can be troublesome (Chapter 5). Often the best approach is to 
truncate a large protein into smaller, biologically relevant sections. Hopefully by 
producing a compact domain the crystallisation potential can be enhanced and (some) 
structural questions answered. The expression and purification procedures established 
in this thesis for the separate PX and Bar domains of sorting nexin 1 (Chapter 5) have 
brought the structural understanding of the phosphoinositide and membrane specificity 
of this protein one step closer, with initial crystallisation trials on these domains still 
proceeding. Structural studies of larger segments of SNX1 are desirable and potential 
ways to progress this work have been proposed. The requirement for "packable" 
protein in crystallography can also result in unexpected conformations being selected 
due to their crystallisation ability. The partially closed conformation of the apo 
GRHPR is an example of this and indicates the importance of using knowledge from 
other, related structures (where possible) in the interpretation of features within a 
crystal packing environment. 
Although protein structures are undeniably important, they provide limited information 
on the complex interplay of the many proteins present within the cell milieu. The 
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ability of both GRHPR and its cytosolic companion L-LDH to utilise the same 
substrates (glyoxylate and hydroxypyruvate), one (GRHPR) producing a desirable 
product whereas the other (L-LDH) products that are potentially pathological 
(hyperoxaluria and L-glycerate aciduria), has only been partially examined. It was 
anticipated that GRHPR would demonstrate a clear kinetic advantage over L-LDH with 
these substrates under physiological conditions: this, surprisingly, proved not to be the 
case (Chapter 4). This has led to the proposal that it is the cellular conditions 
themselves that distinguish between these pathways, with the concentration of other 
substrates (such and lactate) and the ratios of reduced and oxidized co-enzymes that are 
likely to dictate the effective operating preferences of these enzymes in normal 
glyoxylate (and hydroxypyruvate) metabolism. 
The work undertaken during this thesis on the interactions of two plant RKIP/PEBP 
proteins, TFL1 and FT, with their potential phosphorylated ligands has shown that even 
when the crystallisation and structure of a protein has been established, it is not always 
a simple step to move to higher level complexes (Chapter 6). Neither soaking the 
expected small molecule ligand into preformed crystals nor including the ligand prior 
to crystallisation (co-crystallisation) successfully produced the desired complex 
structures. Although not successful, this work has allowed the acquisition of 
experience with these techniques that might be more successfully deployed on other 
systems in the future. 
The variety of ways by which proteins achieve specific binding to ligands or substrates 
is immense. Looking directly at the molecular structures of such complexes remains 
the best way to understand these key interactions. Despite its limitations, such as those 
encountered in these studies, X-ray crystallography remains the most widespread and 
best technique to determine molecular structures. The advances that have been made in 
the projects detailed in this thesis would not have been possible without the successful 
development and application of this important method. 
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Appendix 1 
Publication arising from this thesis; 
Mdluli K, Booth MP, Brady RL, and Rumsby G. (2005). A preliminary account of the 
properties of recombinant human glyoxylate reductase (GRHPR), LDHA and LDHB 
with glyoxylate, and their potential roles in its metabolism. Biochim Biophy Acta, 
1753,209-16. 
Booth MP, Conners R, Rumsby G, and Brady RL. (2006). Structural basis of substrate 
specificity in human glyoxylate reductase/hydroxypyruvate reductase. JMo1 Biol, 360, 
178-89. 
The GRHPR ternary structure and structure factors have been deposited in the Protein 
Data Bank (PDB; www. pdb. com), reference code 2GCG. 
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